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Safety testing procedures and risk assessment analysis of newly developed chemicals are 
mandatory to attest them as non-toxic for human handling. The European Union implemented 
several regulations enforcing safety testing and has recently banned the use of animals for 
toxicology studies for human safety. 
From in vitro cell-based assays to reconstructed human epidermis (RHE) models, there are 
several non-animal alternatives for toxicology studies to determine human safety. Cell-based 
assays are not accurate enough to predict the toxic potential of chemicals as they are a two-
dimensional (2D) representation of skin cells. Three-dimensional (3D) RHE models are better, 
as they allow for differentiation of skin epidermal layers (i.e. stratum corneum). Commercially 
available RHE models are now the gold standard for toxicity studies for human safety and some 
of these have been validated by the Organization for Economic Cooperation and Development 
(OECD) for skin irritation and corrosion testing (two major categories of skin toxicity).  
The aim of this study was to develop an open source 3D epidermal skin culture based on 
Poumay’s work. Using the Alvetex Strata scaffold, cell seeding was optimised using 1x106 
keratinocytes for a 30 day culture period for best differentiation of the stratum corneum layer 
(confirmed by immunofluorescence staining of involucrin). Further optimization of vitamin C 
and calcium supplements did not seem to improve distribution of keratinocytes throughout the 
scaffold. Ultimately, the best results were achieved by the addition of a human-based collagen 
coat to the Alvetex Strata Scaffold, where development of stratum corneum was confirmed by 
collagen and involucrin staining. Moreover, development of the stratum basale layer was 
confirmed by cytokeratin 14 immunofluorescence.  
Evaluation of the 3D epidermal skin culture was tested following OECD Testing Guideline 
(TG) 439 for skin irritation in 12 reference chemicals from the 20 reference chemicals list in 
TG 439. Results showed the 3D epidermal skin culture was able to distinguish non-irritant from 
irritant chemicals using 10 different keratinocyte donors. Comparative performance analysis 
with a monolayer (2D) keratinocyte culture, a commercial RHE model and a collagen-based 
RHE models were performed. Results showed similar outcomes between the different models, 
while the monolayer culture performed poorly in discriminating irritant from non-irritant 
chemicals. Overall, these results were indicative of the predicative capacity of the 3D epidermal 
skin culture for in vitro testing of skin irritation.  
The second aim of this project was to use a skin explant assay, developed by Alcyomics, 
as a novel in vitro test for assessment of immunotoxicity caused by aggregation of monoclonal 
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antibodies (mAbs). mAbs are important therapeutics but their potential for aggregation has 
become a critical quality parameter that can turn into a potential health risk during the 
administration of mAb therapeutics to patients. While the extent of immunotoxicity in patient 
populations is uncertain, reports show that it can lead to immune responses via cell activation 
and cytokine release. Our results showed that aggregated mAbs caused adverse immune events 
by evidence of tissue damage, expression of cell death markers and overall increase of IFN-γ 
(pro-inflammatory cytokine). These results showed that the skin explant assay could be a 
promising tool for predicating immunotoxicity caused by mAb aggregation. 
In conclusion, this study has provided further insight on the assessment of skin toxicity 
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1. Introduction and scientific aims 
 
1.1. The human skin structure 
The human skin is a major organ of the human body. It is actively involved in the defense 
against exogenous damaging substances or microorganisms. Because of its physiological 
properties which create a complex web of interacting structures, the skin is a protective shield 
from the exterior environment and helps maintain the homeostasis of the body (Bouwstra & 
Ponec, 2006; Naish & Syndercombe Court, 2014). It is composed of three layers – epidermis, 
dermis and hypodermis. The epidermis, the outermost layer of human skin consists of different 
strata (layers) constructing an epidermal barrier, the first impermeable barrier of protection 
against the exterior. This epidermal barrier consists of multiple layers of keratinocytes, under 
different stages of differentiation. The basal layer of the epidermis (stratum basale) consists of 
undifferentiated keratinocytes, while the outermost layer (stratum corneum) is composed of 
terminally differentiated keratinocytes that have migrated from the stratum basale (Figure 1) 
(Eckert & Rorke, 1989; Presland & Dale, 2000). While keratinocytes represent most of the cells 
present in the epidermis, there are also specific immune cells present, such as dendritic cells or 
Langerhans cells.  Keratinocytes are in close contact with Langerhans cells to form an immune 
barrier against the outside environment (Janeway, Travers, Walport, & Shlomchik, 2001; Naish 
& Syndercombe Court, 2014). 
 
 
Figure 1. Structure of epidermis. The human skin is composed of different layers – epidermis, dermis 
and hypodermis. The epidermis is the outermost layer, representing the first immune barrier against the 
outside environment and it is subdivided in specific strata with different immune cell types. Skin cells 
(keratinocytes) regenerate from the bottom to the top layers, meaning that the upper layers (stratum 
corneum) are usually composed of dead keratinocytes (Naish & Syndercombe Court, 2014). 
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1.2. Assessment of skin sensitization 
Nowadays, skin sensitization has become a pressing issue, since exposure to allergenic 
compounds present in commercial products like cosmetics and other skin products can trigger 
skin allergic sensitization, an inflammatory reaction of the skin. The contact of these exogenous 
compounds with human skin can trigger an immune reaction by interaction with antigen-
presenting cells (APC, as the case of dendritic cells), leading to T cell activation (Bouwstra & 
Ponec, 2006; Louis-dit-sully et al., 2014). The interesting aspect of this allergic sensitization is 
that it is intrinsically dependent on the host’s immune features (immunobiological system) and 
in some cases its predisposition (genetic background) to develop sensitization against a certain 
antigen. As so, it is very important to understand the immune mechanism behind allergic 
sensitization and how the exposure to allergens and the immune cells involved in the process 
of skin inflammation takes place.  
The pathway by which skin sensitization takes place involves allergen exposure, antigen 
recognition by dendritic cells as Langerhans cells and consequent T cell activation. This 
molecular response causes an inflammatory response (cytokine release, vasodilation and 
transepidermal water loss) followed by the onset of symptoms (swelling, oedema and/or 
erythema) (Louis-dit-sully et al., 2014). The epithelium is the most important skin layer 
involved in the skin sensitization process, since it is the first physical layer of protection. More 
specifically, within the stratum corneum, desmosomes and free lipids (as cholesterol esters and 
free fatty acids) surround any dead keratinocytes. This arrangement of dead cells and free lipids 
makes the epithelium an effective barrier against exogenous allergenic compounds (Imokawa, 
Kuno, & Kawai, 1991; Schurer & Elias, 1991).  Skin sensitization occurs due to penetration of 
the stratum corneum and it is dependent on the concentration and time of exposure of the 
allergen against the barrier capacity of the stratum corneum.  
Topical allergen exposure causes priming of the immune system by recruitment of dendritic 
cells, T cell activation and cytokine production. Initially, dendritic cells interact with the 
allergen by internalizing it and presenting it to responsive T cells, triggering them to activate 
and proliferate (Louis-dit-sully et al., 2014). Considering the diversity of T cell receptors 
present in the T cell repertoire, only naïve T cells with affinity to the allergen antigen receptor 




1.3. Evolution of allergic sensitization assessment  
As an effort to reduce the occurrence of skin sensitization, legislation on commercialization 
of chemicals has been implemented. All products commercially available are thoroughly 
screened for the presence of possible sensitizers before entering the market to assure no risk of 
sensitization to humans. Many of the chemical compounds present in these new products are 
missing valuable safety information, hence the need to always perform a risk assessment for 
sensitization. The experimental approach of sensitization started with animal testing in the 
1940s, mainly in guinea pigs and rabbits (Chase, 1941; Landsteiner & Chase, 1941) and it is 
still a standard approach in some countries such as the United Stated of America, Japan and 
China.  However, a general concern for the use of animals in safety tests has led to a conceptual 
change and increase in alternative methods for testing compound safety, more specifically in 
Europe.  
 
1.3.1. Animal-based experimental approaches  
One of the first experimental approaches for sensitization was the Draize test, 
established in the 1940s (Draize, Woodard, & Calvery, 1944). This approach is performed 
using guinea pigs or rabbits, where the testing product is topically applied onto the animal skin 
and evaluated during a period of time for visible skin damage symptoms (inflammation, 
swelling, erythema or oedema). This experimental approach was largely replaced in the 1980s 
by the mouse local lymph node assay (LLNA), a more quantitative and manageable approach 
(I Kimber, Mitchell, & Griffin, 1986; I Kimber & Weisenberger, 1989). LLNA was accepted 
by different regulation committees regarding validation of alternative methods to animal testing 
(i.e. Interagency Co-ordinating Committee on the Validation of Alternative Methods, 
ICCVAM) as an improvement to Draize guinea pig testing, since it reduced the number of 
animals required  in the assessment of skin sensitization (minimum of 8 guinea pigs compared 
to a minimum of 4 mice) (Dean et al., 2001a, 2001b). LLNA is one of the few animal 
experimental approaches validated for skin sensitization, corrosion and irritation testing which 
is still currently used in countries like the United States of America (Dean et al., 2001a, 2001b; 
OECD, 2010).  
LLNA relies on the principle of antigen-specific T cell proliferation. It measures the ability 
of an exogenous compound to cause skin sensitization according to its ability to induce lymph 
node cell proliferation (T cell proliferation within the lymph node) after topical exposure to the 
compound (Frank Gerberick, Ryan, Dearman, & Kimber, 2007). The output response of 
23 
 
lymphocyte proliferation is measured by incorporation of 3H-thymidine into the DNA of newly 
formed lymph node T cells. The test compound is topically exposed to mice ears daily for three 
days and on the fifth day following initial exposure, mice are intravenously injected with a dose 
of radiolabelled thymidine. Animal sacrifice is then required for excision of the draining lymph 
nodes for assessment of T cell proliferation (Frank Gerberick et al., 2007; Ian Kimber & 
Dearman, 2010). The outcome of T cell proliferation is measured with regards to the vehicle 
control, as an index of stimulation.  To be considered a sensitizer (compound that causes skin 
sensitization), the effect of exposure to the compound is measured by following the EC3 value 
rule (Frank Gerberick et al., 2007). This means a three-fold increase of T cell proliferation when 
compared to the vehicle control should be observed. As the LLNA can give a quantitative 
measure of sensitization, it can be used as an estimation of relative potency.  This is based on 
the hypothesis that T cell proliferation is dependent not just on the incidence of skin 
sensitization but rather on its extent (as a causal quantitative effect). Thus, LLNA is used for 
assessment of skin sensitization and relative potency effect and it is currently considered the 
gold-standard approach for risk assessment of new compounds. However, recent findings have 
raised concerns for this method as a valid in vivo reference tool for assessment of chemical 
sensitization, as results showed that sensitization endpoint was not specific enough and could 
exclude known human sensitizers as they did not reach the sensitization threshold in the LLNA 
method (i.e. nickel chloride). Therefore, this recent report calls for a careful review of the in 
vivo reference data using LLNA method, possibly to be replaced by a more suitable assessment 
method (Kolle, Hill, Raabe, Landsiedel, & Curren, 2019).   
Alternatively, there is also a human-based predictive assay for skin sensitization – the 
human repeated insult patch test (HRIPT). This assay is been used for the last few decades as 
a confirmatory test for skin sensitization (Marzulli & Mamach, 1974; Stotts, 1980). Briefly, 
this assay consists of two phases – an induction phase (exposure to the test sensitizer) and a 
challenge phase (exposure to a different area to challenge sensitization). During the induction 
phase, the test sensitizer is applied to the torso back area of the human volunteer in the form of 
a patch for a 24-hour period. The skin responses are read after 48 hours, to check for occurrence 
of skin allergies. This process is repeated for the next 15 days as a “repeat insult”, as the name 
of the assay suggests. After a rest period of at least 15 days, a challenge exposure is again 
performed in the torso back area tested during the induction phase and in a new area (naïve 
area), using the same method of a patch test for 24 hours. Occurrence of skin allergies are 
checked for the subsequent days. While there can be some variations to this protocol (type of 
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patch, duration of exposure, grading of skin allergies), the human repeat insult patch test is still 
widely acknowledged for assessment of skin sensitization (Mcnamee et al., 2008). 
Direct predictive comparisons between LLNA and the HRIPT methods have shown a good 
correlation of the sensitization threshold. From a dataset of 57 chemicals,  46 were correctly 
identified as sensitizers in both LLNA and HRIPT methods, with a correlation of r = 0.77 
(Schneider & Akkan, 2004). From a different dataset of 26 skin-sensitizing chemicals, 
correlation between LLNA and HRIPT methods was reported as r = 0.90 (David A. Basketter 
et al., 2005). 
Even though there are several studies reporting a significant correlation between animal 
models and human testing (Marzulli & Maibach, 1975; Schneider & Akkan, 2004), there are 
many others indicating that this relationship is not so linear (Frankild, Volund, Wahlberg, & 
Andersen, 2000; Nixon, Tyson, & Wertz, 1975; Phillips, Steinberg, Maibach, & Akers, 1972). 
While results may show that rabbits and mice are suitable animal models to assess skin 
sensitization because they report similar visible effects of skin damage by swelling, erythema 
or oedema, it is imperative to recall that these results are based on a non-human model. Thus, 
interspecies variability has a major effect in the assessment of skin sensitization and all data 
should be extrapolated with caution.  
The TGN1412 clinical trial (an immunomodulatory drug also known as CD28 super-
agonist monoclonal antibody)  is one of the most unfortunate examples of this hazardous 
correlation between animal models and human test trials (Attarwala, 2010). All preliminary 
safety studies of TGN1412 as potential immunomodulatory drug were performed in rodents 
and primates and was unable to predict that, when tested in man it would lead to a pro-
inflammatory cytokine storm and ultimately to multiple organ failure. As a result, during phase 
I clinical trials, six healthy volunteers developed multiple organ failure. Investigations 
concluded that the results from animal testing were misrepresentative since the animal model 
lacked expression of CD28, a cell receptor that binds to memory CD4+ T cells and induces a 
pro-inflammatory cytokine cascade in humans (Stebbings, Eastwood, Poole, & Thorpe, 2013). 
Because of this difference in the response between the test species and humans, it was 
impossible to predict any adverse effects. Ultimately, the preclinical safety testing that led to 
this human trial was not suitable or not properly representative of the human condition to which 





1.3.2. Mathematical models for evaluation of skin sensitization  
The LLNA method was developed as a tool to assess the sensitization potential of 
chemicals. An output of a stimulation index of 3 or higher would characterize the test chemical 
as a sensitizer. As use of LLNA increased for characterization of a larger range of sensitizers, 
cross-comparison of the stimulation indexes between the guinea pig and LLNA methods 
showed consistent results. For example, chemicals regarded as weak sensitizers in the guinea 
pig test would also present a low stimulation index in the LLNA test, while strong sensitizers 
would have a much higher stimulation index in the LLNA test (D. A. Basketter et al., 2000; Ian 
Kimber & Basketter, 1997). From these observations it was questioned whether LLNA could 
be used not only for identification of skin sensitizers, but also to calculate their potency via 
calculation of the concentration required to produce a positive 3-fold sensitization reaction. If 
possible, assessment of potency could then be used as a Quantitative Risk Assessment (QRA) 
tool for skin sensitization.  
QRA is a new in silico approach for assessment of skin sensitizers (Felter, Robinson, 
Basketter, & Gerberick, 2002; Felter, Ryan, Basketter, Gilmour, & Gerberick, 2003). It focuses 
on extrapolation of sensitization data from animal studies, as the LLNA method, for prediction 
of potency threshold of skin sensitization in humans using the HRIPT method. While the 
HRIPT method is not actually performed, the extrapolated threshold from LLNA data is used 
to lower the sensitization threshold considering several factors (as human variability, chemical 
exposure time and concentration). From this, an acceptable exposure level (upper limit 
threshold) is defined for a sensitizing chemical and compared to its consumer exposure level 
(if such sensitizing chemical was commercially marketed). If the consumer exposure level is 
higher than the acceptable exposure level, this becomes a safety issue as the marketed product 
has a higher exposure threshold than what is regarded as safe. If the acceptable exposure level 
is higher than the consumer exposure level, then the likelihood of sensitization occurrence is 
low and there is no imminent safe risk. QRA approach is very helpful for occupational health 
risk assessments as it does not normally require any human testing. However, in cases of 
uncertainty during the risk assessment analysis, safety testing using HRIPT might contribute to 





Alternatively, another potential in silico approach for characterization of skin sensitization 
is the use of quantitative structure-activity relationships (QSAR) regression models. The 
foundation for QSAR use started from the hypothesis of a possible quantitative correlation 
between the physicochemical properties of a chemical and its ability to be a skin sensitizer. For 
instance, how can the physicochemical properties as a set of predictors variables correlate to 
the potency of skin sensitization (response variable). This is because sensitizer chemicals that 
penetrate the skin will incur in covalent modifications of skin proteins and disrupt the cellular 
mechanisms, leading to an event of sensitization. The mechanism of action of chemicals into 
skin has been investigated for years (Landsteiner & Chase, 1939; Mayer, 1954) but it was only 
in 1982 that the physicochemical parameters of sensitizers were combined with a mathematical 
model to generate a quantitative structure-activity relationship (QSAR) (D. W. Roberts & 
Williams, 1982). Integration of QSAR models with LLNA data has also been shown (David A. 
Basketter, Roberts, Cronin, & Scholes, 1992), as well as prediction of skin sensitization 
according to chemical reactivity domain (Aptula, Patlewicz, & Roberts, 2005; David W. 
Roberts, Aptula, & Patlewicz, 2006). As the QSAR tool are improving and are evaluated 
against existing skin sensitization databases, it allows for better identification of sensitizing 
chemicals (either commercialized chemicals or those in development phase) without resorting 
to animal studies. There are in fact some computer-based predictive systems – Derek, TOPKAT 
and TOPS-MODE as in silico QSAR tools developed for prediction frameworks for skin 
sensitization (Kumar, Tangadpalliwar, Desai, Singh, & Jere, 2016) or even ocular irritation 
(Bhhatarai, Wilson, Parks, Carney, & Spencer, 2016). 
 
1.3.3. Legislation on safety testing  
The European Union (EU) is the major driving force in the implementation of legislation 
for safety testing, as the case of the Registration, Evaluation, Authorisation and Restriction of 
Chemicals (REACH) legislative action in 2006 (European Commission, 2006) and the 
Cosmetics Regulation action in 2009 (European Commission, 2009). REACH action addresses 
the impact chemical production and usage might have on human and environmental health, 
making risk assessment of all new compounds as mandatory. One of the key aspects of this 
action is the recommendation of alternative approaches to animal testing, either by predictive 
in silico modelling methods or by in vitro assays. The Cosmetics Action aimed to eliminate 
animal testing for cosmetics products, by establishing a 10-year prohibition phase of animal 
testing. This cosmetic ban was fully regulated and put into action from 11th March 2013, 
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marking the end of animal suffering for cosmetics purposes (European Commission, 2009). 
Together, these two legislative actions have dramatically changed the numbers of experimental 
animals used in cosmetic testing (European Commission, 2007, 2013). Moreover, assessment 
of sensitization by using animal models presents a major ethical dilemma associated with 
unnecessary discomfort and pain to which animals are subjected. Animal welfare supporters 
forced the cosmetic industry to look for safe and non-animal alternatives. The most famous 
case is perhaps the multimillion-dollar investment done by L’Oréal, a giant cosmetics brand, 
in 1997. To be ahead of the animal testing problem, L’Oréal acquired Episkin, a biotechnology 
company that developed in vitro animal alternatives, i.e.3D skin tissues for testing of adverse 
outcomes. And in 2011, L'Oréal opened its Predictive Evaluation Centre in Lyon, France. This 
allowed L’Oréal to use the lab-produced 3D skin tissues to test the efficacy of ingredients and 
tolerance of L’Oréal products before they were commercially ready. This in-house testing is a 
very smart strategic move as it results in cost-effective safety testing of all L’Oréal products 
with no animal suffering and good public outreach.  
But a lot still had to be done regarding animal use for scientific purposes. In 2011, the 
European Union Reference Laboratory for alternatives to animal testing (EURL-ECVAM) was 
officially created as a scientific research validation hub in Europe. Its key role was to validate 
methods that reduce, refine or replace (known as the golden 3Rs) animal use for safety testing 
and efficacy of chemicals and other compounds designed for human use. Research labs 
developing alternative methods to use of animal models can submit their work to EURL-
ECVAM for validation which, if approved, could become a benchmark method for non-animal 
safety testing worldwide.  
 
1.3.4. The golden 3Rs for animal alternatives  
Economical and ethical regulations have opened a need for more reliable alternative 
methods that could replace, reduce and refine animal experimentation. This concept was first 
introduced in 1959 by Russel and Burch as the golden 3Rs – reduce, refine and replace (Russel 
& Burch, 1959). In it, Russel and Burch defined the “reduction” concept as alternative methods 
that would provide the same information using less animals, like developing better 
experimental designs with relevant statistical support. The “refinement” concept would appeal 
for minimal pain and suffering throughout animal experimentation, encouraging any condition 
that would improve the animal well-being (i.e. anaesthetics, bigger cages, sacrifice before 
terminal pain). Lastly, and the most praised concept, the “replacement” concept would call for 
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animal-free alternative methods as in silico models or in vitro cell-based assays to assess human 
safety. In fact, the “golden 3Rs” can be achieved in the same alternative method, as an in vitro 
cell-based assay would replace the need of animal experimentation or reduce the number of 
animals required if the in vitro assay is used as a screening test during the pipeline development 
(Michael Balls, 2005). The “golden 3Rs” were officially included in Directive 86/609/EEC, as 
an attempt to regulate animal experimentation for scientific purposes across the European 
Union (European Commission, 1986). This directive was the first official document to demand 
priority of a scientifically reliable alternative method over animal experimental studies for 
scientific purposes (“Replacement and Reduction” concepts). However, this directive is no 
longer in force and was replaced by Directive 2010/63/EU, stating protection of animals used 
for scientific purposes as mandatory (focusing on the “Refinement” concept) (European 
Commission, 2010). 
 
1.3.5. Alternative non-animal approaches using skin models 
In response to the increasing EU legislations banning animal testing, several animal-
alternative models of reconstructed human skin have been developed and commercialized as 
replacements of the established animal models for sensitization testing. Human in vitro skin 
assays present a more genuine feedback in mimicking in vivo immunological responses since 
1) they are based in a human test condition; 2) are more reflective of the tissue 
microenvironment where cells reside and 3) are more predictive of the in vivo behavior of the 
cells. 
It all started in 1975 with the ground-breaking work of Rheinwald and Green, pioneers of 
cell tissue techniques regarding reconstructed human epidermis (RHE) models. It was the first 
report on successful in vitro culturing of human keratinocytes (Rheinwatd & Green, 1975). 
Using 3T3 fibroblasts as feeder layer, they were able to generate multiple colonies of 
keratinocytes from a single keratinocyte cell. This discovery was of immense importance, since 
it allowed for isolation and culture of larger quantities of keratinocytes in a monolayer culture.  
For many years following Rheinwald and Green´s pivotal work, monolayer culture of 
keratinocytes was the conventional technique for skin metabolism, skin disease (as burn wound 
or psoriasis) and skin toxicity studies (as cell death and/or cell viability upon chemical 
exposure).  
It rapidly became a standard protocol due to its reproducibility and consistency. From this, 
several in vitro two-dimensional (2D) monolayer cell-based assays were developed to assess 
skin sensitization.  
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One of the many in vitro cell-based assays developed for skin sensitization is the 
KeratinoSens™ assay. This test assay uses an immortalized cell line from human keratinocytes 
transfected with a luciferase report gene plasmid under the control of the antioxidant response 
element (ARE). It is an ARE-Nrf2 luciferase method because it detects activation of the Keap-
1/Nrf2 signaling pathway, the regulator of cellular responses to oxidative and electrophilic 
stress. It allows for quantitative measurement of sensitization by light signalling of the 
luciferase gene induction (Emter, Ellis, & Natsch, 2010). It is widely used for assessment of 
skin sensitization to chemicals (Belot, Sim, Longmore, Roscoe, & Treasure, 2017; Natsch, 
Emter, Gfeller, Haupt, & Ellis, 2015; Settivari et al., 2015), as it has a reported 77% predictive 
capacity (79% sensitivity  and 72% specificity) in a testing set of 145 chemicals (Natsch et al., 
2013). This assay was formally validated by ECVAM in 2015 and a detailed protocol can be 
found in Testing Guideline 442D – “in vitro Skin Sensitisation: ARE-Nrf2 Luciferase Test 
Method” (OECD, 2015b). 
The human cell line activation (h-CLAT) assay is another assay which is commonly used 
for assessment of skin sensitization. It measures dendritic cell activation by expression of CD86 
and CD54 cell surface markers on THP-1 cells, a human monocytic leukaemia cell line. 
Increased expression of CD86 and CD54 markers upon exposure to the test chemical indicates 
activation of dendritic cells and T cell priming, confirming the test chemical as sensitizer (as 
opposed to a non-sensitizer that will not elicit expression of CD86 and CD54) (Sakaguchi et 
al., 2006). Co-expression of CD86 and CD54 has an overall accuracy of 89% in prediction of 
sensitizers (Sakaguchi et al., 2006). This assay was formally validated by ECVAM in 2018 and 
a detailed protocol can be found in Testing Guideline 442E – “in vitro skin sensitisation assays 
addressing the key event on activation of dendritic cells on the adverse outcome pathway for 
skin sensitisation” (OECD, 2018) 
Formerly known as MUSST (myeloid U937 skin sensitization test), U-SENSTM is also an 
in vitro test for the assessment of skin sensitization. It is similar to h-CLAT test and measures 
the CD68 marker for dendritic cell activation, but it is performed using a myeloid U-937 cell 
line instead (Ade, Martinozzi-teissier, Pallardy, & Rousset, 2006; Piroird et al., 2015). This 
assay was formally validated by ECVAM in 2018 and a detailed protocol can be found in 
Testing Guideline 442E – “in vitro skin sensitisation assays addressing the key event on 
activation of dendritic cells on the adverse outcome pathway for skin sensitisation” (OECD, 
2018). The reported predictive capacity of this assay is of 71%, with a 71% sensitivity and 70% 
specificity and this assay (Natsch et al., 2013). 
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However, growing concerns for the predictive capacity of these 2D test assays have 
questioned their feasibility and relevance to human safety. Monolayer 2D skin cultures do not 
resemble real human skin because they do not present stratified epidermal layers, and this is 
considered a crucial feature for an accurate in vitro model of skin. Considering that monolayer 
cultures grow in submerged conditions on a flat surface (bottom of a plastic well plate), this 
does not provide favourable conditions for keratinocytes to differentiate into the different 
stratum of real skin (Klicks, Molitor, Ertongur-fauth, & Hafner, 2017; Vollmers et al., 2012). 
In fact, 2D culture conditions may actually alter cell morphology or even gene expression 
(Hewitt et al., 2013). These concerns have triggered a change in the cell culture realm, with the 
focus changing from monolayer cell cultures to multilayer three-dimensional (3D) models. This 
resulted in the development of new in vitro RHE models, that are more physiologically similar 
to real human skin as they present a multi-layered cell organization with different stages of cell 
differentiation, mimicking the different skin layers of human skin. The establishment of RHE 
models have opened a world of new possibilities regarding skin studies such as cell-cell 
interactions, cell differentiation, skin barrier functionality, skin metabolism and even wound 
healing studies (Klicks et al., 2017).  
Overall, these reconstructed skin models can either be epidermal equivalents (where the 
multi-layered keratinocytes grow on a synthetic scaffold) or full-skin equivalents (in which the 
multi-layered keratinocytes representing the epidermis grow on top of a fibroblast matrix 
representing the dermis). Nevertheless, both versions of the skin equivalent models present a 
stratum corneum layer due to the air-liquid interface (ALI), mimicking a typical human 
epidermal barrier. One of the very first 3D model of skin was described in 1976 (Freeman, Igel, 
Herrman, & Kleinfeld, 1976), where pig skin was used as a “collagen bed” for the expansion 
and differentiation of human keratinocytes. This was later optimized by the use of a collagen 
matrix as base layer to culture keratinocytes to an air-liquid interface (Lillie, MacCallum, & 
Jepsen, 1980). From this primordial 3D model of skin, many more models have emerged over 
the years becoming more applicable and easier to access.  
Nowadays, there are many commercially available RHE models available as end-point 
products for assessment of skin testing. While all skin reconstructed models are based on a 
multi-layered keratinocyte approach, they differ in the origin of the keratinocyte cells provided 
(usually from abdominal or foreskin as surgical waste), in the specifications of the membrane 
(either coated with collagen from an animal source or polycarbonate), the insert size and its 
application for testing purposes. The most commonly used RHE model for skin irritation and 
skin corrosion in vitro testing is the EpiDermTM model from MatTek 
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(https://www.mattek.com/products/epiderm/). This is a ready-to-use RHE model consisting of 
human-derived epidermal keratinocytes from foreskin or abdomen region, cultured on a 
collagen coated scaffold with an insert size of 0.6 to 4cm2 depending on cell culture 
requirements. This RHE is phenotypically similar to human skin, as it also presents a multi-
layered epidermal region, with a stratum corneum, stratum spinosum and stratum basale regions 
(Figure 2).  
 
 
Figure 2. Histological comparison between human skin and a commercially available RHE model.  The commercially 
available RHE model from MatTek, EpiDermTM shows histological similarity with human skin, with presence of the different 
epidermal layers – stratum corneum, stratum spinosum and stratum basale.    
 
 
The marketing point of this RHE model is the fact that is validated by ECVAM for different  
in vitro testing purposes – skin irritation (Hartung, 2007) and skin corrosion (ECVAM, 2000) 
as described further in section 1.6. Thus, this RHE is the leading RHE in the market for 
toxicology studies. Moreover, the continuous R&D investment from MatTek in this RHE 
model will eventually result in its ECVAM validation for further applications like phototoxicity 
or drug absorption studies. 
As mentioned before, a cosmetic company (L’Oréal) bought EpiSkin to acquire its 3D skin 
models for in house toxicology testing of its products. L’Oréal is also selling its 3D skin model 
as a ready-to-use assay for toxicology testing to cosmetics, pharmaceutical and chemical 
manufacturers (http://www.episkin.com). There are two commercially available RHE models 
being sold by L’Oréal/Episkin – the EpiSkinTM and the Skin EthicTM. The EpiSkinTM model 
consists of keratinocytes from the abdomen region cultured in a collagen-coated scaffold and 
can be used for skin irritation, corrosion, UV exposure and permeability studies. The Skin 
EthicTM can also be used for the same applications but instead of a collagen-coated scaffold, 






validation for skin irritation (ECVAM, 2009c; Hartung, 2007) which increases their marketing 
value. L’Oréal/Episkin is also currently working on expanding their ECVAM validation 
portfolio for phototoxicity and absorption studies.   
Smaller scale companies like Cell Systems® GmbH also have a commercially available 
RHE model, the epiCS (previously known as EST1000®). Information regarding this RHE 
model is not very much known as there is no specifications about the origin of keratinocytes 
used for this RHE model. It is known, however, that keratinocytes are grown in a polycarbonate 
scaffold with an insert size of 0.6cm2. This RHE model can be used for skin corrosion and 
irritation studies, as well as phototoxicity and absorption studies. Full details of all RHE models 





Table 1. Characteristics of commercially available Reconstructed Human Epidermis (RHE) skin models. RHE models differ in the origin of cells, the scaffold specifications and its 
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These RHE models are widely available as “ready-to-use” products with guaranteed 
quality control performance and reproducibility. Such high standards of good manufacturing 
practice and its predictive capacity have enabled some of these RHE to be validated by EURL-
ECVAM criteria for testing of skin toxicity for irritation and corrosion purposes. This 
validation “endorsement” represents a great marketing value, since the validated RHE model 
can then be considered a benchmark RHE model for skin testing. While these commercially 
available reconstructed models of human epidermis are trademark protected (by their “know-
how” and cell culture requirements), there are some open source protocols for the development 
of reconstructed human epidermis models (Groeber et al., 2016; Jung et al., 2014; Pedrosa et 
al., 2017; Roger et al., 2019). 
 
1.4. Animal-free toxicity test methods for regulatory decision-making  
Rheinwald and Green’s work was the starting point for investigating skin toxicity, with 
years of further development and improvement of new in vitro animal-alternative assays for 
assessment of topical toxicity to chemicals. Governmental organizations have become involved 
in this issue, making sure that experimental protocols and guidelines regarding assessment of 
toxicity are openly accessed and followed in a standardized fashion. The Organization for 
Economic Cooperation and Development (OECD) is an intergovernmental economic 
organization founded in 1961 with the goal of worldwide economic and trade improvement. It 
provides a platform for good practices, policy recommendations or general guidelines that will 
promote growth and stability regarding economic, environmental and social issues.  
The need for a change regarding animal-based toxicity approach was the priority for both 
the regulatory and governmental authorities as the OECD, enforcing the use of mechanistic 
pathway-based data (molecular/cellular level), incorporating computational in silico methods 
and animal-free in vitro assays from human data (National Research Council, 2007). But 
because there was a risk of insufficient knowledge regarding how pathway-based toxicity 
methods would result in toxic adverse outcomes at the organism level, a new regulatory 
framework was developed to collect, evaluate and establish link elements between the different 
levels of biological organization. In 2012, OECD launched a new program for the development 
of adverse outcomes with regulatory relevance, called Adverse Outcome Pathway (AOP) 
(OECD, 2012b). It is a structural representation of critical toxicological events that could 
ultimately lead to an unexpected adverse outcome. AOPs have a broad range since they are a 
linear progression covering from molecular scale events up to organism responses (Figure 3). 
An AOP starts with a molecular event of toxic consequences that is followed by causally related 
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key events of increased toxicity, ultimately leading to an adverse outcome of regulatory 
importance. The adverse outcome can occur at the organism or population level and result in 




Figure 3. Schematic representation of an Adverse Outcome Pathway (AOP). AOPs are a conceptual map for toxicity 




AOPS are tools of great relevance for risk assessment of new products or assays involving 
human safety, as in the case of skin toxicity (Vinken, 2013).  In fact, OECD guidelines highly 
recommend elaboration of AOPs for any newly developed product or method related to human 
safety during risk assessment. This is because AOPs allow to shape the available knowledge 
on a specific substance from in silico and in vitro assays approaches into a framework, 
identifying possible information gaps in its toxicity profile and ultimately mapping the 
sequence of events leading to an adverse outcome. Therefore, an AOP is crucial to improve the 
predictive capacity of these in silico and in vitro assays approaches, highlighting the importance 
for animal-free toxicity testing approaches.  
OECD has released the OECD’s AOP Knowledge Base tools – the AOP Portal, the AOP 
Wiki and the Effectopedia, a web-based platform that aims to collect all available information 
on how chemicals induce adverse outcomes into an AOP “encyclopaedia”. The AOP Portal 
(https://aopkb.oecd.org/) is the main focus of this AOP Knowledge Base, and it works as a 
user-friendly search engine for AOP key events and data input. It is an important search tool 
for all OECD endorsed AOPs.  
The AOP Wiki is the most commonly used tool as it allows for development of new AOPs 
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published research on network pathways of toxicity or information of newly developed 
chemicals (https://aopwiki.org/).  
Finally, Effectopedia focuses on improving of the predicative capacity of in silico and in 
vitro tools using the AOP data input from the AOP Wiki. This AOP “encyclopaedia” allows 
the user to input test data into an interface template and generate quantitative relationships 
between pathway elements and key events for adverse outcomes. The user-friendly model 
template makes it simple to upload data in a standardized manner and compare against relevant 
information provided by other users in the database. This will not only allow to share and 
improve AOP information but also improve the interface model´s predictive capacity for in 
vitro toxicity tools (https://www.effectopedia.org/).  
The first AOP officially endorsed by the OECD related to skin sensitization, named “Skin 
Sensitization Initiated by Covalent Binding to Proteins” (reference: 
ENV/JM/MONO(2012)10/PART1) (European Commission, 2012). This AOP describes four 
key events that lead to skin sensitization by covalent binding of chemical substances to proteins. 
The first key event is at the molecular level, where the chemical interacts with the skin proteins 
by covalently binding to lysine residues. This is considered the site of action. The second key 
event is at the cellular level, the keratinocytes. This level is described as an inflammatory 
response with gene expression for cell signalling pathways. The third key event refers to 
activation of dendritic cells, with expression of cell activation markers and cytokine release. 
Lastly, the fourth key event concerns T cell proliferation, measured in the murine Local Lymph 
Node Assay (at organism level). This AOP includes 3 levels of biological organization – 
molecular, cellular and organism events that leads to skin sensitization as an adverse outcome. 
More AOPs have since been endorsed and published by the OECD and can be found in the 
OECD “Series on Adverse Outcome Pathways” section of the OECD online library 
(https://www.oecd-ilibrary.org/environment/oecd-series-on-adverse-outcome-pathways.com). 
Overall, AOPs are very important risk assessment tools as they bring together existent 
knowledge into a predictive platform, allowing to prioritize risk assessment (by improved and 
updated knowledge by users) and refine predictive tools. AOPs can also be included in the 
development of QRA and QSAR tools as they contribute with a hierarchical order of adverse 
events. This will refine the predictive capacity of QSAR tools for the different biological levels 
(molecular, cellular, organ, organism). 
AOPs have raised the standards for assessment of toxicology, since it requires a more 
detailed planning and toxicity impact of any newly developed product or assay for toxicology 
purposes. Alongside AOP’s guidelines, OECD has also provided several testing guidelines 
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(TG) as standardized protocols for assessment of skin toxicity (OECD, 2013, 2014, 2015a). 
These TGs have become imperative for the commercialization of RHE and its testing purposes 
and are now widely followed for validation and commercialization purposes. As so, AOPs have 
been implemented in all marketing strategies and TGs have become the standard for research 
development of new in vitro assays for skin toxicity. These two perspectives are crucial for any 
in vitro assay seeking OECD approval.  
 
1.5. Validation of alternative skin equivalent 3D methods  
Formal validation of an alternative method should only occur if that alternative method is 
to be used for regulatory purposes – i.e. a regulatory toxicity in vitro test for human safety or 
production and handling of chemicals (M. Balls & Fentem, 1999). If the alternative method is 
only to be used for fundamental research, in-house product development or product safety 
purposes, it does not require formal EURL-ECVAM validation. 
Any alternative in vitro skin model seeking formal EURL-ECVAM validation for 
regulatory toxicology needs to prove comparable reliability, reproducibility and scientific 
relevance to the conventional animal test (Michael Balls et al., 1995; CPMP, 1997; Liebsch & 
Spielmann, 2002).  
Reliability is defined as reproducibility of the in vitro assay results for intra- and inter-
laboratory conditions over time (Michael Balls et al., 1995). Scientific relevance is defined by 
the scientific usefulness and added value of a specific alternative method for a scientific 
purpose (Michael Balls et al., 1995; CPMP, 1997). These two parameters are deeply linked, as 
an alternative method that shows reliable results, but no added value, is as irrelevant as an 
alternative method with a relevant scientific scope but showing unreliable results. 
The reliability and scientific relevance of any alternative in vitro test should be investigated 
using substances with known in vivo toxicity effects as suitable reference standards (M. Balls 
& Fentem, 1999; Michael Balls et al., 1990). Such reference standards should i) be easily 
obtained in a chemically pure and stable form, ii) should cover the complete in vivo toxicity 
spectrum (from low to high toxicity level) and iii) correlate with known reproducible in vivo 
toxicity data (preferably human data).  
There are five main processes that an in vitro alternative method needs to go through for 
EURL-ECVAM validation: test development, pre-validation, formal validation, independent 
assessment and regulatory acceptance (M. Balls & Fentem, 1999; Michael Balls et al., 1995; 
Hartung et al., 2004).  
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Firstly, test development of an in vitro alternative model involves definition of its scientific 
purpose and its target organ (i.e. skin, eye, liver), as well as the type of assessment it delivers 
(toxic, potency, hazard or risk assessment) and the chemical spectrum (range of chemicals 
possible to test in the model). A detailed protocol should also be included to allow for inter-
laboratorial transferability. 
Secondly, a pre-validation test is mandatory before formal validation as this step will focus 
on any necessary protocol optimization or standardization, risk assessment and identification 
of critical steps regarding test design and procedure and initial inter-laboratorial transferability 
strategy.  
Only after pre-validation, can validation by inter-laboratorial blind performance take place. 
A blind inter-laboratorial test validation is crucial to show the in vitro alternative model’s 
reliability and relevance. This performance analysis can include a “training set” with the coded 
chemical test range. Data analysis and assessment of outcome results of the blind inter-
laboratorial test validation are then published and submitted for independent assessment.  
The published results from the inter-laboratorial test validation are reviewed by 
independent panels, at either national or international level. The independent panel can include 
governmental bodies, industry associations or societies and it should be representative of the 
toxicological, industrial and animal welfare communities. However, all members of the panel 
should be independent to any alternative model being revised. If the independent panel agrees 
that the in vitro alternative method meets the criteria for test development and validation, the 
validated in vitro alternative method is then submitted to the EURL-ECVAM office for 
consideration for regulatory acceptance (OECD, 2005).  
Currently, not many alternative models going through this process have been validated, 
despite years of exhaustive research and validation efforts. Failure to achieve validation can be 
caused by insufficient in vivo data or in vivo data from animal studies that does not have relevant 
comparison to human studies. Additionally, design of experiments lacking proper statistical 
analysis or protocol transferability is sufficient to delay validation (M. Balls & Fentem, 1999).  
 
1.6. Validated 3D skin models for regulatory skin toxicity  
Currently, only a few in vitro assays have been approved by OECD for regulatory skin 
toxicity in the different classification groups of topical toxicity. This is not because the currently 
available RHE models are not good enough to be validated, but rather because the validation 
process can be lengthy and expensive (as described in the section before). 
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According to OECD guidelines, there are different categories of topical toxicity – irritation 
(eye and skin), corrosion (skin), phototoxicity and sensitization (skin). This study will only 
focus on skin irritation. The difference between skin irritation and skin corrosion relies in the 
severity and irreversibility of the damage caused by the testing chemical.  Corrosion refers to 
irreversible damage of the skin (visible necrosis through the epidermis layer), while irritation 
refers to reversible damage to the skin following application of test chemical (itching and/or 
rash symptoms).  
OECD has released two very important testing guidelines for assessment of irritation and 
corrosion. Testing Guideline 439 (TG 439) refers to testing of chemicals for in vitro skin 
irritation in reconstructed human epidermis test models and it should be used to determine the 
skin irritancy of chemicals (OECD, 2013). Testing Guideline 431 (TG 431) refers to testing of 
chemicals for in vitro skin corrosion in reconstructed human epidermis test models and it use 
allows identification of non-corrosive and corrosive substances (OECD, 2014). 
Current regulatory requirements as the “Classification, Labelling and Packaging (CLP) 
regulation 1272/2008”  (European Commission, 2008) demand detailed information regarding 
the irritation or corrosion potential of a new chemical, as part of the AOP and risk assessment 
regarding its handling, transport or storage. Therefore, all new chemicals have to be tested for 
topical toxicity using the OECD testing guidelines for irritation chemicals - TG 439 (OECD, 
2013), or corrosion chemicals - TG 431 (OECD, 2014).  
Currently, the accepted testing methods for skin irritation and corrosion include both in 
vivo animal testing (Draize rabbit test, TG 404 (OECD, 2015a)) and in vitro test methods (based 
on RHE models). To date, EURL-ECVAM has only validated three of the currently available 
RHE models for skin irritation (Table 2) and four for skin corrosion testing (Table 3). 
 
 









current SOP1 for 
testing method 
EpiDermTM 
TG 439 – skin 
irritation 
2009 (Hartung, 2007) (MatTek, 2008) 
EpiSkinTM 2007 (Hartung, 2007) (EpiSkin, 2009) 
SkinEthicTM RHE 2009 (ECVAM, 2009d) (SkinEthics, 2009) 













current SOP1 for 
testing method 
EpiDermTM 
TG 431 – skin 
corrosion 
2000 (ECVAM, 2000) (MatTek, 2012) 
EpiSkinTM 1998 (ECVAM, 1998) (EPISKIN, 2013) 
SkinEthicTM RHE 2006 
(Kandárová et al., 
2006) 
(SkinEthic, 2012) 
epiCS 2009 (ECVAM, 2009a) (EpiCS, 2012) 
1 Standard operating procedure 
 
 
1.7. Testing Guidelines for skin toxicity testing 
Presently, the only regulatory accepted method for evaluation of skin irritation is Testing 
Guideline 439 (OECD, 2013). TG 439 defines skin irritation as reversible skin damage caused 
by application of a test chemical for up to 4 hours as defined by the Globally Harmonised 
System (GHS) of Classification and Labelling of chemicals (REF) (UN, 2009). According to 
GHS guidelines, there are several criteria that need to be met for a substance to be classified as 



















Table 4. Classification of corrosive and irritant substance under Globally Harmonised System (GHS) criteria. A 
substance is classified as corrosive (category 1) or irritant (category 2) according to performance criteria from in vivo or in 
vitro results. 
Category Classification Criteria 
Category 1 
Corrosive  
- Human experience showing irreversible damage to the skin; 
- Structure or mode of action similar to a substance already classified as 
corrosive; 
- pH extremes of <=2 and >=11.5 including acid/alkali reserve capacity; 
- Positive results in a valid and accepted in vitro skin corrosion test; 
- Animal experience or test data that indicates that the substance causes 
irreversible damage to the skin following exposure of up to 4 hours. 
Category 2 
Irritant 
- Human experience or data showing reversible damage to the skin following 
exposure of up to 4 hours; 
- Structure or mode of action similar to a substance already classified as 
irritant; 
- Positive results in a valid and accepted in vitro skin irritation test; 
- Animal experience or test data that indicates that the substance causes 
reversible damage to the skin following exposure of up to 4 hours. 
 
However, many commercially available chemical products are still labelled as “no GHS 
category”. This means that the toxicity test results for that chemical were not substantial enough 
to classify it as irritant or corrosive (UN, 2009).  Therefore, these chemicals might still be 
hazardous by lack of relevant in vivo or in vitro scientific data.  
TG 439 provides a detailed protocol for identification of irritant chemicals from GHS 
category 2 using an in vitro RHE model with similar physiological properties to human 
epidermis. For EURL-ECVAM validation, any in vitro alternative model needs to demonstrate 
reliability and accuracy performance by determination of irritancy of 20 reference chemicals 
(Table 5).  
Performance results from the proposed in vitro alternative model (i.e. reliability and 
accuracy) need to be comparable or better than the Validated Reference Methods (VRM). 
Currently, the 3 accepted VRMs are the 3 RHE models validated by EURL-ECVAM: 
EpiSkin™, EpiDerm™ SIT (EPI-200) and SkinEthic™ RHE. These RHE models are 
considered VRMs because they were used to define the Performance Standards of TG 439 
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(ECVAM, 2009b). Performance Standards of TG 439 include viability, reproducibility, quality 
control and predictive capacity (sensitivity and specificity). 
In order to facilitate TG 439 validation, EURL-ECVAM guidelines determined that the list 
of reference chemicals include chemicals that are commercially available and representative of 
the full range of Draize irritancy scores (from non-irritant to strong irritant); have a well-defined 
chemical structure; and they are not associated with an extremely toxic profile (e.g. 
carcinogenic or toxic to the reproductive system) and they are not associated with prohibitive 
disposal costs (ECVAM, 2009b). Therefore, Table 5 includes chemicals ranging from low 
irritation potential (in vivo Draize score of 0) to high irritation potential (in vivo Draize score 
of 3), chemicals lacking GHS in vivo data (non-classified chemicals) and irritant chemicals 
with GHS category 2 (classified chemicals).  
Regarding protocol guidelines, TG 439 skin irritation assessment with RHE models 
measures the initial events of cell death (keratinocytes) upon chemical exposure by cell 
viability, focusing only on damage to the stratum corneum. Quantification of cell viability is 
performed by direct MTT ([3-(4,5- Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, 
Thiazolyl blue; CAS number 298-93-1] dye reduction. Threshold for irritancy is defined as a 
reduction in cell viability greater than 50%. 
TG 431 skin corrosion assessment with RHE models measures the ability of the chemical 
to penetrate the stratum corneum and become cytotoxic to the skin layers bellow. Cell viability 
is also measured by reduction of MTT viability dye. Threshold for corrosion is defined as a 
reduction in cell viability greater than 50% (threshold differs according to the RHE used but 
explanation of threshold can be found in TG 431). 
Not considering specific features inherent to each in vitro model, TG 439 (skin irritation) 
and TG 431 (skin corrosion) have similar protocols. Both guidelines are based in direct topical 
exposure of a well characterized chemical according to GHS standards for a short time period. 
This is followed by a washing step (to mimic a real human response after chemical exposure) 
and assessment of toxicity is assessed after an incubation period by defining the cell viability 
by MTT reduction. However, specific protocol parameters should be followed for each RHE 
requirements including volume of testing chemical, chemical application time, medium volume 







Table 5. Minimum List of Reference Chemicals for Determination of Accuracy and Reliability Values for Similar or 

















1-bromo-4-chlorobutane 6940-78-9 Liquid 0 Cat. 2 No cat. 
diethyl phthalate 84-66-2 Liquid 0 No cat. No cat. 
Naphthalene acetic acid 86-87-3 Solid 0 No cat. No cat. 
Allyl phenoxy-acetate 7493-74-5 Liquid 0.3 No cat. No cat. 
Isopropanol 67-63-0 Liquid 0.3 No cat. No cat. 
4-methyl-thio-
benzaldehyde 
3446-89-7 Liquid 1 Cat. 2 No cat. 
Methyl stearate 112-61-8 Solid 1 No cat. No cat. 
Heptyl butyrate 5870-93-9 Liquid 2 No cat. No cat. 
Hexyl salicylate 6259-76-3 Liquid 2 No cat. No cat. 
Cinnamaldehyde 104-55-2 Liquid 2 Cat. 2 No cat. 
Classified chemicals 
1-decanol 112.30-1 Liquid 2.3 Cat. 2 Cat. 2 
Cyclamen aldehyde 103-95-7 Liquid 2.3 Cat. 2 Cat. 2 




86604-75-3 Solid 2.7 Cat. 2 Cat. 2 
di-n-propyl disulphide 629-19-6 Liquid 3 No cat. Cat. 2 
Potassium hydroxide 
(5% aq.) 
1310-58-3 Liquid 3 Cat. 2 Cat. 2 
Benzenethiol, 5-(1,1-
dimethylethyl)-2-methyl 
7340-90-1 Liquid 3.3 Cat. 2 Cat. 2 
1-methyl-3-phenyl-1-
piperazine 
5271-27-2 Solid 3.3 Cat. 2 Cat. 2 
Heptanal 111-71-7 Liquid 3.4 Cat. 2 Cat. 2 
Tetrachloroethylene 127-18-4 Liquid 4 Cat. 2 Cat. 2 





1.8. Development of a novel reconstructed human epidermis culture  
The EURL-ECVAM validated models mentioned above present two similar features - first, 
their protocol is patent protected to protect the “know-how” involved in their production; 
secondly, most of these RHE models are not entirely animal-free as they rely on animal-based 
collagen-coated scaffolds for differentiation of keratinocytes. 
The protected protocol specifications for production of these RHEs is proportionally 
correlated with their financial cost. Additionally, the costs involved in shipment of the models 
and possible customs fees impose a heavy monetary burden for research purposes. It could be 
argued that standardized and quality controlled RHE models for testing purposes are worth 
such investment, but the constant purchase necessity of these RHE models can easily make a 
cheaper alternative more appealing. Some research labs worldwide are focusing on open source 
reconstructed epidermis (OS-REp) models to combat the purchase of commercial RHE models 
for research purposes. As the main advantage to use open source RHE models is the monetary 
cost, since in house development of an RHE model is cheaper than the commercialisation of 
one. However, it also means that quality control and standardization of the RHE model is not 
guaranteed as it is not limited by strict Good Laboratory Practises (GLP) and Good 
Manufacturing Practices (GMP). Therefore, research labs using open source RHE need to be 
make sure they have an optimized protocol that will always provide consistent RHE models 
over time for different users. This is key for a good performance of the RHE model. Therefore, 
it is crucial to have excellent cell culturing techniques and adequate laboratory training, as well 
as a good source of primary cells.  Moreover, it also means lengthy development times as cell 
culturing is required for open sources RHE, while commercially available RHE models are 
ready to use. Consequently, open source RHE models can be more advantageous from a 
financial perspective but adequate laboratory practices need to be put in place to guarantee 
standardized quality and performance of the RHE model. 
The concept for open source was first introduced in the informatics world around 1980s, 
with LINUX (Linus Torvald's Uniplexed Information and Computing System) as the first open 
source software. Later, the first open access platform relevant for the scientific field started 
with the introduction of open access repositories (as PUBMED) and open access journals (as 
the Public Library of Science, PLOS One Online Journal). These open access platforms 
changed the way the user can access information freely for non-commercial purposes. Bringing 
the concept of open access into the skin toxicity domain allows for easy access to protocols and 
guidelines on how to develop in-house RHE models for toxicity testing. This was done by the 
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pioneering work of Yves Poumay (Y Poumay et al., 2004), published in 2004 and it is, 
presently, the foundation for some OS-REp protocols currently published (Mewes et al., 2016; 
Pedrosa et al., 2017). This work aimed to develop an open source 3D epidermal skin culture 
that could fulfil the quality standards of RHE models for toxicity studies. 
Poumay’s work (Y Poumay et al., 2004) describes a free access protocol for establishment 
of a reconstructed epidermal model, using human epidermal keratinocytes (Figure 4). Primary 
keratinocytes isolated from a skin explant were seeded onto a polystyrene scaffold and left 
submerged in culture medium for a maximum period of 24 hours. Afterwards, culture medium 
was replaced but the volume of the new medium added was now reduced in order to only reach 
the scaffold, leaving the keratinocyte layer exposed to the air to encourage keratinocyte 
differentiation into the different epidermal layers. This concept was described as the Air-Liquid 
Interface (ALI), in which the keratinocytes grow in between a liquid and air phase (Pruniéras, 
Régnier, & Woodley, 1983). ALI resembles the real skin microenvironment as the top layer 
(stratum corneum) also grows in between a liquid and air phase. The 3D RHE model was left 
in the ALI phase for 14 to 19 days, to allow differentiation of the keratinocytes into the different 
skin layers – organized layers of stratum basale, stratum spinosum and stratum corneum that 
can resemble real human epidermis.  
This current thesis aimed to replicate Poumay’s work, using an open source protocol with 





Figure 4. Schematic representation of the development of a 3D reconstructed human epidermis. Primary keratinocytes 
are seeded onto a polystyrene scaffold and left submerged for an initial period of 24 hours. Afterwards, scaffold is raised into 
air-liquid interface (ALI) for 14 to 19 days. The final 3D reconstructed epidermis presents typical features of human skin, with 


















The fact that the commercially available RHE models are not entirely animal-free, can be 
seen as a disadvantage for the culture and differentiation of skin cells. While not significant for 
the output of the skin irritation assay, it is still an important feature as it depreciates the concept 
of creating animal-free RHE models for safety testing in humans. Therefore, this thesis aimed 
to develop an open source 3D skin culture model using no animal collagen for the assessment 
of in vitro skin irritation following TG 439 (Chapter 4). Following the work originally 
developed by Poumay et al. (2004), the open source 3D skin culture model was developed using 
a porous scaffold containing no animal-based collagen or polycarbonate – the Alvetex® 
scaffold membranes. 
 
1.9. Limitations of RHE models for skin sensitization 
The global development and acceptance of in vitro assays for skin sensitization over in 
vivo models was greatly empowered by regulatory bodies seeking to end animal suffering. 
Rapidly, these in vitro assays fulfilled all legal requirements to halt animal testing for skin 
toxicity purposes. Among the many advantages of using in vitro assays over in vivo models, is 
the fact that in vitro assays are usually faster (no need for animal breeding and/or sacrifice) and 
more standardized than in vivo animal models (Liebsch & Spielmann, 2002; Zucco, De Angelis, 
Testai, & Stammati, 2004).  
In vitro assays also usually require smaller amounts of the test substance than in vivo 
models, which could be important during discovery and development phase if substance 
availability is low. Moreover, the use of in vitro assays during a substance development phase 
could result in better and earlier screening of safe substances for human consumption (Zucco 
et al., 2004). Additionally, it would stop the need for data extrapolation from in vivo animal 
models (Worth & Balls, 2001).  
But while the in vitro assays are a major step forward regarding safe alternative approaches 
to animal testing, full safe prediction of skin sensitization with these models is not yet realistic 
as they are not fully equivalent to in vivo human skin. The major drawback of these models is 
the fact that they only focus on the molecular and cellular stages of the AOP hierarchy, leaving 
out the organ and organism stages. This disadvantage is major as any adverse outcomes in the 
organ and organism stages would not be predicted by the in vitro assays, jeopardizing human 
safety. Moreover, these in vitro assays also lack sufficient skin barrier function (SCCS - 
Scientific Committee on Consumer Safety, 2010) and generally present a higher permeability 
rate (Schäfer-korting et al., 2008; Schmook, Meingassner, & Billich, 2001; Schreiber et al., 
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2005). This could be seen as an advantage, by increasing the sensitivity threshold of the model 
but it can also lead to an overrated prediction of sensitization due to the higher rate of 
permeability. 
Considerable efforts have been made to increase the complexity of in vitro models to 
mimic real in vivo human skin. However, to build more physiologically relevant human skin 
models, other skin components such as pigmentation, immunity, innervation and 
vascularization which are involved in the sensitization process would need to be incorporated, 
which remains a serious challenge (Abaci, Guo, Doucet, Jackow, & Christiano, 2017). 
Consequently, these models are less suitable for testing the efficacy of biopharmaceutical or 
cosmetic products, in which important inflammatory responses (cell activation, cell damage, 
cytokine release) are important output parameters. Therefore, screening of biopharmaceuticals 
and cosmetics is more often performed in cell-based assays than in in vitro 3D models 
An alternative to the RHE models for skin sensitization assays (and without resourcing to 
in vivo animal models) is ex vivo human skin samples. These ex vivo skin explants are usually 
obtained from plastic surgery as disposable tissue. Due to the increase of abdominoplasty 
procedures and breast augmentation surgery, it has become easier to gain access to disposable 
human skin samples. Ex vivo human skin is considered the best surrogate for in vivo human 
skin, since it holds normal skin barrier function, presents a mature stratum corneum and 
comprises innervation and vascularization (Franz, Lehman, & Raney, 2009).  
There is an array of companies that specialize in providing normal and diseased human 
skin tissue samples for testing purposes, such as Tissue Solutions (UK), GenoSkin (France), 
SeraLab (Spain) or BioPredict (USA). But the difficulty remains in being able to replicate the 
in vivo microenvironment with the tissue and the immune cells, and the cause-consequence 
relationship they have in vivo. Alcyomics Ltd (www.alcyomics.com) is one of few companies 
that can replicate this in vivo niche, by providing a model which uses autologous (from the 
same individual) tissue and immune cells for in vitro safety testing on in-house ex vivo skin 
models. 
Therefore, this work aimed to use the Alcyomics ex vivo skin model, Skimune®, to 
evaluate immunotoxicity by aggregated monoclonal antibodies (Chapter 5). Compared to the 
open source 3D skin culture model, the ex vivo skin model comprises of skin tissue and immune 
cells (i.e Dendritic Cells and T cells) so the measurement of immunotoxicity is more 




1.10. Alcyomics  
Alcyomics is a UK based Newcastle University spin out company founded by Professor 
Anne Dickinson in 2007. It provides a human in vitro pre-clinical safety service for testing 
novel compounds (biopharmaceuticals, cosmetics, chemical) before human administration. The 
technology available at Alcyomics is a suitable alternative to animal testing, because it can 
accurately predict the likelihood of adverse immune events in a human perspective (Ahmed et 
al., 2016, 2019). 
 
1.10.1. A novel skin explant assay for  assessment of adverse immune 
reactions  
Alcyomics developed a novel human in vitro skin explant assay (patent EP2524227) for 
assessment of adverse immune reactions. Originally developed for graft-versus-host disease 
(Dickinson et al., 1998; Sviland & Dickinson, 1999; Vogelsang et al., 1985), a systemic post-
transplant complication, it was further modified and patented as an autologous skin explant 
model for predicting adverse immune reactions to chemicals (Ahmed et al., 2016). The initial 
step of this assay consisted of priming of dentritic cells with the test chemical and consequent 
T cell activation. Afterwards, these primed cells were co-cultured with a skin biopsy from the 
same donor (hence an autologous system) to see if the test compound induced tissue damage 
(Figure 5). The output of this skin explant assay is in situ histopathological characterization of 




Figure 5. Alcyomics in vitro skin explant assay. This autologous assay consists on isolation of monocytes from a blood sample. Monocytes are maturated into Dendritic Cells (DCs) 
and incubated with test compound and autologous T cells. Primed T cells are co-cultured with autologous skin biopsy. Histopathological assessment of damage is done according to a 
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The assay has since been further modified for assessment of immune reactions to 
monoclonal antibodies (Ahmed et al., 2019). The skin and immune cell microenvironment 
should be considered as a “surrogate” microenvironment for the in vivo response, allowing 
assessment of systemic immune activation. Therefore, it can be used as a first-line tool to 
predict adverse immune reactions (hypersensitivity and immunotoxicity) to biopharmaceuticals 
and cosmetic products, assessment of dose-responses to compounds or for comparative studies 
with other biomolecules. Moreover, it can be used during the different stages of a product 
development pipeline, either in the initial stages of product screening (i.e. product optimization) 
as well as the preclinical stage testing. Overall, this in vitro skin explant assay is a cost- and 
time-efficient in vitro screening tool for assessment of immunotoxicity. 
 
1.10.2. Immunotoxicity of monoclonal antibodies  
Monoclonal antibodies (mAbs) are a major class of biological drugs, representing a 
multi-million dollar revenue stream each year in the biopharmaceutical market 
(EvaluatePharma, 2014). The increased commercial interest around mAbs for therapeutic use 
relies in the fact that mAbs are designed to be very target specific (and therefore more efficient) 
and are also well tolerated by the human body (meaning lower changes of rejection/side effects) 
(Carter, 2001; Reichert & Valge-Archer, 2007) than small molecule drugs.  
Orthoclone OKT3 was the first commercial mAb to be introduced onto the market, in 1986 
(Starzl & Fung, 1986). It was approved for the prevention of kidney transplant rejection. From 
that year on, mAb products have rapidly risen as lead products in the biopharmaceutical market. 
There are more than 20 commercially available mAbs approved for a range of therapies – 
ranging from use in oncology, immunological disorders, neurodegenerative pathologies, 
cardiology and also as diagnostic tools (EvaluatePharma, 2014). The drive behind mAb 
development is fuelled by the increased need of cost-effective therapies, by the increased 
success rates of newly developed mAb and lastly, by the emerging realm of in silico protein 
engineering tools (as proteomics and genomics).  
Most of the commercially available antibodies are Immunoglobulin G (IgG) structure type 
(Figure 6) as this isoform accounts for almost 75% of all immunoglobulins found in the human 
blood (Roitt & Delves, 1998). An IgG antibody is a large molecule, weighting around 150kD. 
It is composed of two different polypeptide chains – a double heavy chain (50kD) and a double 
light chain (25kD). There are two major components in an IgG mAb – the Fc fragment and the 
Fab fragment. While the Fab fraction binds to the antigen receptor, the Fc fragment is 
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responsible for the immune response, stimulating activation of different immune cells 
(macrophages, neutrophils, NK cells…) (Janeway et al., 2001).  
 
 
Figure 6. Structure of the IgG antibody. The IgG antibody is composed of two heavy chains (50kD) 
and two light chains (25kD) that are bonded by disulphide bridges. The antibody can be divided in two 




However, large-scale production of mAbs is a challenging process that demands a complex 
industrial process. Filtration of IgG samples during its manufacturing process is quite common, 
in order to remove all large aggregates. However, residual small-size aggregates (below the 
0.22µm membrane filter limit) can surpass the filter and remain in the IgG solution. These 
residual aggregate species can aggregate into large aggregates during manufacturing, shipping 
and storage stages if exposed to specific stress factors.  
Temperature is one such critical parameter since thermal changes can affect the 
conformational structure and stability of the IgG molecule (Vermeer & Norde, 2000). This 
imposes a serious production failure cost as it can lead to an irreversible aggregation status of 
the batch. At higher temperatures, the disulphide bridges binding the polypeptide chains of the 
antibody can start to weaken and even unbind by denaturation (Luo et al., 2011). This leads to 
an unfolding of the overall structure, leading to an unstable conformational state (Joubert, Luo, 
Nashed-Samuel, Wypych, & Narhi, 2011; Menzen & Friess, 2014; Vermeer, Bremer, & Norde, 
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1998; Vermeer & Norde, 2000). pH can also induce antibody aggregation via protein instability 
(Buchner, Renner, Lilie, Hinz, & Jaenicke, 1991; Joubert et al., 2011; Talley & Alexov, 2010). 
Acid-induced changes can promote loss of native structure, by means of secondary structure 
refolding (Kent, Schroeder, & Sharma, 2018). More specifically, Vermeer et al. showed that 
while the Fab fragment is very sensitive to heat stress, the Fc region is more sensitive to pH 
(acidic conditions) (Vermeer & Norde, 2000). A recent study has also shown that interaction 
between pH and temperature as critical parameters for aggregation increased occurrence of 
aggregation in 3 mAbs, as mAbs were subjected to rapid thawing cycles with a pH variation 
from 3 to 7 (Kent et al., 2018). 
Physical or mechanical stress can also potentiate antibody aggregation such as stirring 
during manufacture (Kiese, Papppenberger, Freiss, & Mahler, 2008), storage, shipping or 
shaking during administration of the antibody (Peters, Capelle, Arvinte, & van de Garde, 2013). 
Protein aggregation is a consequence of denaturation conditions (such as temperature, pH and 
stirring), driven by free non-specific hydrophobic interactions of unfolded antibody molecules. 
Commercially available mAbs are formulated to be very stable endpoint products but exposure 
to these stress factors can compromise mAb stability.  
Taking into account the size of protein aggregates, their characterization becomes quite 
complex. Affinity chromatography methods for separation of larger aggregates can be very 
difficult as aggregates will constrain or even block the chromatography columns (Evans, 2015). 
Therefore, multi-technique analysis or combination approaches would provide more 
information. New analytical techniques like analytical ultracentrifugation (AUC) (Wafer, 
Kloczewiak, & Luo, 2016), size exclusion chromatography-multi angle light scattering (SEC-
MALS) (Ye, 2006), and asymmetric flow field-flow fractionation multi-angle light scattering 
(AF4-MALS) (Fraunhofer & Winter, 2004) are the current most reliable methods for 
quantifying low levels of aggregates. AUC allows for the quantitative description of protein 
aggregation and formulation of large supramolecular complexes based on their sedimentation 
properties (Berkowitz, 2006). Sedimentation velocity (SV)-AUC is a hydrodynamic approach, 
which provides details of particle mass and shape and is particularly useful for studying 
multicomponent irreversible and reversible mixtures of species (Cole, Lary, Moody, & Laue, 
2008).  
Considering the panoply of protein-based therapeutics, there is concern that protein 
aggregation can be one potential cause of immunogenicity in humans. However, little is known 
about mAb aggregation following patient administration. While there is a significant chance 
that mAb preparations alone will cause some degree of immunotoxicity (Baert et al., 2003; 
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West, Zelinkova, Wolbink, Kuipers, & Rs, 2008), mAb aggregation can exponentially increase 
the likelihood of causing an adverse immune event.  
Previous reports have shown that detection of aggregated mAb samples can be found in 
human biological fluids such as serum (Filipe et al., 2011; Filipe, Poole, Oladunjoye, 
Braeckmans, & Jiskoot, 2012) and plasma (Filipe et al., 2011). Furthermore, aggregated mAbs 
have been shown to give rise to in vitro cell proliferation via activation of dendritic cells 
(Rombach-Riegraf et al., 2014) and T cells (Ahmadi, Bryson, Cloake, Welch, Filipe, Romeijn, 
Hawe, Jiskoot, Baker, et al., 2015; Joubert et al., 2012, 2016). These in vitro results are derived 
from cell-based assays that mimic the normal immune response (e.g. dendritic cells and T cells), 
from cell activation and proliferation to cytokine secretion. In vivo response to mAb 
aggregation from animal-based studies show that heat-aggregated IgG aggregates lead to cell 
activation (Bessa et al., 2015; St. Clair et al., 2017).  
So far, previous studies focusing on assessing the immunotoxic profile of aggregated mAbs 
were either cell-based or performed in animal models (mice and primates). The lack of human-
based in vitro assays makes it difficult to truly understand mAb immunotoxicity as a potential 
threat to humans. This project intends to contribute with valuable insights by using a novel in 
vitro skin explant assay for assessment of immunotoxicity of aggregated monoclonal antibodies 
(Chapter 5). 
 
Overall, and while many efforts have been done for development of in vitro safety testing 
methods as replacement for animal studies, there is still a long road to go for development of 
the most suitable in vitro method that can truly mimic the in vivo microenvironment of the 
human skin. From epidermal models to ex vivo skin models, there has been a massive progress 
for optimization, commercialization and validation of a panoply of different in vitro skin 
models. Further efforts to combine these in vitro skin models with in silico approaches have 
raised the legislative standards for risk assessment analyses and adverse pathway frameworks.  
Currently, there are several commercially available in vitro skin models in the form of 
Reconstructed Human Epidermis models or full-thickness skin models for assessment of 
different magnitudes of sensitization – irritation, corrosion, immunotoxicity. From patented to 
open source models, it is possible to choose different methods as screening test method. 
However, much needs to be taken into consideration regarding these models like origin of cells, 
reproducibility, commercial cost, applications, use of animal components, standardization of 
protocols… And while issues like skin irritation have been a priority for regulatory authorities, 
immunotoxicity as a secondary form of sensitization still lacks proper attention due to its 
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novelty. Increased concerns for immunotoxicity in the context of aggregated monoclonal 
antibodies has driven researchers to develop more accurate in vitro assays for detection of 
immunotoxicity by immune cell activation and/or proliferation. 
Therefore, this project was developed to bring a new insight into the issues mentioned 
above following a general research hypothesis: How can we improve assessment of 
sensitization using in vitro test methods, in a more accurate and human relevant manner? Two 
parallel approaches were formulated to try answering this research hypothesis: 
- Is it possible to develop an open source in vitro epidermal model that can compete with 
the commercially available ones for assessment of skin irritation? Can this optimized 
in vitro epidermal model be free of animal components, reproducible and demonstrate 
accurate identification of irritants vs non-irritant chemicals in the context of safety 
testing regulations? 
- Considering immunotoxicity as a form of sensitization, is it possible to assess 
immunotoxicity using a human-based in vitro assay for the effect of aggregated 
monoclonal antibodies? 
 
Several small tasks and aims were outlined to answer these research hypotheses as 








1.11. Aims  
This project is divided in two segments of assessment of skin toxicity and sensitization for 
human safety. The initial emphasis of this PhD project was to develop an open source 3D 
epidermal skin culture of human epidermis for the assessment of skin irritation testing (OECD 
TG 439) in accordance with the Globally Harmonized System (GHS) of Classification and 
Labelling Category 2. For this, several tasks were performed using the 3D epidermal skin 
culture, namely: 
 Establishment of a 3D epidermal skin culture by optimization of cell density, nutrient 
requirements and other specifications; 
 
 Optimization of keratinocyte differentiation and phenotype using collagen-coated and 
non-collagen-coated scaffolds; 
 
 Assessment of skin irritation testing following OECD TG 439 protocol using the 
optimized 3D skin culture; 
 
 Comparison of skin irritation testing between the 3D skin culture, monolayer 
keratinocyte culture and commercially available RHE models. 
 
The second focus of this project was regarding sensitization and prediction of adverse 
immune events. Therefore, an in vitro skin explant assay was used to assess immunotoxicity 
by aggregated monoclonal antibodies. Additional assays such as T cell proliferation and 
cytokine release were also used for further assessment of immunotoxicity by aggregated 
monoclonal antibodies. Similar to the previous aim, several tasks were performed using the ex 
vivo skin explant, as following: 
 Assessment of immune activation by aggregated and non-aggregated monoclonal 
antibodies by the ex vivo skin explant assay; 
 
 Assessment of immune activation of aggregated and non-aggregated monoclonal 













2. Materials & Methods  
 
Part I – Development of a 3D skin culture model for skin irritation testing  
 
2.1. Isolation of primary keratinocytes for 3D culture  
All skin samples were obtained from healthy donors after informed consent. Keratinocytes 
were isolated from skin explant biopsies, either taken from the from abdominal region (by a 
4mm punch biopsy) or foreskin region (surgically removed). Use of skin biopsies was approved 
by the Local Research Ethics Committee. Skin biopsies were collected and kept in ex-vivo 
medium (X-VivoTM 15, Lonza) and processed on the same day. The skin explant biopsy was 
subjected to enzymatic digestion with dispase (Sigma) to allow separation of the epidermis 
from the dermis. After enzymatic incubation for at least 18 hours at 4ᵒC, the epidermis was 
separated from the dermis with the use of forceps. The epidermal layer was incubated with 
Trypsin (Sigma) for 5 minutes at 37ᵒC to improve the dissociation process. The trypsin was 
neutralized with an equal volume of Epilife® medium (Life Technologies GmbH) and the 
epidermis was transferred into a cell culture flask (T25 cm2 area) for seeding of keratinocytes 
in Epilife® medium. The Epilife® medium was supplemented with 1% Human Keratinocyte 
Growth Supplement (HKGS) (Life Technologies GmbH), 1% penicillin/streptomycin solution 
(Sigma) and 1% amphotericin B (Life Technologies GmbH). This was considered passage 0. 
Keratinocytes were cultured at 37ᵒC with 5% CO2 in an incubator. Medium exchange was 
required every two days, with addition of fresh 20 mL Epilife® medium. Keratinocytes were 
subcultured to passage 1 after reaching 80% confluency. The flask was washed with phosphate-
buffered saline (PBS, Sigma), detached by incubating for 5 minutes with trypsin, centrifuged 
and resuspended in Epilife® medium. After determination of the cell number, the keratinocytes 
were seeded at a concentration of 5x105 cells/flask into a 175 cm2 culture flask. Passage 2 and 
3 were performed following the same protocol. 
 
2.2. Monolayer culture of keratinocytes  
Keratinocytes were seeded at passage 3 at 5x103 cells/well in flat-bottom 96-well plate 




2.3. Assembly of the 3D skin culture 
Keratinocytes were seeded in Alvetex Strata scaffolds (from Reprocell Europe, polystyrene, 
15µm pore size, 24mm outer insert diameter, 20mm membrane area) at passage 3 and kept 
submerged in Epilife® medium enriched with CaCl2 (1.5mM concentration, Sigma) for 24 
hours. Medium was afterwards aspirated, from both the bottom of the well and the inside of the 
insert and replaced with 4mL fresh Epilife® enriched with HKGS (1%), CaCl2 (1.5mM) and 
vitamin C (100µg/mL, Sigma) reaching to just the bottom of the insert. This was considered 
the beginning of the Air Liquid Interface (ALI) for the 3D skin culture model. The model was 
cultured under these conditions for 30 days, with medium being replaced every two days. 
Different cell concentrations (1x106, 1.5x106 and 2x106cells/scaffold) and ALI times (14, 21 
and 30 days) were tested.  
 
2.4. Skin irritation testing following Testing Guideline 439  
Skin irritation testing was conducted according to the Testing Guideline (TG) 439 defined 
by EURL-ECVAM (OECD, 2013). From the List of Reference Chemicals in TG 439, 12 
chemicals were chosen to be tested in both the monolayer cell culture and the RHE model (the 
chemicals tested are shown in Table 6). Tests were performed in triplicate for all donors. 
Chemicals were tested with stock concentration, no further dilution performed as defined by 
OECD TG 439. Negative and positive controls were also used, PBS being defined as the 
negative control and 5% aqueous SDS solution as the positive control. 
For the monolayer keratinocyte culture, 30µL of each testing chemical was added to the 
Epilife® medium and left to incubate for 24 hours. Medium was then discarded, and the cells 
washed with PBS before addition of fresh medium for the cell viability assay. Chemical testing 
was performed using keratinocytes from 10 healthy donors.  
For the 3D skin culture, the models were transferred to a new plate containing Epilife® 
medium prior to the chemical testing. As stated on TG 439, 30µL of each testing chemical was 
dispensed directly on top on the 3D skin culture, covering the entire surface of the scaffold and 
left to incubate for 35 minutes. After topical exposure, all 3D skin culture models were rinsed 
with PBS (both outside and inside the insert), transferred to a new plate containing fresh 
Epilife® medium and maintained in the incubator for a further 42 hours. Chemical testing was 




Table 6. Test chemicals for the skin irritation test TG 439. For each chemical, Chemical Abstract Service (CAS) number 
is listed, as well as physical state, in vivo score based on Draize irritancy score and in vivo category according to Globally 
Harmonized System (GHS). 







1-bromo-4-chlorobutane 6940-78-9 Liquid 0 No cat. 
Allyl phenoxy-acetate 7493-74-5 Liquid 0.3 No cat. 
Isopropanol 67-63-0 Liquid 0.3 No cat. 
4-methyl-thio-benzaldehyde 3446-89-7 Liquid 1 No cat. 
Heptyl butyrate  5870-93-9 Liquid 1.7 No cat. 
Hexyl salicylate 6259-76-3 Liquid 2 No cat. 
1-decanol 112-30-1 Liquid 2.3 Cat. 2 
1-bromohexane 111-25-1 Liquid 2.7 Cat. 2 
di-n-propyl disulphide 629-19-6 Liquid 3 Cat. 2 
Heptanal 111-71-7 Liquid 3.4 Cat. 2 
Tetrachloroethylene 127-18-4 Liquid 4 Cat. 2 
 
2.5. Cell viability of the test  chemicals 
Cell viability assay for each chemical was performed according to TG 439, using the 3-
(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) assay. 3D skin culture 
models were incubated with 300µL of MTT solution (1mg/mL, Sigma) at 37ᵒC for 3 hours 
protected from light to allow formation of formazan crystals. After this incubation period, MTT 
was removed and the models washed with PBS. Formazan crystals were extracted by 
incubation with 2mL isopropanol (Sigma) for 1 hour with constant low speed shaking on a plate 
shaker. Afterwards, 200µL in triplicate of the extraction solution from each chemical was 
transferred to a 96-well plate and the Optical Density (OD) was measured at 575nm using a 
plate reader (Thermo). 
2.6. Calculation of cell viability  
The OD mean for the triplicates of each testing chemical was calculated. For each chemical, 
the relative cell viability was calculated in comparison to the negative control, by the following 
equation: 
% 𝑐𝑒𝑙𝑙 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 = (
𝑂𝐷𝑡𝑒𝑠𝑡𝑖𝑛𝑔 𝑐ℎ𝑒𝑚𝑖𝑐𝑎𝑙
𝑂𝐷𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
) × 100 
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According to the Performance Standards from TG 439, for a chemical to be considered an 
irritant, it should cause a reduction in viability greater than 50%. Therefore, the threshold for 
irritancy will be defined in this study as 50% viability. Performance Standards also apply to the 
test controls, in which the positive control should cause a cell viability no higher than 10% 
(compared to the negative control). 
 
2.7. Statistical analysis  
Average mean of each chemical was analysed by one-way analysis of variance (ANOVA) 
and significant mean differences were determined by Dunnett posthoc test, by comparison 
between all chemical conditions to the negative control. A Chi-Square (χ2) test of independence 
was carried out to determine if classification of irritants and non-irritants by each in vitro 
method was accurate (comparison of observed versus expected). A two-way ANOVA was 
performed to determine difference of performance between each in vitro model with chemicals 
(non-irritant and irritant) and in vitro models as independent variables.  
All statistical tests were carried out using Prism GraphPad software (version 5). Statistical 
differences were considered significant if p value <0.05. 
 
2.8. Collagen-coated scaffolds 
Two types of collagen-coated scaffolds were used as “direct” comparison to the 3D skin 
culture model. The first scaffold was a Corning transwell® insert previously coated with type 
I and III collagen (Transwell®-COL scaffolds, Corning, 0.4µm pore size, 24mm outer insert 
diameter).  
The second scaffold was the Alvetex Strata (from REPROCELL, UK) coated with human 
collagen (Sigma, recombinant). The collagen solution was prepared in a 1:1 dilution with 
ethanol absolute and applied to the scaffold. Overnight incubation in a laminar flow hood was 
required to allow the scaffold to dry completely. Prior to the seeding of keratinocytes, scaffolds 
were washed with PBS to remove any excess collagen-Ethanol solution. 
In both conditions, keratinocytes were seeded and submerged in enriched Epilife® for 24 
hours before starting ALI. Different times for the ALI were tested – 14, 19 and 21 days for 
Transwell®-COL scaffolds and 3,7, 14, 19, 21 and 30 days for Alvetex Strata coated with 




2.9. Commercially available alternatives for skin irritation testing  
A commercially available RHE model was bought from MatTek (EpiDermTM 24-well 
model, USA) for an in-house comparative study with the 3D skin culture model. Upon receipt 
of the EpiDermTM models, the models were transferred to a new 24-well plate containing fresh 
Epilife® medium and left to incubate overnight at 37°C and 5% CO2. Skin irritation testing 
was performed using the same chemicals as the monolayer culture and the 3D skin culture 
models (see Table 6), following the manufacturer’s protocol (MatTek, 2004). 30µL of test 
chemical were dispensed on top of the models and left to incubate for 1 hour (35 minutes in the 
incubator and 25 minutes at room temperature). The models were then rinsed with PBS and 
transferred to a new 6-well plate with 0.9mL Epilife® medium and incubate for 42 hours with 
medium exchange every 24 hours. MTT viability test was performed after those 42 hours, 
transferring the models to a new 6-well plate containing 300µL of MTT solution at 1 mg/mL.  
 
2.10. Histological and immunofluorescence analysis of the 3D skin culture  
3D skin culture models were fixed in 4% formaldehyde for at least 24 hours before 
disassembling of the scaffold and embedding in paraffin. Tissue sections (4µm thick) were 
prepared for histological staining (Hematoxylin and Eosin - H&E and collagen) and 
immunofluorescence (involucrin for the stratum corneum and cytokeratin 14 for the stratum 
basale).  
Collagen and immunofluorescence staining were performed in paraffin embedded 3D 
epidermal skin models. Therefore, 4µm sections of the 3D epidermal skin models were cut in 
a microtome, incubated overnight in a benchtop oven at 37°C and for 1 hour at 60°C before 
rehydrated. Rehydration was achieved by washing slides containing sections of the 3D 
epidermal skin models for 3 minutes in Xylene, 100% ethanol, 95% ethanol, 70% ethanol and 
distilled water, blotting excess in between each wash. After staining, all slides were dehydrated 
again by submerging in distilled water, 70% ethanol, 95% ethanol, 100% ethanol and xylene 
for 3 minutes and covered with a glass cover slip glued with DPX synthetic resin (mixture of 
distyrene, a plasticizer (tricresyl phosphate), and xylene, Sigma). Slides were left to dry 
overnight before taken for imaging on microscope.  
Collagen staining was performed using the picro-sirius red stain kit (Abcam), following the 
manufacturer’s instructions. 1 drop of picro-sirius red solution was added to each slide, making 
sure it covered the whole sample. Slides were left to incubate for one hour at room temperature 
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in the dark and washed afterwards with acidified water (distilled water with 5% acetic acid) 
twice. Slides were blotted and dehydrated as mentioned above. Imaging was performed using 
a Zeiss AxioImager at 10x zoom. Images were not modified or manipulated at any point. 
Immunofluorescence labelling of the epidermal differentiation markers - stratum corneum 
(involucrin) and basal layer (cytokeratin 14) was performed using anti-involucrin (ab68 from 
Abcam) and anti-cytokeratin 14 (ab7800 from Abcam) antibodies with in-house optimized 
protocol. Alexa Fluor 488 and 647 (Life technologies) were used as species-specific secondary 
antibodies, at a concentration of 1µg/mL (see Table 7 for summary of all antibodies used). 
After rehydration of the slides, antigen retrieval was performed with 10mM citrate buffer 
(pH=6) in a microwave for 5 minutes twice. Slides were then washed in 5mM TBS (pH=7.6) 
for 5 minutes and prepped for permeabilization step.  0.2% Triton-X (in PBS) was added to all 
slides and left to incubate for 10 minutes at room temperature. Slides were then washed with 
TBS. A blocking step with 100µL of 10% Goat Serum solution diluted in PBS (Sigma) was 
added to all slides and left to incubate for 30 minutes at room temperature. A washing step with 
TBS was performed to remove all traces of the goat serum. All slides were incubated with anti-
involucrin (1mg/ml diluted with 10% goat serum solution at 1:400) and anti-cytokeratin 14 
(1mg/ml diluted with 10% goat serum solution at 1:250) primary antibodies (Abcam) for 1 
hour. Null primary slides were coated with 10% goat serum solution instead for background 
unspecific binding from the secondary antibody. After incubation, sections were washed twice 
in TBS for 5 minutes. Slides were then incubated with the secondary antibody (AF488 for 
involucrin and AF647 for cytokeratin 14). A mix solution was prepared containing both 
secondary antibodies diluted at 1:200 in the 10% goat serum solution. 100µL of the mix 
solution was added to all slides and slides were incubated for 2 hours at room temperature in a 
moist chamber in the dark. After the 2-hour incubation period, slides were washed twice in 
TBS for 5 minutes and dehydrate as mentioned before. Slides were covered with Fluoroshield 
Mounting Medium with DAPI (ab104139 from Abcam) and left overnight at 4°C. Microscopy 
images of histopathological skin damage were taken using a Zeiss AxioImager with Apotome 






Table 7. Summary of antibodies used for immunofluorescent staining of the 3D epidermal skin culture.  




Abcam 1mg/mL 1:400 






Abcam 1mg/mL 1:400 
Cytokeratin 14 – basal 
layer 
(primary antibody) 
Goat Serum  
(G9023-5ML) 
Sigma - 1:10 Blocking solution 
Anti-Mouse IgG 












2 mg/mL 1:200 
Secondary Antibody 
for Anti-Cytokeratin 14 
Mounting 
Medium with 
DAPI - Aqueous, 
Fluoroshield 
(ab104139) 
Abcam 20mL 1:1 
Mounting medium 
designed to preserve 
fluorescence when 









Part II – Assessment of immunotoxicity of aggregated mAbs using an in vitro skin 
explant assay 
 
2.11. Human and blood samples 
All blood and skin samples were obtained from healthy volunteers after informed consent. 
Each volunteer donated 60mL of peripheral blood and two 4mm skin biopsies. 55mL of 
peripheral blood was used to isolate peripheral blood mononuclear cells (PBMCs) by density-
gradient centrifugation (15 minutes at 2500rpm) with LymphoprepTM medium (Sigma). 
PBMCs were collect by aspiration and washed with PBS before counted with Trypan blue 
solution for cell concentration correctness.  The remaining 5mL of peripheral blood were used 
to purification of serum. The blood collection tube was centrifuged at 2500rpm for 5 minutes 
and serum was collected from the top layer into a 1.5mL Eppendorf tube. Heat inactivation of 
serum was performed by incubating the Eppendorf tube with the serum sample for 30 minutes 
at 56°C in a waterbath. Serum sample was then frozen down at -80°C until used.  
Skin biopsies (abdominal area) were collected fresh with a 4mm punch biopsy and 
transferred to ex vivo X-VivoTM medium (Lonza) until used. Before processing, skin biopsies 
were washed in PBS (Sigma) and was trimmed of excess fat. The skin was dissected into small 
sections for the skin explant test. 
 
2.12. Skin explant assay for immunotoxicity of aggregated mAbs  
The skin explant assay was performed as previously described (Ahmed et al., 2016) with 
small modifications. Small sections of the skin biopsy were incubated in autologous medium – 
Roswell Park Memorial Institute (RPMI) culture medium (Sigma) supplemented with 1% 
penicillin/streptomycin solution (Sigma), 1% L-glutamine supplement (Sigma) and 20% of the 
donor’s heat-inactivated serum (instead of Foetal Bovine Serum, FBS). To perform the skin 
explant assay for immunotoxicity of aggregated mAbs, PBMCs from the same donor were 
added to the skin explant incubated in autologous medium at a concentration of 1x106 
cells/well, as well as the non-aggregated or aggregated (heat stressed) mAb samples at 1 µg/mL 
and 10 µg/mL for 3 days. Therefore, skin explants were collected after the 3 days incubation 
period and fixed in formalin for at least 24 hours, preparing the skin explants for a hematoxylin 
and eosin (H&E) staining. IgG1 (Biorad) was used as negative control for immunotoxicity at 
1µg/mL and included in all assays. OKT3 (eBioscience) was used as positive control for 




The endpoint of this skin explant assay was the histopathological analysis of damage caused 
by exposure to the mAb sample. This output was based on a scoring scale (grades I to IV) 
according to the severity of the skin tissue damage observed (Lerner et al., 1974). Grade I was 
considered negative, with an intact upper keratinocyte layer; grade II showed vacuolisation of 
the epidermis; grade III showed severe damage of the epidermal layer, with cleft formation and 
initial separation of the epidermal and dermal layers and grade IV showed further damage, with 
complete separation of the epidermal and dermal layers.  
Imaging of the histopathological skin damage was performed using a Zeiss AxioImager 
with Apotome (wide field fluorescence) at 10x zoom. Images were not modified or manipulated 
at any point.  
 
2.13. T cell proliferation 
PBMCs were incubated with the mAb samples at 1 µg/ml or 10 µg/mL (cell concentration 
of 1x106 cells/well) for 3 days. IgG1 (Biorad) at 1µg/mL was used as a negative control for T 
cell proliferation. OKT3 (eBioscience) at 1µg/mL was used as a positive control for T cell 
proliferation. After the incubation period, supernatants were collected for cytokine analysis. T 
cell proliferation was assessed by tritiated thymidine ([3H]-Thymidine) uptake by adding 
3.7Mbq to each well at a 1:10 dilution and left for an 16-hour period incubation. Cells were 
harvested onto a filtermat and counted using a β-scintillation counter (PerkinElmer).  
 
2.14. Cytokine release assay 
Multiplex cytokine analysis was performed using both the skin explant assay and the T cell 
proliferation cell culture supernatants using MSD Multi-Spot Proinflammatory panel 1 V-Plex 
kit (Meso Scale Diagnostics) following the manufacturer’s instructions. The biomarkers 
included in this panel were IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13 and 
TNF-α. All diluents and read buffers were included in the kit and prepared according to 
manufacturer’s instructions. Supernatant samples were diluted 1:10 with diluent 2 (from the 
kit) and 50µL of each sample were transferred to the MSD plate. MSD plate was washed 3 
times with wash buffer (included in the kit) and 25µL of detection antibody solution was added 
to all wells. MSD plate was sealed and left to incubate for 2 hours at room temperature in a 
shaking plate at low speed. Afterwards, MSD plate was washed with wash buffer three times 
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and 150µL of read buffer (included in the kit) was added to all wells. Calibrator diluents were 
also prepared for a standard curve by 4-fold serial dilutions of calibrator 1 (included in the kit) 
5 times and included in the same MSD plate containing the samples. The MSD plate was then 
read on an MSD plate reader. Average calculation of concentration of each biomarker was 
calculated by the MSD plate reader software (in pg/mL) for each sample and adjusted for the 
standard curve. 
 
2.15. Immunofluorescence  
Cell death labelling was performed by staining with Anti-Hsp70 (Heat-Shock protein 70) 
(1mg/ml) and Anti-Caspase 3 (casp3) (1mg/ml) antibodies (Abcam) with in-house optimized 
protocol. Alexa Fluor 488 (A488, Life Technologies) was used as the secondary antibody, at a 
concentration of 1 µg/mL (see Table 8 for summary of all antibodies used). After rehydration 
of the slides (same protocol as described in section 2.10), antigen retrieval was performed with 
10mM citrate buffer (pH=6) in a microwave for 5 minutes twice. Slides were then washed in 
5mM TBS (pH=7.6) for 5 minutes and prepped for permeabilization step.  0.2% Triton-X (in 
PBS) was added to all slides and left to incubate for 10 minutes at room temperature. Slides 
were then washed with TBS. A blocking step with 100µL of 10% Goat Serum solution diluted 
in PBS (Sigma) was added to all slides and left to incubate for 30 minutes at room temperature. 
Washing with TBS was performed to remove all traces of the goat serum. All slides were 
incubated with anti-HSP70 (1mg/ml diluted with 10% goat serum solution at 1:20) and anti-
Caspase3 (1mg/ml diluted with 10% goat serum solution at 1:20) primary antibodies (Abcam) 
for 1 hour. Null primary slides were coated with 10% goat serum solution instead for 
background unspecific binding from the secondary antibody. After incubation, sections were 
washed twice in TBS for 5 minutes. Slides were then incubated with the secondary antibody 
(AF488 diluted at 1:200 with the 10% goat serum solution). 100µL of the secondary antibody 
solution was added to all slides and slides were incubated for 2 hours at room temperature in a 
moist chamber in the dark. After the 2-hour incubation period, slides were washed twice in 
TBS for 5 minutes and dehydrate as mentioned before. Slides were covered with Fluoroshield 
Mounting Medium with DAPI (ab104139 from Abcam) and left overnight at 4°C. Imaging of 
the immunofluorescence staining was performed using a Zeiss AxioImager with Apotome 




Table 8. Summary of antibodies used for immunofluorescent staining of the skin explant samples.  




Abcam 1mg/mL 1:20 





Abcam 1mg/mL 1:20 
Caspase 3 
(cell death) 
Goat Serum  
(G9023-5ML) 
Sigma - 1:10 Blocking solution 
Anti-Mouse IgG 












2 mg/mL 1:200 
Secondary Antibody 
for Anti-Cytokeratin 14 
Mounting 
Medium with 
DAPI - Aqueous, 
Fluoroshield 
(ab104139) 
Abcam 20mL 1:1 
Mounting medium 
designed to preserve 
fluorescence when 
imaging tissue samples 
 
2.16. Heat stress protocol for aggregation of monoclonal antibodies 
2.16.1. Degradation of mAb samples  
Herceptin (Trastuzumab) and Rituximab (Mabthera) monoclonal antibodies (IgG1 
class) were commercially bought from the Newcastle Hospital Pharmacy. Herceptin was 
bought as a 600mg/5L solution for injection in a vial, while Rituximab was bought as a 
100mg/10L concentrate for solution for infusion. Upon purchase, both mAbs were prepared 
and diluted to multiple 1mL aliquots of 1 mg/mL stock concentration. Aliquots were used to 
expose the two mAbs to a heat stress protocol by exposure to different heat conditions: 4ᵒC 
(fridge), 37°C (incubator) and 40°C (water bath) for the following time points: 0, 3, 6, 12, 24 
and 48 hours. A positive control for aggregation was also prepared for each mAb, by leaving 
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the samples at 65°C for one hour in an acidic buffer (pH=3). Samples were stored immediately 
after the heat stress protocol at 4°C until further analysis. 
 
2.16.2. Protein analysis of heat stressed mAb samples  
Protein content of the heat stressed mAb samples was quantified by sedimentation 
velocity-analytic ultra-centrifugation (SV-AUC). Sedimentation analysis was carried out using 
a ProteomeLab XL-I analytical centrifuge (Beckman Coulter, Palo Alto, USA). The following 
conditions were used in all centrifugation runs: 40.000-rpm angular velocity, 20ᵒC rotor 
temperature and 280-nm absorbance scanned. Absorbance and interference data were collected 
for each experiment with a minimum of 65 scans. Protein quantification (percentage of 
monomers, dimers and heavier species) was calculated using SEDNTERP software. 
Sedimentation velocity profiles were treated using size-distribution models and refined with 
Bayesian statistics. This quantification was carried out in the Newcastle University Protein and 
Proteome Analysis (NUPPA) facilities as a service. 
Protein characterization was analysed by Transmission Electron Microscopy (TEM). 10µL 
of the mAb stressed samples were deposited on carbon coated TEM grids, after which the grids 
were stained with uranyl acetate (10µL at 150mg/ml) for negative staining. The grid was air-
dried and the excessive staining was removed from the grid specimens by paper blotting. The 
grids were then analysed under acceleration voltage of 100 kV under a Philips CM100 
Transmission Electron Microscope. This characterization was carried out in the Electron 
Microscopy Research Unit of Newcastle University.     
 
2.17. Statistical analysis 
The T cell proliferation assay endpoint was a log(2) fold-increase Stimulation Index (SI) in 
response to exposure to the test compound. This cut-off value was defined previously in similar 
studies (Rombach-Riegraf et al., 2014). SI were measured by the ratio between the test 
conditions (mAb exposure) and the untreated control (no mAb exposure).  Statistical analysis 
was carried out using repeated measures one-way ANOVA. 
For the skin explant test, statistical analysis was performed to 1) compare the mAb 
concentration (1 and 10 µg/mL) in the same donor by a repeated measures two-way ANOVA 
with a Bonferroni correction (post-test) and 2) to see the effect of the different mAb temperature 
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conditions in the same donor by a one-way repeated measures ANOVA with a Bonferroni post-
test.  
Statistical analysis of the cytokine levels was carried out using repeated measures one-way 
ANOVA. 
All statistical tests were carried out using Prism GraphPad software (version 5). Statistical 
differences were considered significant if p value <0.05. Statistical significance was reported 















3. Development of an open source 3D epidermal skin culture 
 
3.1. Aim 
Reconstructed human epidermis (RHE) models are gaining relevance for in vitro screening 
of chemical compounds that seek regulatory approval before commercialization. Several RHE 
models are already available as commercial kits for toxicology testing and some are, in fact, 
validated by EURL-ECVAM standards for use in irritation and corrosion testing of chemicals. 
However, the high cost of these models can rapidly become a financial burden for scientific 
research. Consequently, research labs are trying to develop their own open source RHE model 
from open source protocols. Therefore, the aim of this chapter was to develop a 3D epidermal 
skin culture based on the previous work by Poumay et. al (2004) using the Alvetex Scaffold 
membranes. 
 
3.2. Results  
To achieve an optimized protocol for the 3D epidermal skin culture, several optimization 
features were performed.  
Origin of the skin cells was from a primary keratinocyte culture, isolated from excess 
foreskin or abdomen explants of healthy volunteers undergoing surgery. Information regarding 
the healthy volunteers was not provided (i.e. age), other than confirmation of no infections or 
co-morbidities that could impair quality of the skin explant provided. Keratinocyte cells were 
isolated as described in section 2.1, starting with isolation of cells, bulking for 80% confluency 
and seeding into the skin model scaffold at passage 3. This is a standard protocol that did not 
required optimization. 
The first optimization step was the scaffold used. The Alvetex Scaffold (standard scaffold) 
and the Alvetex Strata (new scaffold) (Reprocell Europe Ltd.) were used since they are collagen 
and animal-free scaffolds (Table 9). Both scaffold membranes present similar features 
(membrane constitution, height and diameter) but were designed for different applications. 
Alvetex Scaffold membrane was designed for 3D culture of cells cells within the scaffold 
(average void size of 42 µm), while Alvetex Strata membrane was designed to support the 
growth of cells on the surface of the membrane (average void size of 15 µm). This design 
feature proved to be crucial for the adhesion and differentiation of keratinocytes as shown in 
the following results. 
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Table 9. Specifications of the Alvetex scaffold membranes provided by Reprocell Europe Ltd. Two scaffold membranes 
were used for the 3D epidermal skin culture – the Alvetex Scaffold and the Alvetex Strata. Both scaffold membranes present 
similar specifications, except in the void size.  
   
Scaffold material Polystyrene Polystyrene 
Height  13mm 13mm 
Bottom diameter 13mm 13mm 
Void size 42µm 15µm 
Company website https://www.reprocell.com/what-is-alvetex-i70 
 
 
3.2.1. Optimization of the Alvetex Scaffold  
The initial protocol was designed using the Alvetex Scaffold, using 1x106 cells per 
scaffold during a 30 days period of ALI. The culturing conditions were based on previous 
reports by Poumay et. al (2004) and (Mewes et al., 2016) that reported a seeding density of 
around 5x105 keratinocytes/cm2 membrane area as a general rule for optimized cell seeding. 
Considering that both Alvetex membranes have a membrane area of around 1.2cm2, seeding 
1x106 keratinocytes at passage 3 into the Alvetex scaffold membranes was considered 
appropriate.  
The finalised 3D epidermal skin culture can be observed in a total of 4 donors in Figure 7  
(donor 1 and 2) and Figure 8 (donor 3 and 4). Incomplete differentiation and organization of 
the keratinocytes can be observed in the H&E images (indicated by the black arrows), as they 
are scattered and not evenly adhering to the scaffold. This is especially evident in donor 4, 
where there is barely any keratinocytes adherent to the scaffold. Immunofluorescent staining 
of involucrin and cytokeratin 14 showed no positive staining for both markers, indicating that 
the few keratinocytes adherent to the scaffold did not differentiate into the different skin layers.  
Additionally, an excessive infiltration of the keratinocytes into the scaffold can be 
observed in the second donor. Overall, the results from the Alvetex Scaffold using 4 donors 
showed poor keratinocyte adhesion and no further differentiation into different skin layers. The 
general disorganization of the keratinocytes was also confirmed by lack of clear expression of 
protein markers involucrin and cytokeratin 14. Immunofluorescence staining results also 






Figure 7.  3D epidermal skin culture using the Alvetex Scaffold in donor 1 and 2. Experiment was performed using 1x106 cells/scaffold (passage 3) during 30 days at ALI. Incomplete 
differentiation and organization of keratinocytes was observed. Involucrin staining was observed as positive bright green with DAPI (blue staining) for co-localization of cells. Cytokeratin 14 




























Figure 8. 3D epidermal skin culture using the Alvetex Scaffold in donor 3 and 4. Experiment was performed using 1x106 cells/scaffold (passage 3) during 30 days at ALI. Incomplete 
differentiation and organization of keratinocytes was observed. Involucrin staining was observed as positive bright green with DAPI (blue staining) for co-localization of cells. Cytokeratin 14 


























Results from the involucrin immunofluorescent staining showed that keratinocytes seemed 
to form only a very thin stratum corneum layer, meaning one out of possible two scenarios: 1) 
there was not enough keratinocytes seeded to form proper epidermal layers; 2) there was 
enough keratinocytes seeded onto the scaffold, but they did not adhere properly. Considering 
that 1x106 keratinocytes were seeded onto each scaffold, it would seem unlikely that that 
quantity would not be enough to form an even epidermal layer. This together with the fact that 
some keratinocyte infiltration could be observed, suggested that this scaffold was not 
appropriate since its pore size was too large. This would enable keratinocytes to migrate 
through the scaffold rather than layering on the top and differentiating into stratum corneum.  
Therefore, it was decided to change to the Alvetex Strata as this scaffold has a smaller pore 
size (15µm), which could therefore prevent keratinocyte infiltration into the scaffold. However, 
since it is a smaller pore size, different numbers of seeded keratinocytes were tested to see if it 
would be possible to reduce the required number of keratinocytes. Keratinocytes were tested at 
0.5, 1 and 2 x106 cells/scaffold for different incubation times at ALI (14, 21 and 30 days) in 5 
donors, to see if this scaffold could reduce the number of cells needed and the time required to 
develop the model.  
Incubating for 14 days at ALI culture (Figure 9 and Figure 10), H&E results from five 
donors showed poor distribution of the keratinocytes, with several gaps throughout the scaffold 
membrane. An even epidermal layer is almost non-existent at the lowest concentration of 
keratinocytes, 0.5x106 keratinocytes/scaffold in all the donors. Also, there was almost no 
consistent epidermal layer regardless of the concentration of keratinocytes seeded, indicating 
that the poor distribution of the keratinocytes was maybe due to a short ALI culture time. 
Overall, results showed that 14 days at ALI culture was insufficient for proper epidermal 





Figure 9. 3D epidermal skin culture using the Alvetex Strata for 14 days in ALI at different keratinocyte concentrations in donor 1 and 2.  Experiments were performed using different 
keratinocyte numbers – 0.5, 1 and 2x106 cells/scaffold during 14 days at ALI (passage 3). Incomplete differentiation and organization of keratinocytes could be observed (black arrows). Scale bar 
of 200µm is representative and similar in all testing conditions. 
14 days ALI
0.5x106 1.0x106 2.0x106
Donor 1 Donor 1 Donor 1




Figure 10. 3D epidermal skin culture using the Alvetex Strata for 14 days in ALI at different keratinocyte concentrations in donor 3, 4 and 5.  Experiments were performed using 
different keratinocyte numbers – 0.5, 1 and 2x106 cells/scaffold during 14 days at ALI (passage 3). Incomplete differentiation and organization of keratinocytes could be observed (black 
arrows). Scale bar of 200µm is representative and similar in all testing conditions. 
14 days ALI
0.5x106 1.0x106 2.0x106
Donor 3 Donor 3 Donor 3
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At 21 days under ALI conditions, a more consistent epidermal layer was observed (Figure 
11 and Figure 12). Seeding 0.5x106 cells/scaffold seemed to be insufficient, since only a thin 
epidermal layer was developed in all donors. Seeding at 1x106 and 2x106 keratinocytes per 
scaffold resulted in a better distribution of the keratinocytes across the scaffold. However, there 
was still some gaps present in the 3D epidermal skin models cultured with 1x106 keratinocytes, 
as visible in donors 2, 4 and 5.  
In general, the 3D epidermal skin models cultured with 2x106 keratinocytes showed a more 
even epidermal layer. Moreover, the 3D epidermal skin models seem to present formation of 
the stratum corneum, especially visible in donor 2. Presence of gaps was only observed in the 
3D epidermal skin model from donor 3.  
Overall, the 3D epidermal skin models cultured at 21 days in ALI seemed to be an 
improvement from the 3D epidermal skin models cultured at 14 days, as it presented a more 
even distribution of the keratinocytes with formation of the stratum corneum in 4 donors at 
2x106 keratinocytes/scaffold. However, 21 days was still not enough time to allow for proper 







Figure 11. 3D epidermal skin culture using the Alvetex Strata for 21 days in ALI at different keratinocyte concentrations in donor 1 and 2.  Experiments were performed using different 
keratinocyte concentrations – 0.5, 1 and 2x106 cells/scaffold during 21 days at ALI (passage 3). Incomplete differentiation and organization of keratinocytes could be observed (black arrows). 
Scale bar of 200µm is representative and similar in all testing conditions.   
21 days ALI
1x106 2x1060.5x106
Donor 2 Donor 2 Donor 2










Figure 12. 3D epidermal skin culture using the Alvetex Strata for 21 days in ALI at different keratinocyte concentrations in donor 3, 4 and 5.  Experiments were performed using different 
keratinocyte concentrations – 0.5, 1 and 2x106 cells/scaffold during 21 days at ALI (passage 3). Incomplete differentiation and organization of keratinocytes could be observed (black arrows). 
Scale bar of 200µm is representative and similar in all testing conditions. 
21 days ALI
1x106 2x1060.5x106
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H&E results from 30 days under ALI conditions showed the best developed 3D epidermal 
skin culture (Figure 13 and Figure 14). However, seeding at 0.5x106 cells/scaffold still seemed 
to be insufficient as it showed poor distribution of the keratinocytes with several gaps in the 
epidermal layer. Comparing the results using 1x106 and 2x106 keratinocytes/scaffold, a more 
even distribution of the keratinocytes was observed, with a more complete epidermal layer on 
both conditions. All donors presented a well distributed epidermal layer with no gaps 
throughout the scaffold. Beginning of differentiation into stratum corneum was observed 
indicating that keratinocytes were fully organized and adherent to the scaffold. This observation 
together with the fact that 2x106 keratinocytes/scaffold required a challenging amount of tissue 
culture conditions to bulk the keratinocytes, 1x106 keratinocytes/scaffold was used in all further 
experiments. 
As cell optimization results showed that the best conditions for development of the 3D 
epidermal skin models was seeding of 1x106 keratinocytes/scaffold, further optimization was 
then performed with regards to the nutrients required for keratinocyte differentiation – vitamin 







Figure 13. 3D epidermal skin culture using the Alvetex Strata for 30 days in ALI at different keratinocyte concentrations in donor 1 and 2.  Experiments were performed using different 





Donor 1 Donor 1 Donor 1









Figure 14. 3D epidermal skin culture using the Alvetex Strata for 30 days in ALI at different keratinocyte concentrations in donor 3, 4 and 5.  Experiments were performed using different 
keratinocyte concentrations – 0.5, 1 and 2x106 cells/scaffold during 30 days at ALI (passage 3). Differentiation and organization of keratinocytes could be observed (black arrows). Scale bar of 
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3.2.2. Optimization of Vitamin C 
Vitamin C is essential for cell differentiation and it is known to enhance the general 
morphology of the skin layers, by improving the differentiation of keratinocytes into stratum 
corneum (Pasonen-Seppanen et al., 2001) and by helping the formation of dermal-epidermal 
junction (Marionnet et al., 2006). Considering the previous results from the optimization of the 
scaffold and cell concentration, it was decided to investigate if increased vitamin C 
concentration during the culturing of the 3D epidermal skin cultures would improve the 
differentiation process of the keratinocyte, help the development of the stratum corneum and 
the general organization of the basal layer.  
The initial concentration of vitamin C used was 1.5mM solution, defined as the optimal 
concentration from previous studies (Groeber et al., 2016; Mewes et al., 2016; Y Poumay et 
al., 2004). However, considering that nutrients optimal concentrations are always dependent on 
scaffold specifications, it was decided to test the optimal concentration of Vitamin C for the 
Alvetex Strata Scaffold. Therefore, 3 concentrations of vitamin C were tested in a keratinocyte 
monoculture - 1.5mM, 2mM and 3mM. Comparison of cell viability of the different 
concentrations of vitamin C to the baseline condition (no vitamin C) showed no significant 
decrease in cell viability (1.5mM= 96.46%; 2mM= 106.3%; 3mM=115.6%), especially for the 
higher concentration of vitamin C (3mM) indicating that the increase of vitamin C was non-
toxic to the keratinocytes (Figure 15). On the contrary, increasing the concentration of vitamin 
C seemed to promote proliferation of cells as cell viability at 3mM is above 100%. Compared 
to the baseline condition, the positive control for cell death, CuSO4, caused a statistically 




Figure 15. Viability of keratinocyte monoculture with vitamin C. Viability for different 
concentrations of Vitamin C (1.5, 2 and 3mM) were tested in a keratinocyte monoculture. 
Medium in the absence of vitamin C was used as a negative control. CuSO4 was used to assess 
cell death. Results are expressed as mean and standard deviation of three independent 
experiments.  *** p < 0.001. Dotted line represents the 80% viability threshold. 
 
 
An experimental plan was designed to understand the impact of high vitamin C 
concentrations on the formation of skin layers (Figure 16). Considering the previous results, 
keratinocytes were seeded at 1x106/cells/scaffold in all conditions. The variable condition of 
the layout was, therefore, the concentration of vitamin C which was tested at 1.5, 2 and 3mM. 
An extra variable was also tested, the time of ALI culture (21 versus 30 days in ALI), to see if 
increased vitamin C required a shorter ALI period. Thus, it would mean faster development of 


















































Figure 16. Experimental layout for testing high concentrations of vitamin C. Different 
concentrations of vitamin C (1.5, 2 and 3mM) were tested at different ALI times to assess overall 
keratinocyte differentiation into epidermal layers. 1.5mM vitamin C at 30 days ALI was the 
current established protocol (▲), while testing conditions were labelled as Δ. 
 
The results from the H&E staining of the 3D epidermal skin cultures (Figure 17 and Figure 
18) showed improved organization of the keratinocytes and much better developed epidermal 
layers than the initial models developed with the Alvetex Strata (Figure 13). Overall, the 3D 
epidermal skin cultures (Figure 17) showed an even distribution of the keratinocytes throughout 
the scaffold with no unpopulated areas, demonstrating the successful adhesion of the 
keratinocytes onto the scaffold. Additionally, keratinocytes seemed to only populate the top 
part of the scaffold, instead of migrating all the way through the scaffold, possibly indicating 
formation of the basal epidermal layer. Supporting this hypothesis is the presence of nuclear 
keratinocyte cells (deep purple) in the basal layer region across all donors but especially visible 
in donors 3 and 4.  
However, increased concentration of vitamin C did not seem to promote improved 
differentiation of stratum corneum any more than the normal concentration of 1.5mM. In fact, 
the 3D epidermal skin culture at normal concentration (1.5mM) seemed to present a more fully 
developed epidermal layer than the 3D skin culture at 3mM. Formation of the epidermal layers 















Figure 17. Vitamin C optimization in donor 1 and 2. Different concentrations of vitamin C (1.5, 2 and 3mM) were tested at different ALI times to improve overall keratinocyte differentiation 
into epidermal layers (black arrow). Scale bar of 200µm representative and similar in all testing conditions. 
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Figure 18. Vitamin C optimization in donor 3 and 4. Different concentrations of vitamin C (1.5, 2 and 3mM) were tested at different ALI times to improve overall keratinocyte differentiation 
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To confirm that the seeded keratinocytes were able to structurally organize themselves into 
the different skin layers (stratum corneum and stratum basale), two immunostaining analyses 
were performed in addition to the H&E staining – picro Sirius red staining for presence of 
collagen and immunofluorescence staining for presence of involucrin and cytokeratin 14 (skin 
protein markers).  
Histological detection of collagen using Picro Sirius Red staining was performed for all 
testing concentrations of vitamin C. Positive staining for collagen is considered as a bright red 
colour in the stratum corneum area. Therefore, presence of collagen in the 3D skin epidermal 
cultures formed using the Alvetex Strata indicate formation of the stratum corneum layer. The 
results from the Picro Sirius Red Staining showed, in fact, positive detection of collagen in all 
concentrations of vitamin C (Figure 19, representative image of donor 2). Some background 
staining is also possible to observe within the scaffold, most likely resulting from the infiltrated 
keratinocytes. Nevertheless, the clear positive red staining can be found mainly in the stratum 
corneum layer, confirming its presence. 
Further differentiation of the different skin strata was confirmed by immunofluorescence 
staining - stratum corneum was characterized using involucrin antibody, while presence of 
stratum basale was confirmed using cytokeratin 14 antibody. Immunofluorescence results for 
stratum corneum with involucrin (Figure 20, representative image of donor 2) showed positive 
staining (bright pink) for involucrin, confirming the presence of stratum corneum. Staining also 
confirmed a thicker stratum corneum layer at 1.5mM for 30 days (normal condition). 21 days 
in ALI did not appeared to be long enough to form a full layer of stratum corneum, even at a 
higher concentration of vitamin C (i.e. 2 and 3mM at 21 days).  
Regarding formation of the stratum basale, positive staining for cytokeratin 14 (bright 
green) could also be observed (Figure 21, representative image of donor 2). This confirmed the 
presence of an organized stratum basale layer that could not be clearly defined in the H&E 
pictures (Figure 17).   
Overall, these immunostaining analyses have helped confirm the presence of stratum 
corneum and stratum basale layers in 3D the skin epidermal cultures formed using the Alvetex 
Strata. Moreover, they have shown that optimal concentration of vitamin C would be of 1.5mM, 
since this concentration allowed for formation of the stratum corneum (positive staining for 
involucrin) with secretion of collagen (positive staining for collagen) and formation of stratum 





Figure 19. Histological detection of collagen in the 3D skin epidermal models formed using the Alvetex Strata. Histological detection of collagen was performed using Picro Sirius 
Red staining for all testing concentrations of vitamin C. Human skin was used as a positive control for presence of collagen - bright red colour in the stratum corneum region (indicated 
by the black arrow). Scale bar of 200µm is representative and similar in all testing conditions. 
Human skin 1.5mM Vit C 







Figure 20. Immunofluorescence staining of involucrin for vitamin C optimization. Positive staining for involucrin (protein marker for epidermal differentiation of stratum corneum) was 
observed (bright pink) in the different concentrations of vitamin C (1.5, 2 and 3mM) (indicated by the white arrow). Human skin was used as positive control for staining of involucrin. Individual 














Figure 20 (continuation). Immunofluorescence staining of involucrin for vitamin C optimization. Positive staining for involucrin (protein marker for epidermal differentiation of stratum 
corneum) was observed (bright pink) in the different concentrations of vitamin C (1.5, 2 and 3mM) (indicated by the white arrow). Individual DAPI staining and merged staining (involucrin and 














Figure 21. Immunofluorescence staining of Cytokeratin 14 for vitamin C optimization. Positive staining for cytokeratin 14 (protein marker for epidermal differentiation of stratum basale) 
was observed (bright green) in the different concentrations of vitamin C (1.5, 2 and 3mM) (indicated by the white arrow). Human skin was used as positive control for staining of involucrin. 















Figure 21 (continuation). Immunofluorescence staining of Cytokeratin 14 for vitamin C optimization. Positive staining for cytokeratin 14 (protein marker for epidermal differentiation 
of stratum basale) was observed (bright green) in the different concentrations of vitamin C (1.5, 2 and 3mM) (indicated by the white arrow). Individual DAPI staining and merged staining 
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Overall, the results from the vitamin C optimization study showed that although increased 
concentrations of vitamin C (2 and 3mM) helped with better distribution of the keratinocytes 
across the scaffold top, it did not seemed to improve development of the epidermal layers better 
than what was observed under normal conditions (1.5mM). Stratum corneum differentiation 
seemed, in fact, to be better at 1.5mM as higher concentrations of vitamin C only seemed to 
promote general proliferation of cells in a unorganized manner.  
In regard to culturing the 3D epidermal skin cultures at 21 or 30 days in ALI, the epidermal 
constructs left for 30 days in ALI appeared to present thicker layers of stratum corneum. The 
extra 10 days from the 21 days test conditions appeared to have allowed keratinocytes to evenly 
populate the scaffold and not present gaps in between keratinocytes throughout the scaffold. 
Also, it appears that these extra10 days allowed keratinocytes to better differentiate into the 
stratum corneum and stratum basale layers.  




3.2.3. Optimization of CaCl2 
Optimal calcium concentration for 3D skin cultures has been reported between 1mM 
(Hennings et al., 1980), 1.5mM (Mewes et al., 2016; Pedrosa et al., 2017) and 2mM (Manaves 
et al., 2004). In fact, high concentrations of calcium (between 1.5 to 2mM) are believed to 
promote terminal differentiation of cultured keratinocytes than low calcium concentrations 
(less than 1mM) as it inhibits expression of integrin, transmembrane receptors responsible for 
cell adhesion. High calcium concentrations will downplay integrin binding, ensuring 
differentiating keratinocytes will migrate from the basal layer to upper epidermal layers  
(Hennings et al., 1980; Hodivala & Watt, 1994; Pillai, Bikle, Mancianti, Cline, & Hincenbergs, 
1990).  
As stated before, optimal nutrient concentration is always dependent on scaffold and cell 
seeding specifications. Considering that the Alvetex Strata has a membrane area twice as big 
as the scaffolds used in other experiments and that it requires a cell seeding density of 1x106 
keratinocytes/scaffold, it was decided to test 1.5mM of calcium as an initial standard 
concentration. Higher calcium concentrations were also tested, at 2 and 3mM, to understand if 
a high calcium microenvironment would improve development of the 3D epidermal skin 
culture.  
Preliminary viability assay determined that the highest concentration of calcium (3mM) 
was cytotoxic as it presented a cell viability of 73.47%, that is below the 80% viability threshold 
(Figure 22) and was therefore excluded from the optimization. The 2mM concentration showed 
a small reduction of cell viability compared to the normal 1.5mM concentration (1.5mM= 
107.2%; 2mM= 82.24%) but because it was not statistically significant, it was not excluded 
from the optimization experiment. As expected, the positive control for cell death, CuSO4, 





Figure 22. Viability for different concentrations of CaCl2 (calcium - 1.5, 2 and 
3mM) was tested on a keratinocyte monoculture. Medium in the absence of calcium 
was used as a negative control. CuSO4 was used to assess cell death. Results are 
expressed as mean and standard deviation of three independent experiments.  
*** p < 0.001. Dotted line represents the 80% viability threshold 
 
As performed for Vitamin C optimization, the time of ALI culture for the higher 
concentration of calcium was also tested. Once again, it was important to understand if a higher 
concentration of calcium at a shorter ALI period would result in a faster development of the 3D 
epidermal skin culture. Therefore, the high concentration of 2mM calcium was tested at both 
21 and 30 days at ALI culture time in five donors.  
H&E results comparing the different concentration of calcium and time of ALI showed 
that 2mM (high calcium) condition did not improve the overall organization of the epidermal 
layer than the standard 1.5mM calcium concentration (Figure 23 and Figure 24). Looking with 
more detail at the 3D skin culture with 2mM of calcium for 21 days, it is possible to see a 
general disorganization of the keratinocytes, with visible gaps throughout the scaffold. No 
proper formation of stratum corneum could be observed and this was confirmed by the 
involucrin immunofluorescence staining (Figure 26). Compared to the standard concentration 
of 1.5mM, the 3D skin cultures at 2mM for 30 days did not showed further improvement of the 
stratum corneum.  
As mentioned before in section 3.2.2, H&E staining was complemented with two 
immunostaining analyses – picro Sirius red staining for presence of collagen and 
immunofluorescence staining for presence of involucrin and cytokeratin 14 (protein markers).  
Histological detection of collagen showed positive staining in the stratum corneum layer, 


















































using the Alvetex Strata (Figure 25, representative image of donor 3). Some background 
staining is also possible to observe within the scaffold, especially for the 2mM and 3mM 
conditions. This is most likely resulting from the infiltrated keratinocytes. Nevertheless, the 
clear positive red staining can be found mainly in the stratum corneum layer, confirming its 
presence. 
Development of the epidermal layers was also confirmed by immunofluorescence staining 
of involucrin (Figure 26, representative image of donor 3) and cytokeratin 14 (Figure 27, 
representative image of donor 3). However, it seems that the positive staining of the stratum 
corneum and stratum basale layers is not as pronounced as previously seen for the vitamin C 
optimization. Additionally, there is a lot of background staining within the scaffold region in 
all calcium concentrations for both involucrin and cytokeratin 14 staining. This could be due 
to unspecific binding of the antibodies to the scaffold mesh or the difficulty to wash them off 
due to the scaffold pore size.  
The information collected from all these immunostaining analyses has helped confirm that 
1.5mM of calcium provides the best conditions for formation of stratum corneum and stratum 




Figure 23. Calcium optimization for donor 1 and 2. A standard (1.5mM) and high (2mM) concentration of calcium were tested at different ALI times (21 and 30 days) using the Alvetex Strata 
to improve overall keratinocyte differentiation into epidermal layers (black arrows). Scale bar of 200µm representative and similar in all testing conditions.   
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Figure 24. Calcium optimization for donor 3 and 4. A standard (1.5mM) and high (2mM) concentration of calcium were tested at different ALI times (21 and 30 days) using the Alvetex Strata 
to improve overall keratinocyte differentiation into epidermal layers (black arrows). Scale bar of 200µm representative and similar in all testing conditions.   
calcium
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Figure 25. Histological detection of collagen in the 3D skin epidermal models formed using the Alvetex Strata. Histological detection of collagen was performed using Picro Sirius Red 
staining for all testing concentrations of Calcium (CaCl2). Human skin was used as a positive control for presence of collagen - bright red colour in the stratum corneum region (indicated by the 
black arrow). Scale bar of 200µm representative and similar in all testing conditions.  
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Figure 26. Immunofluorescence staining of involucrin for calcium optimization. Positive staining for involucrin (protein marker for epidermal differentiation of stratum corneum) was observed 
(bright pink) at the different concentrations of calcium (1.5 and 2mM) for 21 and 30 days at ALI culture (indicated by the white arrow). Human skin was used as positive control for staining of 












Figure 27. Immunofluorescence staining of cytokeratin 14 for calcium optimization. Positive staining for cytokeratin 14 (protein marker for epidermal differentiation of stratum basale) was 
observed (bright green) at the different concentrations of calcium (1.5 and 2mM) for 21 and 30 days at ALI culture (indicated by the white arrow). Human skin was used as positive control for 









Cytokeratin 14 DAPI Merged
105 
 
As mentioned above, increased concentrations of calcium did not seem to improve the 
development of the epidermal layers any further than the normal concentration of 1.5mM. 21 
days of ALI was, again, not sufficient to allow a consistent distribution of the keratinocytes 
throughout the scaffold. The results indicate no reduction of ALI time would be possible as 30 
days at ALI was the optimal time frame. Considering that results from the 2mM concentration 
showed a (non-significant) cell viability reduction and no improvement in differentiation of the 
epidermal layers, it was decided to continue with the normal 1.5mM concentration of calcium 
for the development of the 3D epidermal skin cultures. 
Ultimately, results showed that optimized conditions for development of 3D epidermal 
skin cultures using the Alvetex Strata were 1x106 keratinocytes per scaffold, cultured for 30 




3.2.4. Optimization of collagen coated scaffold  
A comparative analysis with a different scaffold was performed to evaluate performance 
of the Alvetex Strata. The scaffold chosen was the Corning® Transwell®-COL collagen coated 
(rat tail purified collagen) scaffold as this scaffold is currently used in many protocols for 
development of 3D skin models. Protocol for adhesion of cells was similar to the Alvetex  
scaffold, but the collagen-coated scaffold was tested for 14, 19 and 21 days following 
guidelines in the literature (Jung et al., 2014; Pedrosa et al., 2017; Y Poumay et al., 2004). 
Keratinocyte culture medium was enriched with 1.5mM vitamin C and calcium, defined as 
optimal conditions from the results of sections 3.2.2 and 3.2.3. 
Results from the H&E staining of 3 donors showed good formation of stratum corneum, 
with typical “wave shape” stratification of dead keratinocytes (Figure 28). However, it was also 
possible to observe the stratum corneum formed was very thin, especially for the 3D skin 
models formed at 14 and 19 days and almost no basal keratinocytes are present. From the three 
timepoints, 21 days seemed to present a more consistent stratum corneum, considering donor 2 
as the best sample.  
Histological detection of collagen was also performed to confirm formation of the stratum 
corneum (Figure 29, representative image of donor 2). When compared to human skin and to 
the commercially bought epidermal model, EpiDermTM from MatTek, the 3D skin models 
formed using the Corning® Transwell®-COL collagen coated scaffold did not show a strong 
positive collagen staining throughout the entire stratum corneum layer. Nevertheless, collagen 
staining was visible in the stratum corneum (as red staining), suggesting proper organization of 
the seeded keratinocytes into a stratum corneum layer.   
Further characterization of the stratum corneum by immunofluorescence staining showed 
positive staining for involucrin, the protein marker for detection of stratum corneum (Figure 
30, representative image of donor 2). Confirming the H&E results, involucrin staining was 
stronger at 21 days, suggesting that this timepoint would allow for a better developed stratum 
corneum layer.   
Overall, the 3D epidermal skin models formed showed even distribution of the 
keratinocytes and no migration into the scaffold (as opposed to the models using the Alvetex 
Strata). Considering all results from the H&E, Picro Red Sirius and immunofluorescence 
stainings, the 3D epidermal skin models formed for 21 days at ALI seemed to present the best 
formation of the stratum corneum. Therefore, 21 days at ALI results indicate that this 
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incubation time provides better epidermal development when using the Corning® Transwell®-




Figure 28. Development of a 3D epidermal skin model using the Corning® Transwell®-COL collagen coated scaffold. Different times of ALI were tested with this animal-based collagen 
coated scaffold – 14, 19 and 21 days. Organization of keratinocytes into an epidermal layer can be observed (black arrows). Scale bar of 200µm is similar in all testing conditions.   
14 days 19 days 21 days
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Figure 29. Histological detection of collagen in the 3D epidermal skin models formed using the Corning® Transwell®-COL collagen coated scaffold. 
Histological detection of collagen was performed using Picro Sirius Red staining for all ALI culture timepoints – 14, 19 and 21 days. Human skin and EpidermTM 
(commercially bough epidermal model from MatTek) were used as a positive control for presence of collagen - bright red colour in the stratum corneum region 
(indicated by the black arrow). Scale bar of 200µm is similar in all testing conditions.   
Human skin EpiDermTM









Figure 30. Immunofluorescence staining of involucrin for the 3D epidermal skin models formed using the Corning® Transwell®-COL collagen coated scaffold. 
Positive staining for involucrin (protein marker for epidermal differentiation of stratum corneum) was observed (bright pink) in the different timepoints of ALI (14, 19 
and 21 days) (indicated by the white arrow). Human skin and EpidermTM (commercially bough epidermal model from MatTek) were used as a positive control for 
staining of involucrin. Individual DAPI staining and merged staining (involucrin and DAPI) showed co-localization of epidermal cells. Scale bar of 200µm is 




















































































As previously mentioned, the focus of this task was to develop a comparative performance 
analysis between a commercially made collagen-coated scaffold and the Alvetex Strata with 
added coated collagen. Because the use of the Alvetex Strata required optimization of ALI 
culture time, it was decided to also test the use of the Alvetex Strata Scaffold with added coated 
collagen for different ALI culture times. So, more timepoints were added to the previous ones 
tested with the Corning® Transwell®-COL collagen coated scaffold – day 3, day 7 and day 30. 
This way, it was possible to recreate a continuous “timeline” of keratinocyte differentiation into 
the different skin layers to better understand the cellular organization of keratinocytes into 
stratum corneum and stratum basale. Additionally, it was important to assess if the use of a 
collagen layer onto the Alvetex Strata would help prevent infiltration of keratinocytes into the 
scaffold. As previously mentioned, keratinocyte culture medium was enriched with 1.5mM 
vitamin C and calcium, defined as optimal conditions from the results of sections 3.2.2 and 
3.2.3. 
Results from the H&E staining using collagen showed general good adhesion to the 
scaffold membrane with an even distribution of the keratinocytes through the scaffold (Figure 
32). The day 3 timepoint was clearly not enough as ALI culture time, since there are barely any 
keratinocytes attached to the scaffold. Increasing the ALI culture time to 7 days seemed to 
improve adhesion of keratinocytes and its consequent proliferation, but this timepoint is still 
not enough for proper development of the 3D epidermal skin culture models. These conclusions 
are also supported by the fact that there is no collagen present in the stratum corneum of any of 
the 3D epidermal skin models formed at 3 and 7 days of ALI culture time (Figure 34). 
The 3D epidermal skin models formed at 14 days of ALI culture time seemed to provide 
enough time for a reasonably formed stratum corneum layer, especially in donor 1, where a 
characteristic “wave” shaped stratum corneum. Donor 2 and 3 present a very thin stratum 
corneum layer that is confirmed by positive staining for collagen in Figure 34. The three 
remaining timepoints – 19, 21 and 30 days of ALI culture time did not seem to improve any 
further the formation of the stratum corneum layer. It is possible to observe a characteristic 
“wave” shaped stratum corneum in donors 1 and 2 at the 30 days timepoint in ALI with positive 
collagen secretion (Figure 34) but not as evident as the stratum corneum formed in the 3D 
epidermal skin model from donor 1 at 14 days of ALI. Therefore, these results might suggest 
that 14 days of ALI culture time might be enough to provide good formation of the stratum 






Figure 31. 3D epidermal skin culture using the Alvetex Strata coated with human collagen for 3 and 7 days. The Alvetex Strata was coated with human collagen to improve the 
cellular organization of the stratum corneum and prevent further keratinocyte infiltration into the scaffold. The culturing time for keratinocytes was tested at 3 and 7 days of ALI culture 
time in three donors. Organization of keratinocytes into an epidermal layer can be observed (black arrows). Scale bar of 200µm is similar in all testing conditions. 
3 days 7 days
Donor 1 Donor 1
Donor 2 Donor 2











Figure 32. 3D epidermal skin culture using the Alvetex Strata coated with human collagen for 14 and 19 days. The Alvetex Strata was coated with human collagen to improve the 
cellular organization of the stratum corneum and prevent further keratinocyte infiltration into the scaffold. The culturing time for keratinocytes was tested at 14 and 19 days of ALI 
culture time in three donors. Organization of keratinocytes into an epidermal layer can be observed (black arrows). Scale bar of 200µm is similar in all testing conditions. 
14 days 19 days
Donor 1 Donor 1
Donor 2 Donor 2









Figure 33. 3D epidermal skin culture using the Alvetex Strata coated with human collagen for 21 and 30 days. The Alvetex Strata was coated with human collagen to improve the 
cellular organization of the stratum corneum and prevent further keratinocyte infiltration into the scaffold. The culturing time for keratinocytes was tested at 21 and 30 days of ALI 
culture time in three donors. Organization of keratinocytes into an epidermal layer can be observed (black arrows). Scale bar of 200µm is similar in all testing conditions.  
21 days 30 days
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Figure 34. Histological detection of collagen in the 3D epidermal skin models formed using the Alvetex Strata coated with human 
collagen. Histological detection of collagen was performed using Picro Sirius Red staining for all ALI culture timepoints – 3, 7, 14, 19, 
21 and 30 days. Human skin and EpidermTM (commercially bough epidermal model from MatTek) were used as a positive control for 
presence of collagen - bright red colour in the stratum corneum region (indicated by the black arrow).  Scale bar of 200µm is similar in 
all testing conditions. 
Human skin EpiDermTM
3 days 7 days
14 days 19 days









It was expected that addition of collagen would prevent keratinocyte fallout into the 
scaffold as the scaffold pores would be filled with collagen fibres, forming a collagen matrix 
so keratinocytes could differentiate on top of the scaffold. Compared to the 3D skin cultures 
made without collagen coating, the collagen coating did seem to increase keratinocyte 
infiltration into the scaffold. H&E results showed that the 3D epidermal skin models formed 
using the collagen coated scaffold are much more populated with keratinocytes, being almost 
impossible to see unoccupied scaffold. However, it did not seem to inhibit formation of stratum 
corneum, as it can be seen in donors 1 and 2 at 14 and 30 days of ALI with consequent collagen 
detection.  
Further characterization of the stratum corneum formation was performed by 
immunofluorescence staining of involucrin (Figure 35, representative image of donor 1). 
Expression of involucrin was consistent throughout the different timepoints of ALI and even 
similar to the involucrin staining expressed in human skin and in the commercially available 
RHE model (MatTek EpiDermTM). Therefore, the results from the immunofluorescence 
staining have helped confirm the presence of stratum corneum in the 3D epidermal skin models 
formed using the Alvetex Strata coated with collagen.  
Altogether, the results from the collagen optimization have shown that is possible to 
develop 3D epidermal skin models using the Alvetex Strata coated with collagen, as it will 
allow for proper formation of the stratum corneum with collagen formation and involucrin 
expression. The output 3D model from the Alvetex Strata is also similar to the ones from 
commercially available models, as in the case of the EpidermTM (from MatTek) and the 
Corning® Transwell®-COL collagen coated scaffold.  
Considering the different timepoints, results have shown that there is not much difference 
between the standard 14 days of ALI and longer time periods (21 or 30 days), so perhaps 14 






Figure 35. Immunofluorescence staining of involucrin for collagen coated 3D skin models. Positive staining for involucrin (protein marker for epidermal differentiation of stratum corneum) 
was observed (bright pink) in the 3D epidermal skin models formed using Alvetex Strata coated with collagen (day 14, 19, 21 and 30) (indicated by the white arrow). Human skin and EpidermTM 















































































































Figure 35 (continuation). Immunofluorescence staining of involucrin for collagen coated 3D skin models. Positive staining for involucrin (protein marker for 
epidermal differentiation of stratum corneum) was observed (bright pink) in the 3D epidermal skin models formed using Alvetex Strata coated with collagen (day 14, 19, 21 
and 30) (indicated by the white arrow). Human skin and EpidermTM (commercially bough epidermal model from MatTek) were used as a positive control for staining of 














































































































3.3. Reproducibility of the 3D epidermal skin cultures 
 
In addition to the optimization process of the 3D epidermal skin cultures, it is also important 
to consider its reproducibility and variability between donors. All 3D epidermal skin cultures 
were constructed by the same operator following the same protocol, but minor technical 
variations could still influence the reproducibility of the 3D epidermal skin cultures. As 
keratinocytes are centrifuged to remove any trace of culturing medium before seeding, 
resuspension of the keratinocytes was sometimes difficult due to cell clumping. Therefore, and 
while taking this into account, there could have been some minor differences in the pipetting 
volume of the keratinocytes into the scaffold. Moreover, cell clumping could also have resulted 
in an uneven adhesion of the keratinocytes into the scaffold.  
Additionally, it is also important to consider donor variability. Although keratinocytes were 
isolated, cultured and seeded at the same passage number and corrected for cell concentration 
of 1x106 keratinocytes/scaffold, it could still result in a not similar growth and differentiation 
of the keratinocytes into the epidermal layer.  
However, and considering all these limitations, the 3D epidermal skin cultures developed 
showed an overall consistency and resemblance across all donors. Slight observed differences 
in different donors were discussed throughout the previous sections of optimization.  
Further reproducibility studies on the development of the 3D epidermal skin cultures should 
include development of these models by a different operator to better evaluate transferability 
of the protocol and culture technique.  
 
3.4. Discussion of the results 
Optimization of the 3D epidermal skin culture was carried out considering several aspects 
– cell number, culture period, vitamin C concentration, calcium concentration and scaffold 
properties. Results from all cell culturing conditions in this chapter suggest that the optimized 
protocol for development of the 3D epidermal skin models would be seeding 1x106 
keratinocytes in a collagen-coated Alvetex Strata membrane for 14 days of ALI. 
Cell number is a very important feature because it will determine the maximum number of 
3D skin cultures that can be constructed from one donor. A larger number of cells per scaffold 
would require laborious cell culture, bulking of cells at low passage numbers and large volumes 
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of culture medium which could be very challenging. This could increase the likelihood of 
infections or stress resulting in unwanted differentiation of the keratinocytes while still in the 
culture flask or the keratinocytes reducing their proliferative capacity. The use of 1x106 cells 
per scaffold showed good cell adhesion, consistent distribution through the scaffold and proper 
differentiation of the epidermal layers without encumbering lengthy cell culture work, it was 
used as the optimal cell number required for development of the 3D epidermal skin cultures. 
Optimizing the duration time of culture is important to reduce the turnover of the 3D 
cultures for in vitro testing studies. Previous protocols for the development of 3D skin models 
have used 14, 19 and 21 days of ALI, for good formation of the stratum corneum and stratum 
basale layers.  However, results using the Alvetex Strata showed that 21 days of ALI was not 
sufficient to guarantee reasonable differentiation of the epidermal layers. This was a crucial 
feature to guarantee quality standards of the 3D skin culture and incomplete formation of the 
stratum corneum could compromise the results of the test they would be used for. The optimal 
time of 30 days of ALI was used for development of the 3D epidermal skin cultures as it showed 
the best results of epidermis formation.  
Optimization of vitamin C and calcium showed some improvements in the distribution of 
the keratinocytes in the 3D epidermal skin culture compared to normal concentrations. The 
importance of calcium addition in keratinocyte cultures has been controversial. Calcium was 
identified as vital for growth and differentiation of keratinocytes in culture in the early 1980s 
by direct relationship of extracellular calcium concentration and differentiation markers of 
mouse keratinocytes  (Hennings et al., 1980). This association was immediately considered 
fundamental for keratinocyte culture and calcium was from this point forward an inarguable 
requirement for epidermal differentiation (Elsholz, Harteneck, Muller, & Friedland, 2014; 
Pillai et al., 1990). However, it is important to highlight that such findings were related to 
mouse keratinocytes and more recent studies using human keratinocytes have actually disputed 
the fundamental role of calcium in keratinocyte differentiation. In 1984, conditions such as cell 
density were shown to be more relevant to keratinocyte differentiation than calcium 
concentration (Wille, Pittelkow, Shipley, & Scott, 1984). Further reports showing how cell 
concentration affects the expression levels of differentiation markers cytokeratin 1 and 10 
(Drozdroff & Pledger, 1993; Yves Poumay & Pittelkow, 1995) corroborate the notion that 
calcium stimulus on keratinocyte differentiation is not significant. In fact, some authors claim 
these findings are irrelevant (Yves Poumay & Coquette, 2007), and others went as far as stating 
that calcium relevance in keratinocyte differentiation is overestimated (Kolly, Suter, & Mu, 
2005). While no consensus has yet been agreed regarding calcium requirement in 3D culture 
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of keratinocytes, the results observed in this chapter showed that normal concentration of 
calcium (1.5mM) was sufficient to guarantee good keratinocyte differentiation.  
With regard to using a collagen base in the scaffold, results from the Corning® 
Transwell®-COL scaffolds showed good stratification of the stratum corneum but almost no 
evidence of stratum basale. That together with the fact that the Corning® Transwell®-COL 
scaffolds use animal-based collagen is discouraging for the development of a 3D animal-free 
skin equivalent model. The Alvetex Strata coated with human collagen could possibly be the 
best optimized 3D epidermal skin model, as it showed good formation of the stratum corneum 
with formation of collagen. Moreover, it allowed for development of the 3D epidermal skin 
models in the shortest ALI time – 14 days.  
Overall, the aim of this project was to develop an open source 3D epidermal skin culture 
with relevant epidermal stratification. The results showed that this was achieved using the 
Alvetex Strata membrane using 1x106 keratinocytes per scaffold for 30 days ALI culture, 
enriched with 1.5mM vitamin C and calcium concentrations. H&E results showed stratification 
of the epidermal layers, stratum corneum and stratum basale and this was also confirmed by 
expression of the protein markers involucrin and cytokeratin 14. While presence of the stratum 
basale was not phenotypically well defined in the H&E pictures (Figure 17), positive staining 
for cytokeratin 14 confirmed its presence (Figure 21). This indicated that while keratinocytes 
might not resemble a typical stratum basale layer with round shaped keratinocytes, the basal 
cells were still present in the 3D skin epidermal cultures developed. The fact that keratinocytes 
of the stratum basale did not present a well-defined round shape could be attributed to the 
scaffold properties. It is a porous scaffold, acting as a “sponge” so the keratinocytes can adhere 
and be in contact with the culture medium from below. So, the lack of a proper scaffold bottom 
structure could inhibit the phenotypic development of the stratum basale.  
All the phenotypic characteristics mentioned above are of crucial important for 
development of in vitro skin models. Because the major drive force for development and 
commercialization of an in vitro alternative skin models needs to be its close resemblance to 
the in vivo human skin microenvironment, so any safety testing or screening will provide a 
relevant readout for human purposes. Considering that three in vitro 3D models were used in 
this chapter, phenotypic comparison of the different skin layers from each model is expected 
(Figure 36).  
Starting from the outer epidermal layer, formation of the stratum corneum is visible in all 
three in vitro skin models, with its characteristic “wave shape”. This layer is consistently the 
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most well-defined layer across the three in vitro skin models. As for the inner layers, the stratum 
spinosum and the stratum basale, phenotypic resemblance to human skin is not so evident. The 
cells from the stratum spinosum present a large purple tone nuclei that is possible to observe in 
all in vitro 3D models. There is just a visible difference in the consistency and thickness of this 
layer across the in vitro 3D models, since the stratum spinosum is much more defined in the 
EpiDermTM RHE model. The same observations are valid for the stratum basale, which should 
be composed of a single layer of “square-shaped” keratinocytes in the bottom of the epidermis. 
Nevertheless, immunofluorescence staining using cytokeratin 14 indicated presence of stratum 
basale in both the 3D epidermal skin culture using the Alvetex Strata coated with human 
collagen and in the 3D skin model using the Corning® Transwell®-COL scaffold. 
 
 
Figure 36. Comparison between the different 3D epidermal skin models used to real human skin. Phenotypic comparison 
of the different epidermal skin layers – stratum corneum, stratum spinosum and stratum basale – between A) human skin, B) 
the EpiDermTM RHE model (from MatTek), C) the 3D epidermal skin culture using the Alvetex Strata coated with human 
collagen and D) the 3D skin model using the Corning® Transwell®-COL scaffold. 
 
Ultimately, optimization results from this chapter showed that the D epidermal skin culture 
developed using the Alvetex Strata coated with collagen is phenotypically relevant to human 





















4. Assessment of skin irritation testing using a 3D epidermal skin culture 
 
4.1. Aim  
OECD performance standards for 3D epidermal models can be found in the form of Testing 
Guidelines. In fact, the use of 3D epidermal models following the appropriate Testing 
Guidelines is mandatory for official EURL-ECVAM validation of the RHE models.  
Testing Guideline (TG) 439 refers to skin irritation testing using reconstructed skin models. 
It contains a detailed protocol for assessment of skin irritation by determination of cell viability. 
Skin irritants differ from non-irritants by causing a reduction in cell viability of more than 50%. 
ECVAM used this Testing Guideline to validate 3 commercially available 3D epidermal skin 
models for assessment of skin irritation - EpiDermTM, EpiSkinTM and SkinEthic RHE (Table 
2).  
Morphology of the 3D epidermal models is a very important quality control parameter as 
described in OECD TG 439. In fact, morphology of the in vitro skin explant can impact the 
assessment of skin irritation testing described in OECD TG 439. Parameters like incorrect 
organization of the keratinocytes throughout the epidermal layer or background interference 
from the scaffold should be carefully considered as they can hamper the damage caused by the 
chemical exposure and ultimately affect the readout from the skin irritation testing, by not 
correctly identifying a non-irritant or irritant chemical.  
Therefore, it was imperative to complement optimization of the 3D epidermal model using 
two Alvetex scaffold membranes (chapter 3) with the assessment of the skin irritation testing 
(chapter 4). All the histological results concerning morphology of the developed 3D epidermal 
skin culture are described in Chapter 3 and results showed that the Alvetex Strata was the best 
scaffold to use. Consequently, the aim of this chapter was to evaluate the 3D epidermal skin 
culture developed using the Alvetex Strata for its ability to assess skin irritation, by distinguish 
between non-irritant and irritant chemicals. 
 
4.2. Results 
The 3D epidermal skin cultures were tested using a skin irritation testing assay following 
the OECD Testing Guideline 439. Briefly, the 3D epidermal skin model was exposed to a non-
irritant or irritant chemical for 30 minutes, followed by a washing step to mimic a real-life 
scenario. Damage to the skin cells was assessed by keratinocyte cell death using a MTT 
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viability test. The readout from the MTT test directly indicates skin irritancy, if cell viability 
falls below a 50% viability threshold upon exposure to the testing chemical.  
4.2.1. Skin irritation testing using the Alvetex Scaffold 
Results from Chapter 3 showed that the standard Alvetex Scaffold did not allowed for 
complete epidermal formation. However, preliminary skin irritation testing was performed 
using this model as a 3D culture model to evaluate the scaffold performance in the same 4 
donors. Only negative and positive controls were tested – PBS and 5% SDS in aqueous solution, 
respectively, as stated in TG 439. An additional positive control was used as test chemical, 
Triton-X 1% (Figure 37). 
 
Figure 37. TG 439 Skin irritation testing of the 3D epidermal skin cultures using the Alvetex 
Scaffold. PBS and 5% SDS in aqueous solution were used as negative and positive control 
respectively, following the TG 439 protocol. Triton-X (T-X) 1% was used as additional test 
condition. Results are expressed as mean and standard deviation of three independent experiments 
measured at 575nm.  *** p < 0.001 
 
While histological results from Chapter 3 showed that the Alvetex Scaffold did not allow 
for complete epidermal differentiation, it still performed well in the skin irritation testing. 
Compared to the negative control (PBS), 5% SDS (positive control) caused a significant 
reduction in cell viability of more than 90%. Triton-X 1% also achieved similar results 
(showing a cell viability of 5.9%), showing that the 3D epidermal skin culture using the Alvetex 



















































4.2.2. Skin irritation testing using Alvetex Strata 
 
Skin irritation testing was also performed in the 3D skin epidermal cultures using the 
Alvetex Strata. Preliminary irritation testing was performed in the same conditions as the 
Alvetex Scaffold membrane for the 3 timepoints tested - 14, 21 and 30 days of ALI (Figure 38) 
in the same 5 donors used for the construction of the 3D epidermal skin model. 
 
 
Figure 38. TG 439 Skin irritation testing of the 3D epidermal skin cultures using the Alvetex 
Strata. Irritation testing was performed in all 3 optimization timepoints for ALI – 14, 21 and 30 
days. PBS and 5% SDS in aqueous solution were used as negative and positive control 
respectively, following TG 431. Triton-X (T-X) 1% was used as additional test condition. Dotted 
line represents the 50% viability threshold. Results are expressed as mean and standard deviation 










































































































































Results showed that 3D epidermal skin cultures cultured for 14 days at ALI failed to 
accurately distinguish the irritant controls (5% SDS and TX-1%) from the non-irritant control 
(PBS). While the reduction in cell viability caused by the positive controls was significantly 
different from the negative control (p<0.0001), it still failed to reach the 50% viability threshold 
established by the TG 439.  
The viability results from the 3D epidermal skin cultures cultured for 21 and 30 days at 
ALI showed significant reduction in cell viability by the positive controls below the 50% 
viability threshold (p<0.0001). At 21 days, the 3D epidermal skin models showed a cell 
viability of 35% for 5% SDS solution and a 38% viability for T-X 1% solution. At 30 days, the 
3D epidermal skin models showed a cell viability of 12% for the 5% SDS solution and a 14% 
viability for the T-X 1% solution. These preliminary results showed that the optimized 3D 
epidermal skin cultures performed well according to OECD TG 439 standards. Considering the 
histological results from Chapter 3, only the 3D epidermal skin cultures cultured for 30 days at 
ALI were considered for further skin irritation testing. Therefore, a more detailed evaluation of 
the 3D epidermal skin culture model was performed using 12 chemicals (6 irritant and 6 non-
irritant) from the Validated Reference Methods List of test chemicals (Table 6), each chemical 
tested in 10 independent tests. 
Viability results for each tested chemical were calculated in comparison to the negative 
control, PBS and are given in Table 10, as well as the mean value of the 10 independent donors 
in which chemicals were tested. Cell viability of the positive control, 5% SDS in aqueous 
solution, was of 22.25±0.86% (p<0.001) when compared to the 100% viability of the negative 
control. These results showed the stability and consistency of the 3D epidermal cultures in 
culture across different donors, which was also a quality control parameter of the OECD TG 
439. An extra positive control was also tested in all donors, Triton X-1%. This chemical is used 
as positive control for acute eye irritancy, as specified in OECD TG 405 (OECD, 2012a). 
Results from the 3D epidermal skin culture showed that the optimized model could also classify 
TX-1% as an irritant, since it caused an average viability of only 36.79±2.23% (p<0.001).  
Regarding the non-irritant chemicals tested, the 3D epidermal skin culture was able to 
correctly classify 4 out of the 6 chemicals tested as non-irritants since the viability was above 
the 50% threshold– allyl phenoxy-acetate (62.70±3.56%; p<0.001), isopropanol 
(78.81±2.35%), heptyl butyrate (71.09±2.50%; p<0.001) and hexyl salicylate (72.73±3.44%).  
1-bromo-4-chrlorobutane (44.03±2.19%; p<0.001) and 4-methyl-thio-benzaldehyde 
(45.07±3.03%; p<0.001) showed viability below the 50% viability threshold, indicating them 
as false positives for irritancy. However, if considering the specifications of these chemicals 
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mentioned on Table 6, both chemicals are classified as non-irritant in in vivo assays with no 
GHS category. This means that there is not enough in vivo data to support classification of these 
chemicals as irritants, so they are classified as non-irritants. It could be argued that these 
chemicals are in fact irritants and that the 3D epidermal skin culture is sensitive enough to 
determine their irritancy. However, further validation is required to confirm this hypothesis. 
Regarding the irritant chemicals tested, all 6 irritants were correctly categorised by the 3D 
epidermal skin culture showing a viability below 50%: 1-decanol (36.48±1.80%; p<0.001), 1-
bromohexane (35.19±4.08%; p<0.001), di-n-propyl disulphide (37.16±1.19%; p<0.001), 




Table 10. Cell viability results for the 3D epidermal skin culture with the Alvetex Strata for skin irritation testing following TG 439. 6 non-irritant (■) and irritant (□) chemicals from TG 
439 for skin irritation were tested in the 3D epidermal skin culture in 10 donors with 30µL of the testing chemical dispensed directly on top of the skin model cells. Cell viability is reported as 
percentage of viability for each chemical is calculated in comparison to the negative control (PBS). For each donor, chemical test was performed in triplicate and viability is reported as average 
of 10 independent tests with standard deviation (SD).  
Chemical 
% Cell viability ± Standard Deviation (SD) 
Donor 1 Donor 2 Donor 3 Donor 4 Donor 5 Donor 6 Donor 7 Donor 8 Donor 9 Donor 10 
Total 10 
donors 
PBS  (- ctrl) ■ 100.10±0.75 100.00±2.71 100.00±6.56 100.00±11.42 100.00±2.28 100.00±0.67 100.00±0.37 100.00±1.57 100.00±0.30 100.00±0.31 100.01±2.49 
1-bromo-4-
chlorobutane ■ 36.15±0.65 48.09±0.89 26.43±1.70 60.11±10.78 50.85±5.55 20.93±0.24 93.51±1.03 33.89±0.18 35.20±0.41 35.15±0.44 44.03±2.19 
allyl phenoxy-
acetate ■ 63.34±12.42 46.50±1.40 81.43±3.79 71.45±5.05 94.98±1.23 76.03±0.05 76.03±0.05 36.92±1.16 41.32±5.35 39.01±5.13 62.70±3.56 
Isopropanol ■ 90.89±1.61 44.77±0.49 82.38±0.93 76.15±1.40 75.96±2.62 55.67±0.24 94.36±1.76 89.75±6.87 93.02±4.26 85.14±3.36 78.81±2.35 
4-methyl-thio-
benzaldehyde ■ 35.27±1.20 45.93±1.42 21.62±1.64 84.66±8.33 50.85±5.76 52.42±5.34 52.42±5.34 36.25±0.97 35.62±0.09 35.67±0.19 45.07±3.03 
heptyl butyrate ■ 69.36±2.93 50.68±2.82 73.52±2.20 85.37±5.34 90.49±9.56 53.20±0.41 84.11±0.88 66.63±0.51 68.86±0.24 68.71±0.09 71.09±2.50 
hexyl salicylate ■ 69.35±2.10 97.62±4.37 70.82±1.73 77.22±10.99 89.53±12.53 32.09±0.23 88.96±1.73 68.22±0.09 66.70±0.34 66.84±0.24 72.73±3.44 
5% SDS 
 (+ ctrl) □ 32.99±0.44 19.39±0.14 24.97±0.72 36.79±1.17 44.23±4.27 18.23±0.12 10.43±0.04 9.71±0.51 12.43±0.09 13.37±1.14 22.25±0.86 
1-decanol □ 33.14±1.63 42.11±1.45 23.17±1.10 78.10±4.72 45.51±0.55 45.95±6.05 43.51±1.78 18.17±0.46 17.54±0.11 17.59±0.12 36.48±1.80 
1-bromohexane 
□ 
46.29±2.10 53.21±2.14 25.38±2.54 55.67±16.39 58.33±15.30 24.68±0.00 30.03±0.53 15.67±0.19 17.31±0.09 25.34±1.54 35.19±4.08 
di-n-propyl 
disulphide □ 30.57±0.86 59.12±1.63 26.78±1.47 53.01±4.012 43.91±0.88 39.78±1.25 40.15±1.03 19.01±0.24 29.60±0.09 29.64±0.45 37.16±1.19 
Heptanal □ 34.39±0.63 45.06±1.21 22.74±1.40 13.21±0.67 56.62±3.30 41.16±0.16 28.13±0.39 20.19±0.65 29.50±0.44 29.60±1.58 32.06±1.04 
Tetrachloro 
Ethylene □ 47.32±2.36 59.48±3.56 29.38±1.03 55.32±12.31 50.64±3.13 28.13±0.39 27.65±0.52 19.57±0.81 26.13±0.18 26.17±0.79 36.98±2.51 




Figure 39.  In vitro testing of TG 439 skin irritation using the 3D epidermal skin culture with Alvetex Strata. A. In vitro performance testing of the 3D epidermal skin culture using six non-
irritants (blue stripped columns) and six irritants (pink stripped columns). Results are expressed as mean and standard deviation of ten independent experiments.  ***p<0.001 when compared to 
the negative control (- ctrl), PBS (blue filled column). Positive control (+ ctrl) as 5% SDS in aqueous solution (pink filled column). Dotted line represents the 50% viability threshold. B. 






































































































































































































































































































Altogether, these results substantiate the performance of the optimized 3D epidermal skin 
culture for skin irritation testing. Furthermore, a skin irritation testing comparative analysis was 
performed using a commercially available RHE model (EpiDermTM, MatTek), a keratinocyte 
monolayer culture and a 3D skin model using a collagen-based scaffold (Corning).  
 
4.2.3. Skin irritation testing using EpiDermTM (MatTek) 
A commercially available 24-well plate RHE model was obtained from MatTek 
(EpiDermTM). This RHE model consists of differentiated human-derived keratinocytes cultured 
in inserts at ALI (culture time of ALI is not specified). The origin of keratinocytes is also not 
specified, and therefore it was not known if all 24 model wells consisted of keratinocytes from 
the same donor or a pool of keratinocyte donors. We therefore considered all 24 well models 
of the EpiDermTM model as from one single keratinocyte donor. Therefore, the three replicates 
for each condition of skin irritation testing are not independent replicates. 
Results from the skin irritation testing using the EpiDermTM RHE model from MatTek 
showed that this RHE was able to correctly classify 5 out of 6 non-irritants and 5 out of 6 
irritants (Figure 40) according to the irritancy threshold of 50% viability. Allyl phenoxy-acetate 
(134±6.29%; p<0.001), isopropanol, (69.1±2.62%; p<0.001), 4-methyl-thio-benzaldehyde 
(110.4±5.66%; p<0.001), heptyl butyrate (104.3±9.57%) and hexyl salicylate (111.3±4.17%; 
p<0.001) were correctly classified as non-irritants as the viability observed was above 50%, 
while 1-decanol (20.5±0.67%; p<0.001), 1-bromohexane (23.4±0.85%; p<0.001), heptanal 
(21.6±0.82%; p<0.001), tetrachloroethylene (20.38±0.8%; p<0.001) and TX-1% (19.9±0.38%; 
p<0.001) were correctly classified as irritants showing viability below the 50% threshold. 
However, the viability results of 4-methyl-thio-benzaldehyde (110.4±5.66%; p<0.001), heptyl 
butyrate (104.3±9.57%) and hexyl salicylate (111.3±4.17%; p<0.001) were all above 100% cell 
viability, meaning that their viability is greater than PBS viability (100%). This discrepancy 
could be due to technical error during the experiment.  
Similar to the results from the 3D epidermal skin models with the Alvetex Strata Scaffold, 
the viability following exposure to 1-bromo-4-chlorobutane viability was again below the 
irritancy threshold (29.7±0.79%; p<0.001), considering this chemical as a false positive irritant. 
On the contrary, di-n-propyl disulphide was categorised as a false negative since it results 







Figure 40. In vitro testing of TG 439 skin irritation using the EpiDermTM RHE model (MatTek). A. In vitro performance testing 
of the commercially available RHE model using six non-irritants (blue stripped columns) and six irritants (pink stripped columns). 
Results are expressed as mean and standard deviation of 1 experiment.  ***p<0.001 when compared to the negative control (- ctrl), 
PBS (blue filled column). Positive control (+ ctrl) as 5% SDS in aqueous solution (pink filled column). Dotted line represents the 
50% viability threshold. B. Representative image of the EpiDermTM RHE model. 
 
Overall, the skin irritation testing results for the EpiDermTM RHE model were in 
accordance with the OECD TG 439 standards of irritancy - 50% viability threshold. However, 
four non-irritant chemicals showed a viability greater than 100% and one non-irritant chemical 
was classified as false negative. This together with the fact that all 24 RHE models are possibly 
derived from the same donor could justify the irregularity of the skin irritation testing results. 
Further repeat of this work would be required, however it would again not be possible to 
determine if the new EpiDermTM RHE model would be developed using keratinocytes from the 
same donor as the previous bought one. 
Considering that the epidermal model is a commercially available RHE model and it is 
widely used for toxicity studies regarding skin irritation, results showed that the 3D epidermal 
skin culture could correctly classify as many non-irritants from irritants as the EpiDermTM RHE 
model. These findings validate the applicability of the 3D epidermal skin culture for skin 
































































































































































































































































































4.2.4. Skin irritation testing using a keratinocyte monolayer culture  
To better understand the behavioural difference between keratinocytes in a monolayer 
2D culture and keratinocytes in a 3D multilayer culture, a monolayer keratinocyte culture of 
the same 10 donors used for the 3D epidermal skin culture were developed for skin irritation 
testing. 
As expected, keratinocytes in monolayer culture did not show the same outcome as the 3D 
epidermal skin culture when following the OECD TG 439 guidelines. While the monolayer 2D 
culture was able to correctly identify the positive controls – 5%SDS (11.80±3.63%; p<0.001) 
and TX-1% (36.50±8.07%; p<0.001), it could only correctly identify 3 out of 6 non-irritants. 
Allyl phenoxy-acetate (51.26±7.91%; p<0.001), heptyl butyrate (68.55±15.74%; p<0.001) and 
hexyl salicylate (75.36±19.55%; p<0.001) were correctly classified as non-irritants, by 
showing a cell viability above 50%. All 6 irritant chemicals were correctly identified by the 
monolayer 2D culture - 1-decanol (18.16±3.46% viability; p<0.001), 1-bromohexane 
(24.18±10.49%; p<0.001), di-n-propyl disulphide (24.64±5.78%; p<0.001), heptanal 
(28.96±6.78%; p<0.001) and tetrachloroethylene (24.94±4.31%; p<0.001) showing a viability 
below 50% (Table 11 and Figure 41). 
Once again, 1-bromo-4-chlorobutane was below the irritancy threshold (32.67±22.04%; 
p<0.001), being classified as a false positive. Isopropanol (26.68±9.74%; p<0.001) and 4-
methyl-thio-benzaldehyde (21.49±5.77%; p<0.001) were also classified as false positives in 
the keratinocyte monolayer culture.  
Ultimately, performance of the keratinocyte monolayer culture was sub-standard compared 
to the 3D epidermal skin culture and to the EpiDermTM RHE model. Keratinocytes in a 
monolayer culture are not differentiated, do not present stratified layers and do not grow at ALI 
conditions (but rather in submersed culture medium). Therefore, these keratinocytes will 
behave differently from fully stratified keratinocytes that grow at ALI as real human skin. The 
results from the skin irritation testing have shown that monolayer culture is not suitable for skin 
irritation testing, since it was not able to correctly identify irritants and non-irritants. 
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Table 11. Cell viability results for the keratinocyte monolayer culture for skin irritation testing following TG 439. 6 non-irritant (■) and irritant (□) chemicals from TG 439 for skin irritation 
were tested in a keratinocyte monolayer culture in 10 donors with 30µL of the testing chemical dispensed in the cell culture supernatant. Cell viability is reported as percentage of viability for 
each chemical is calculated in comparison to the negative control (PBS). For each donor, chemical test was performed in triplicate and viability is reported as average of 10 independent tests with 
standard deviation (SD). 
Chemical 
% Cell viability ± Standard Deviation (SD) 
Donor 1 Donor 2 Donor 3 Donor 4 Donor 5 Donor 6 Donor 7 Donor 8 Donor 9 Donor 10 
Total 10 
donors 
PBS  (- ctrl) ■ 100.00±1.57 100.00±0.30 100.00±0.40 100.00±11.91 100.00±16.31 100.3±1.20 99.75±0.30 100.30±0.77 103.3±6.15 99.33±5.30 100.30±5.33 
1-bromo-4-
chlorobutane ■ 13.89±0.18 15.20±0.41 15.15±0.44 24.74±2.09 80.79±7.04 29.39±9.78 34.45±4.41 25.15±0.44 34.74±2.91 74.12±6.60 32.67±22.04 
allyl phenoxy-
acetate ■ 49.42±4.20 56.32±0.53 46.51±0.22 55.71±0.92 36.21±1.61 49.42±3.59 62.57±5.07 52.01±4.66 58.71±3.29 42.87±6.20 51.26±7.91 
Isopropanol ■ 16.32±0.53 16.92±1.16 19.88±4.44 18.13±3.34 20.61±0.51 33.32±4.89 40.92±4.44 35.13±3.66 38.13±2.76 26.61±5.16 26.68±9.74 
4-methyl-thio-
benzaldehyde ■ 16.25±0.97 15.62±0.9 15.67±0.19 14.43±0.42 23.15±0.25 26.25±0.97 26.37±8.08 25.95±0.47 26.10±1.58 26.15±3.7 21.49±5.77 
heptyl butyrate 
■ 
66.63±0.51 58.86±0.24 48.71±0.09 100.10±3.10 77.91±13.59 67.63±1.32 58.86±4.24 55.46±5.46 90.11±3.10 79.58±6.00 68.55±15.74 
hexyl salicylate 
■ 
68.22±0.10 56.70±0.34 56.84±0.24 108.8±14.15 98.85±17.52 69.22±1.21 75.20±10.02 55.84±3.49 88.77±7.26 98.52±7.56 75.36±19.55 
5% SDS 
 (+ ctrl) □ 9.71±0.51 12.43±0.09 13.37±1.14 6.078±0.56 11.33±0.04 9.49±0.67 16.68±5.69 15.12±2.44 8.74±2.40 13.00±2.08 11.80±3.63 
1-decanol □ 18.17±0.52 17.54±0.10 17.59±0.09 12.53±0.42 21.51±0.38 17.67±0.74 16.29±1.40 20.09±3.37 15.19±2.81 25.51±2.37 18.16±3.46 
1-bromohexane 
□ 
15.67±0.19 17.31±0.09 17.02±0.10 33.40±11.50 35.96±8.79 17.17±1.85 18.81±2.00 19.56±3.40 40.07±7.24 39.63±5.41 24.18±10.49 
di-n-propyl 
disulphide □ 16.01±0.24 29.06±0.10 29.64±0.12 18.55±4.64 25.29±3.73 17.26±1.50 27.10±3.07 28.14±3.70 24.55±2.14 30.29±3.06 24.64±5.78 
Heptanal □ 20.19±0.65 29.50±0.44 29.60±0.18 28.91±3.75 35.14±10.81 21.14±1.89 27.50±2.51 29.10±5.90 35.58±2.26 38.47±8.05 28.96±6.78 
Tetrachloro 
Ethylene □ 19.57±0.8 27.38±1.172 26.17±0.19 19.34±1.38 28.16±2.98 21.32±2.16 28.38±2.69 26.42±4.60 23.01±5.00 29.83±1.17 24.94±4.31 




Figure 41. In vitro testing of TG 439 skin irritation using a keratinocyte monolayer culture. A. In vitro performance testing of a keratinocyte monolayer culture seeded 
at 5x103 keratinocytes/well (passage 3) using six non-irritants (blue stripped columns) and six irritants (pink stripped columns). Results are expressed as mean and standard 
deviation of ten independent experiments.  ***p<0.001 when compared to the negative control (- ctrl), PBS (blue filled column). Positive control (+ ctrl) as 5% SDS in aqueous 







































































































































































































































































































4.2.5. Skin irritation testing using a collagen-based scaffold 
As mentioned in Chapter 3 section 3.2.4, the Corning® Transwell®-COL collagen 
scaffold (rat tail collagen-based scaffold) was used as a comparison to the Alvetex Strata. From 
this parallel study, skin irritation testing was also performed but on a smaller scale – 3D 
epidermal skin cultures were developed from keratinocytes of five donors and two non-irritants 
(1-bromo-4-chlorobutane and heptyl butyrate) and two irritants (heptanal and 
tetrschloroethylene) were tested with the negative and positive controls.  
Results from the Corning® Transwell®-COL scaffold showed that this scaffold behaved 
poorly compared to the 3D epidermal skin culture or the monolayer culture (Table 12 and 
Figure 42). It failed to correctly identify the two non-irritants: 1-bromo-4-chlorobutane 
(48.64±14.25%; p<0.001) and heptyl butyrate (47.86±22.58%; p<0.001), showing a viability 
below 50% for both chemicals. However, it did correctly identify the two irritants: heptanal 
(40.60±11.22%; p<0.001) and tetrachloroethylene (33.02±9.16%; p<0.001), as well as the two 
positive controls: 5% SDS in aqueous solution (26.47±8.67%; p<0.001) and TX-1% 
(31.28±10.83%; p<0.001). 
  
Table 12. Cell viability results for the collagen-coated Transwell scaffold (Corning) for skin irritation testing following 
TG 439. Two non-irritant (■) and two irritant (□) chemicals from TG 439 for skin irritation were tested in the collagen-coated 
Transwell scaffold culture in 5 donors with 30µL of the testing chemical dispensed directly on top of the skin model. Cell 
viability is reported as percentage of viability for each chemical is calculated in comparison to the negative control (PBS). For 
each donor, chemical test was performed in triplicate and viability is reported as average of 5 independent tests with standard 
deviation (SD). 
Chemical 
% Cell viability ± Standard Deviation (SD) 
Donor 1 Donor 2 Donor 3 Donor 4 Donor 5 
Total  
5 donors 
PBS  (- ctrl) ■ 99.94±0.56 100.20±0.22 99.86±0.19 100.10±0.11 101.00±1.37 100.20±0.69 
1-bromo-4-
chlorobutane ■ 
68.76±0.33 52.31±14.91 40.17±6.28 32.54±0.19 49.43±5.83 48.64±14.25 
heptyl butyrate 
■ 
49.02±0.17 38.38±9.38 32.39±1.17 31.17±0.29 88.32±10.44 47.86±22.58 
5% SDS 
 (+ ctrl) □ 
30.05±3.68 23.53±2.92 21.17±1.17 19.20±0.11 42.31±2.26 26.47±8.67 
Heptanal □ 48.26±0.17 37.01±9.83 31.12±0.72 30.36±0.11 56.27±3.95 40.60±11.22 
Tetrachloro 
Ethylene □ 
32.52±0.17 30.01±2.03 27.84±2.08 25±0.13 49.72±3.09 33.02±9.16 





Figure 42. In vitro testing of TG 439 skin irritation using a collagen-based Transwell scaffold (Corning).  A. In vitro 
performance testing of the 3D epidermal model using a scaffold coated with collagen (rat tail) for six non-irritants (blue stripped 
columns) and six irritants (pink stripped columns). Results are expressed as mean and standard deviation of three independent 
experiments.  ***p<0.001 when compared to the negative control (- ctrl), PBS (blue filled column). Positive control (+ ctrl) as 
5% SDS in aqueous solution (pink filled column). Dotted line represents the 50% viability threshold. B. Representative image 

















































































































































































































































4.3. Performance analysis of the models for TG 439 
Overall, performance results showed that the 3D epidermal skin culture could correctly 
determine irritants from non-irritants, matching the performance results from the commercially 
available RHE model validated by ECVAM for TG 439, the EpiDermTM RHE model (Table 
13).  
Knowing that the keratinocyte monolayer culture was developed using the same donors as 
in the 3D epidermal skin culture, it would be expected that the performance outcome of both 
tests would be similar for each chemical. However, the keratinocyte monoculture was not able 
to correctly classify non-irritants as well as the 3D epidermal skin culture, identifying 3 non-
irritants as false positives. These findings highlight the difference between 2D and 3D 
conditions, where cell differentiation and behaviour are not similar. 
 
Table 13. OECD TG 439 results from different in vitro skin models. Predictive capacity of each in vitro 
assay is shown as correct classification of non-irritants or irritants (number of positive classifications from the 
total number of chemicals). 
 Non-irritants irritants 
3D epidermal skin culture 4/6 6/6 
EpiDermTM RHE model 5/6 5/6 
Keratinocyte monolayer culture 3/6 6/6 
Corning® Transwell®-COL scaffold 0/2 3/3 
Total 12/20 20/21 
 
Further statistical analysis was performed to understand if classification of non-irritant and 
irritant from all models was performed correctly or was instead due to random classification. 
Null hypothesis was defined as classification between irritants and non-irritants being due to 
random or aleatory classification. Result from the chi-square (χ2) test of independence showed 
that classification of irritants and non-irritants was accurate, as null hypothesis was rejected 
with χ2 (3) = 0.76522, p= 0.8578.  
However, Table 13 also shows that the in vitro skin models were less able to correctly 
classify the non-irritants than the irritant chemicals. This could be supported by the p value of 
each specific category - non-irritant (p=0.227) and irritant (p=0.983). The fact that 
classification of non-irritants had a much lower p value indicates that there is a higher 
probabilistic error for classification of non-irritants being accurate. This could be explained by 
the fact that the non-irritants tested are lacking relevant in vivo GHS data for proper 
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classification as irritants. Therefore, these results could indicate that the non-irritants tested 
could in fact be irritants and that the in vitro models were able to predict their irritancy.  
To compare the predictive capacity of each in vitro model, a comparative two-way ANOVA 
was performed. Null hypothesis was defined as no significant difference between the different 
in vitro models for irritancy. The independent variables were defined as the different chemicals 
(all 12 tested plus the negative and positive controls) and the different in vitro models. The 
result from the two-way ANOVA showed that there was a significant difference between the 
irritants and non-irritants (p=0.0396) but not between the different in vitro models (p=0.8319) 
(Table 14). The statistically significant difference between the chemicals can be explained by 
the fact that it includes both irritants and non-irritants chemicals, which are quite different in 
their irritancy profile. The fact that there was no statistically significant difference between the 
four in vitro models indicates that there is not one in vitro model which performs better than 
the others. While this result suggests that the 3D epidermal skin model developed using the 
Alvetex Strata has an equal predictive capacity to the commercially available EpiDermTM RHE 
model, it also suggests that it is similar to the keratinocyte monolayer culture, even though the 
keratinocyte monolayer culture correctly predicted fewer chemicals than the 3D epidermal skin 
culture. Further testing in a larger chemical dataset would be required to support the fact that 
the 3D epidermal skin model has a better predictive capacity when compared to the keratinocyte 
monolayer culture. 
In conclusion, there results suggest that the 3D epidermal skin model developed using the 
Alvetex Strata could be used for assessment of skin irritation. Moreover, results also suggest 
that it has a similar predictive capacity to commercially available RHE models. However, 






Table 14. Comparison of the predictive capacity of each in vitro model for prediction of irritancy. A two-way ANOVA 
analysis was performed including two independent variables – the chemicals (non-irritant and irritant) and the in vitro models. 
Interaction between the two independent variables was also calculated. Results from the two-way ANOVA are described as F 

















In vitro models 0.055555556 2 0.185185185 0.831893053 
Interaction between 
chemicals and in vitro 
models 
0.388888889 2 1.296296296 0.288426527 
 
4.4. Discussion of the results 
This chapter intended to show the predictive capacity of the 3D epidermal skin culture for 
skin irritation testing following OECD TG 439.  
Performance standards from the OECD TG 439 state that the ability of a 3D skin model to 
distinguish between irritants and non-irritants can only be possible due to proper barrier 
function of the stratum corneum. Skin irritation testing results from the 3D epidermal skin 
culture cultured at different ALI times (Figure 38) perfectly reflects this problem, as the 3D 
epidermal skin culture at 14 days of ALI was not able to correctly identify the positive controls 
as irritants. If considering the histology results from Chapter 3, this 3D construct presented a 
poor epidermal layer, hence no proper epidermal barrier. Consequently, skin irritation testing 
of this 3D construct failed to predict irritant chemicals.  
On the contrary, results from the 3D epidermal skin culture cultured for 30 days at ALI 
showed that the 3D construct was able to distinguish PBS as a non-irritant and 5% SDS as an 
irritant, due to its properly formed stratum corneum. Further justification regarding the quality 
of the stratum corneum of the 3D epidermal skin model was the fact that this model correctly 
predicted 4 out of 6 non-irritants and 6 out of 6 irritants. These results highlight the quality of 
the barrier function of the stratum corneum from the 3D epidermal skin culture, as only 2 non-
irritants were classified as false positive. Damage to the epidermis was only caused by the 
irritant chemicals, which were able to penetrate the stratum corneum layer. 
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While not stated in the OECD Testing Guideline 439 for skin irritation, other 
complementary studies of barrier function could be performed to further assess its integrity as 
barrier integrity is vital for the physiological activities of the skin tissue (in vivo) and skin 
models (in vitro). For example, Transepithelial/transendothelial electrical resistance (TEER) is 
a widely accepted method for assessment of the barrier integrity of skin models, as it measures 
the integrity of the cell’s junctions between the different skin layers through electrical 
resistance (ionic conductance). Strong tight junctions will result in proper barrier integrity for 
assessment of chemical permeability studies (Alexander Jr, Eggert, & Wiest, 2018). 
Additionally, this method could be used in combination with the TG 439 skin irritation testing, 
as TEER is a non-invasive method that can be applied to live cells. Further optimization would 
be required to adapt TEER for assessment of barrier integrity using the 3D epidermal skin 
culture developed with the Alvetex Strata, but collection of those results would only strengthen 
validation of the 3D epidermal skin culture as an in vitro RHE model for assessment of human 
safety.  
Alternatively, it could also be combined with a different Testing Guideline, TG 428 for skin 
absorption studies (OECD, 2004). Briefly, TG 428 describes a diffusion cells mechanism in 
which the testing chemical is applied to a skin sample in the donor chamber and expected to be 
absorbed through the receptor chamber. This absorption is measured during a given time and 
calculated as the difference between the quantity of chemical present in the receptor chamber 
(percentage recovery of absorbed chemical) and the quantity of chemical in the donor chamber 
(percentage of not absorbed chemical) (Bartosova & Bajgar, 2012). 
While this TG might not be applicable for testing of all irritant and non-irritant chemicals 
described in TG 439 for skin irritation, it can still be used as an initial qualitative evaluation of 
skin penetration of these chemicals. Once again, optimization using the 3D epidermal model 
with the Alvetex Strata would have to be performed to guarantee integrity of the 3D structure 
of the skin layers throughout the assay since the TG is described using excised skin samples.  
Combination of TG 428 for skin absorption with TG 439 for skin irritation could be of 
special importance to understand the chemical properties of each testing chemical and maybe 
shed some light on the incorrect identification of 2 non-irritant chemicals - 1-bromo-4-
chlorobutane and 4-methyl-thio-benzaldehyde. Overall, all in vitro assays were able to 
correctly classify all irritants, but some non-irritants were classified as false positives. It may 
be argued that with regards to human safety testing, it would be better to “over” predict rather 
than “under” predict skin irritation. Therefore, the 3D epidermal skin culture model was able 
to correctly predict all irritants and could be regarded as a sensitive in vitro assay for skin 
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irritation testing. The fact that two non-irritant chemicals were wrongly classified as false 
positives, 1-bromo-4-chlorobutane and 4-methyl-thio-benzaldehyde, could be justified by the 
fact that all chemicals were tested in the same culture plate. As so, volatile fractions from the 
most hazardous skin irritants (as the case of tetrachloroethylene that releases a strong odour) 
could negatively influence the outcome of the non-irritant chemicals. This hypothesis could 
help justify the results, but further analysis should be carried out to better understand the impact 
of volatile fractions in skin irritation testing.   
Regarding within-donor variability, the 3D epidermal skin culture model did not present 
significant standard deviations to the average percentage of cell viability. However, the 
keratinocyte monolayer culture using the same donors presented some standard deviation to the 
average value. Considering that both in vitro assays were performed using the same donor cells, 
the standard deviation results indicate that a monolayer cell culture would not perform as well 
as a 3D skin model in skin irritation testing. This hypothesis is of crucial importance for quality 
control standards defined in TG 439, in which states that the in vitro test should have 
physiological resemblance to epidermal skin with proper differentiation of the stratum corneum 
layer. However, statistical analysis carried on evaluating the predictive capacity of each in vitro 
model showed that the in vitro models were able to correctly classified each chemical (as 
opposed to random classification) and that there was no significant performance difference 
between the in vitro models. It is important to take into consideration that these results are 
representative of a small chemical range and it is vital to repeat this in a larger cohort of samples 
with a larger chemical dataset. Only then with the proper statistical power, would the results 
undoubtedly support the use of the 3D epidermal skin culture for skin irritation purposes. 
Eventually, this would help promote the performance capacity of the 3D epidermal skin culture 
over the keratinocyte monolayer culture. Likewise, it would support the high-quality control 
standard of the 3D epidermal skin culture model, as vital pre-validation data for official EURL-
ECVAM validation.   
In conclusion, all results presented in this chapter demonstrate that the 3D epidermal skin 
model is in concordance with OECD TG performance standards for skin irritation and could be 
used for skin irritation studies. Proper ECVAM validation for skin irritation testing would 









Use of Skimune® for testing the immunotoxicity of aggregated 





5. Immunotoxicity by aggregated monoclonal antibodies 
 
5.1. Aim  
Skimune® is already established as an in vitro assay for assessing skin sensitization potential 
to chemicals (Ahmed et al., 2016). We have further advanced in this work by using the modified 
Skimune® assay for monoclonal antibodies, the Skimune® Mab.  
In this chapter, we describe the Skimune® assay as possible application for testing the 
immunotoxicity of aggregated monoclonal antibodies. We investigated the influence of 
aggregated monoclonal antibodies by observing in vitro immune responses using two 
commercially available monoclonal antibodies. Both antibodies were subjected to heat stress 
conditions to induce aggregation followed by characterization of protein content as well as 
comparison of potential immunogenic profiles. Immune activation was assessed by testing the 
heat stressed mAbs samples in the skin explant assay and determining T cell proliferation 
responses, observing histopathological damage in the skin, measuring cytokine release and 
observing for cell death activation.  
 
5.2. Results 
5.2.1. Skimune® for assessment of immunotoxicity to mAbs (native form)  
Three mAbs and one glycoprotein (provided by FUJI) (Table 15) were used for 
assessment of immunotoxicity using the Skimune® Mab skin explant assay. The compounds 













Commercially available as Rituximab, is a 
pharmaceutical drug for the treatment of 
haematological cancers. It inhibits B cell 
activation in early stages of cancer development 
by binding to CD20 protein (thus inducing cell 
apoptosis) (Smith, 2003); 
Very rare cases of cell death 
(Kimby, 2005) and serum 
sickness (Guenno, Ruivard, 
Charra, & Phillipe, 2011) 
anti-B72.3 antibody Is a tumour-associated protein (TAG 72.3) mAb 
used for diagnosis purposes – tumour cells have 
a selective reactivity for TAG 72.3, being 
characteristically over-expressed in breast, 
gastro-intestinal and gynaecologic cancers. 
Thus, anti-B72.3 mAb is widely used as a 
differential diagnosis tool for the diagnosis of 
neoplasms, especially before surgical resection 
(by immunohistochemistry) (Guadagni et al., 
1996); 
None (is used as diagnosis tool) 
recombinant 
Anti-TNF-α 
antibody Is a Tumour necrosis factor-α (TNF) antibody, 
designed to supress the action of TNF-α during 
inflammatory response (Prado, Bendtzen, & 
Andrade, 2017). 
Can lead to formation of anti-
drug antibodies (ADA), causing 
hypersensitivity (Bendtzen, 
2012) 
Lactoferrin glycoprotein large glycoprotein (around 80kD) from the 
transferrin family that can be found in milk, 
saliva and nasal secretions. It has antimicrobial 
properties, especially for infants during breast 
feeding. Its primary role is to capture free iron, 
not allowing bacteria to use it as a growth 
requirement (Almond et al., 2013; Almond, 
Flanagan, Kimber, & Dearman, 2012). 
Wild type lactoferrin elicits IgE 
response (as in food allergy). 
Recombinant form is not so 




T cell proliferation assay was used to measure the proliferative capacity of the cells in 
response to exposure to the testing compounds, by thymidine incorporation per cell division 
for each test condition. Threshold for mAb-induced immune activation was defined as log(2)-
fold increase in the T cell proliferation response, as reported elsewhere (Rombach-Riegraf et 
al., 2014). Supernatants from all test conditions were collected for cytokine release analysis.  
OKT3 as a positive control for T cell proliferation caused significant cell activation above 
the log(2)-fold threshold (p<0.05), with a 3-fold increase response. On the contrary, IgG1 as 
the isotype control showed no significant T cell proliferation above the log(2)-fold threshold.  
No major significant increase of T cell proliferation was observed in response to any of the 
mAb or glycoprotein concentrations (Figure 43) as all concentrations failed to reach above the 




Figure 43. T cell proliferation following exposure to mAb samples. PBMCs were exposed to Anti-
B72.3, Anti-CD20 and Anti-TNF-α antibodies and LactoFerrin at 1 and 10µg/mL and assessed for 
cell proliferation by the 3H-Thymidine uptake assay. Immune activation threshold was positive if it 
was regarded as log(2)-fold increase in the T cell proliferation results (dotted line) *p < 0.05. Mean 
values represented by the red line. 
 
The lack of T cell proliferation is not unsurprising considering the function of these 
compounds. Anti-B72.3 mAb is a diagnostic marker for tumour cells and therefore, would not 
cause any major reaction of the immune system. Anti-CD20 mAb is a pharmaceutical mAb for 
haematological cancers, targeting B cells only by binding to their CD20 antigen receptor. 
However, a recent study has shown that T cells also express CD20 receptor at a low expression 
level and that anti-CD20 antibodies (such as Rituximab and Ocrelizumab) can effectively 
eliminate T lymphocytes with CD-20 expression (Palanichamy et al., 2015). Nevertheless, this 
would only represent a small fraction of the total T cell pool and therefore, no major T cell 
depletion or activation would be likely upon exposure to the anti-CD20 antibody. Anti-TNF-α 
mAb is a neutralizing antibody against TNF-α, downregulating its pro-inflammatory effect 
(Prado et al., 2017). Therefore, this mAb should have a negative effect on the immune cells, 
and this can be observed from the T cell proliferation results. Regarding Lactoferrin, this 
glycoprotein is known to modulate the inflammatory response against microbial infections by 
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direct competition with the lipopolysaccharides (LPS) binding site, preventing activation and 
proliferation of monocytes (Baveye, Elass, Mazurier, Spik, & Legrand, 1999). As a key 
modulator of the immune response, Lactoferrin is not expected to induce any type of cell 
activation. The T cell proliferation results were in concordance with this aspect, as no 
significant increase of T cell was observed for Lactoferrin.  
In line with the T cell proliferation assay, the skin explant assay was also performed in the 
same donors for assessment of immunotoxicity by the testing compounds from FUJI. The same 
four healthy donors from the T cell proliferation assay were tested for each mAb concentration 
and the histopathological damage was assessed according to Lerner scoring scale (Lerner et al., 
1974). This scoring system is based on characterization of skin damage by visual appearance 
of vacuoles or separation of the skin layers. It ranges from a score I (negative score) to a score 
IV (maximum score for damage). The complete description for each score is the following: 
score I for intact upper epidermis layer, score II for minor vacuolisation of the skin, score III 
for start of separation between epidermis and dermis layers and score IV for complete 
separation of the skin layers (Figure 44). 
 
 
Figure 44. Grading score for assessment of skin damage using the Skimune® skin explant assay. The endpoint is a grading 
score of histopathological damage: score I (intact upper epidermis layer), score II (minor vacuolisation of the skin), score III 
(start of separation between epidermis and dermis layers) and score IV (complete separation of the skin layers).
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Results from the Skimune® Mab for skin damage showed that OKT3 as a positive control 
showed significant positive damage, with a consistent grade II response in all 5 donors. For 
B72.3 and CD20 mAbs, the results from the skin explant assay matched with the results from 
T cell proliferation assay, as no major histopathological damage was observed (Figure 45). 
B72.3 only caused a weak grade II damage in 2 out of 5 donors at 1µg/mL and in 1 out of 5 
donors at 10µg/mL. All remaining donors presented a negative grade I. Similarly, CD20 only 
caused a weak grade II damage in 1 out of 5 donors at 1µg/mL. All donors at 10µg/mL 
presented a negative grade I.  
However, in the case of Lactoferrin and Anti-TNF-α significant positive damage was 
observed at 10µg/mL, with a grade III response in 4 out of 5 donors. Moreover, and while not 
statistically significative, Lactoferrin and Anti-TNF-α caused a grade II damage in all 5 donors 
at 1µg/mL. This is considered a weak positive damage response.  
 
Figure 45. Skimune® Mab result with testing of biopharmaceutical compounds. Three monoclonal 
antibodies (Anti-B72.3, Anti-CD20 and Anti-TNF-α) and 1 glycoprotein (LactoFerrin) were tested at 1 and 
10µg/mLwith the Skimune® Mab assay in 5 donors for assessment of immunogenicity. Output of assay is 
measured as grading score of histopathological damage ranging from I to IV. Mean values represented by the 
red line. 
 
Overall, B72.3 and CD20 mAbs did not cause any significant T cell proliferation response 


















































































1µg/mL, Lactoferrin and Anti-TNF-α caused a weak positive grade II histopathological damage 
that escalated to a grade III damage at 10µg/mL in the same donors. However, T cell 
proliferation responses from Lactoferrin and Anti-TNF-α showed no positive activation of 
cells. 
The fact that weak positive skin damage was observed for both Lactoferrin and Anti-TNF-
α testing conditions could be linked to the general storage condition of these testing compounds. 
These compounds were provided by a consortium partner so no specific storage information 
was given (i.e. long-term or short-term storage), except that the compounds were kept at -20°C. 
One could argued that long-term storage could affect the primary structure of the monoclonal 
antibodies, possibly even inducing aggregation. However, this hypothesis would have to be 
further tested with protein analysis studies like similar to the ones performed for the heat 
stressed monoclonal antibodies (section 5.2.2.1). Nevertheless, the fact that the skin explant 
assay was able to detect histopathological damage, while T cell proliferation response was not 
increased supports the predictive role of this skin explant assay for assessment of 
immunotoxicity to novel compounds, showing that it is a more sensitive test.  
Ultimately, four biopharmaceutical compounds from FUJI were tested for immunogenicity 
using the skin explant assay and T cell proliferation assay. Results showed that Anti-B72.3 and 
Anti-CD20 had little to no immunotoxic profile, at both low (1µg/mL) and high concentrations 
(10µg/mL). Regarding Anti-TNF-α and Lactoferrin, they also presented a weak immunotoxic 
profile at 1µg/mL that increased considerably at 10µg/mL, causing significant immune 
damage. Comparing the two in vitro assays, the skin explant assay proved to be a more sensitive 
and accurate assay for assessing immune damage than the T cell proliferation assay as it was 
able to predict immunotoxic damage by Anti-TNF-α and Lactoferrin while T cell proliferation 
assay showed no significant increase.   
 
5.2.2. Skimune® for assessment of immunotoxicity to aggregated mAbs  
In this study, two therapeutic antibodies – Rituximab (chimeric IgG1 mAb) and 
Herceptin (humanized IgG1 mAb), were exposed to a heat stress protocol. The testing 
temperatures were intended to mimic storage conditions at 4°C, normal physiological 
temperature (37°C) and elevated body temperature during an infectious episode (40°C). These 
stress conditions ensured that mAb degradation reflects inadequate storage conditions rather 
than industrial manufacturing.  
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5.2.2.1. Protein analysis of the stressed mAb samples  
To determine the protein content of the heat stressed mAb samples, the aggregated 
samples were analysed by SV-AUC. Only the extreme testing conditions were analysed, at the 
following time points: 4°C for 0 hours, 37°C for 48 hours, 40°C for 48 hours and 65°C for 1 
hour (positive control for aggregation). Overall, the loss of monomers by heat stress was found 
to be very low, with up to 4% aggregation of the total protein content (Table 16). This result is 
in concordance with previously reported studies, where a low level (<3%) of total protein 
content was reported as aggregated (Ahmadi, Bryson, Cloake, Welch, Filipe, Romeijn, Hawe, 
Jiskoot, Baker, et al., 2015).  
Considering 4°C for 0 hours as the baseline condition, more than 97% of the protein content 
was found in the monomer form in both heat-stressed Rituximab and Herceptin. For Rituximab, 
there was no major variation in the monomer content throughout the heat stress protocol, since 
at 37°C for 48 hours there was 97.38% monomer content and at 40°C for 48 hours there was a 
97.73% overall monomer content. Dimer content at baseline was shown to be 1.14% of the 
overall protein content, with a small increase to 1.61% after 48 hours at 37°C and 1.15% after 
48 hours at 40°C. For the larger molecules, e.g. trimers, tetramers and heavier molecules, there 
was a small increase from 0.93% at baseline to 1.48% after 48 hours at 37ᵒC and 1.44% after 
48 hours at 40°C. For Herceptin, the decrease of monomer content was more evident. Starting 
from 97% monomer content at baseline, the monomer content reduced to 94.8% after 48 hours 
at 37°C and to 95.51% after 48 hours at 40°C. Correspondingly, the dimer content increased 
from 1.701% at baseline (0 hours at 4°C) to 2.854% after 48 hours at 37°C and to 2.611% 48 
hours at 40°C. There was also an increase in the appearance of larger molecules, ranging from 
0.468% at baseline to 2.653% after 48 hours at 37°C and to 1.929% after 48 hours at 40°C.  
Size distribution of the sedimentation velocity of the aggregated Rituximab (Figure 46) and 
Herceptin (Figure 47) showed a good distribution of the monomer, dimer and larger molecule 
forms across the different temperature ranges. Size-distribution showed most monomeric 
species sedimented at 6.3S with a molecular weight of 152 kDa when present in solution, 
alongside some dimeric species. These dimeric species had different stoichiometry with both 
elongated configuration and sedimentation close to 8S and more globular configuration with 
sedimentation just below 10 S. At 37°C, even larger species were observed with sedimentation 
up to 15S. This change in protein size reflected the heat stress causing the mAb to become 
heavier as it aggregated. As a result, the sedimentation velocity increased when compared to 
non-aggregated samples.  
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The internal positive control for aggregation (65°C incubation for one hour in acidic 
conditions) aggregated very easily, as expected, with 73% content of larger molecules for 
Rituximab and 69% for Herceptin. Size-distribution of this control showed a lower number of 
monomer content and an increased number of trimers, tetramers and larger molecules (up to 
10-15mers), demonstrating the more aggregated state of this sample.  
Overall, the results from the SV-AUC showed that Rituximab was not as susceptible to 
thermodynamic changes as Herceptin, indicating to be a more stable monoclonal antibody. This 
was because only Herceptin showed variation in content of monomer, dimer and large structure 
molecules throughout the heat stress protocol. These results correlate with the outcome 
predicted by the Bayesian model (red dotted line) calculated by the SEDNTERP software. 
Standard deviation calculated by the root mean square deviation (RMSD) values showed no 








































0 6.412 152.1 97.92 9.25 263.653 1.14 0.93 0.015 
48 6.415 138.3 97.72 9.715 257.707 1.7 0.58 0.017 
37 
0 6.411 153.4 96.16 9.089 258.781 2.69 1.15 0.014 
3 6.411 149.9 97.41 9.27 274.93 1.68 0.91 0.013 
6 6.408 152.5 96.88 9.19 261.938 2.07 1.05 0.011 
12 6.413 149.3 96.69 9.522 270.064 2.28 1.11 0.010 
24 6.426 146.8 99 - - - 1 0.018 
 48 6.424 148.3 97.38 8.34 229.272 1.61 1.48 0.014 
40 
0 6.415 153 97.26 9.042 262.435 2.23 1.24 0.016 
3 6.407 147.4 98.34 8.997 262.004 1.18 1.3 0.017 
6 6.399 149.5 98.16 8.768 249.582 1.15 1.04 0.017 
12 6.397 155.3 98.40 - - - 1.60 0.017 
24 6.425 150.3 97.38 9.461 281.061 1.32 1.42 0.018 
48 6.42 147.6 97.73 9.649 281.75 1.15 1.44 0.016 








4 0 6.441 149 97.96 9.432 263.977 1.701 0.468 0.010 
37 48 6.427 148.1 94.8 9.109 249.839 2.854 2.653 0.010 
40 48 6.421 148.1 95.51 9.235 255.364 2.611 1.929 0.011 
65 1 6.346 132.6 2.661 9.862 256.928 6.107 69.246 0.010 
Quantification of monomers, dimers, and larger molecules in Rituximab and Herceptin monoclonal antibodies (at 1 mg/mL) 
after exposure to a heat-stress protocol (4, 37 and 40°C for 0, 3, 6, 12, 24 and 48 hours). Quantification by sedimentation 
velocity (S), mass (kDa) and percentage in overall mAb sample (%). Standard deviation calculated as Root Mean Square 





Figure 46. Size distribution of the heat-stressed aggregated samples of Rituximab. Quantification of the 
aggregation state of heat stressed Rituximab sample by analytical ultra-centrifugation for 4°C for 0 hours; 
37°C for 48 hours; 40°C for 48 hours and 65°C for 1 hour (black line). The results fit the Bayesian prediction 
model (red dotted line). Monomer species at around 6S with elongated dimers appearing at 8S and globular 




Bayesian prior cP(s) 
Rituximab 40ᵒC, 48h
Rituximab 37ᵒC, 48h





Figure 47. Size distribution of the heat-stressed aggregated samples of Herceptin. Quantification of the aggregation state 
of heat stressed Herceptin sample by analytical ultra-centrifugation for 4°C for 0 hours; 37°C for 48 hours; 40°C for 48 hours 
and 65°C for 1 hour (black line). The results fit the Bayesian prediction model (red dotted line). Monomer species at around 
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5.2.2.2. Visual characterization of the aggregates  
Transmission Electron Microscopy (TEM) allows for the visual characterization of the 
aggregated heat stressed mAb samples and provides a more qualitative analysis of aggregation.  
Compared to the blank grid, loading of mAb samples to the grid showed visible 
microscopic particles that were regarded as small aggregates (Figure 48). TEM results showed 
that the higher the temperature (from 4°C to 65°C), the more visible are the microscopic 
aggregates caused by heat stressed mAb samples. The unstressed mAb samples at 4°C contain 
almost no microscopic particles, whereas the heat stressed samples at 40°C showed small 
aggregates as black masses scattered through the grid (indicated by white arrows). The amount 
of detectable aggregates was greater in the positive control for aggregation at 65°C, as 
confirmed by the previous results of protein analysis.  
Together, TEM and SV-AUC indicate that heat stress modified the secondary structure 
of the mAb and promoted low levels of aggregation. Furthermore, the intensity of the heat 







Figure 48. Visual characterization of two heat-stressed mAb samples by TEM. Comparison of aggregation status of two mAbs, Rituximab and Herceptin, after a heat stress protocol 
(indicated by white arrow). Scale bar of 2.0 nm is similar in all testing conditions.  
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When comparing the protein content of both heat stressed mAbs, heat stressed Herceptin 
showed a slightly increased aggregation level compared to Rituximab. Differences in the 
primary sequence of these mAbs may explain the differences in the degree of aggregation, since 
Rituximab is a chimeric mAb and Herceptin is a humanized mAb (Obrezanova et al., 2015).  
 
5.2.2.3. Aggregated mAb samples induce immune activation  
In view of the observations that heat stress can alter mAb structure and induce 
aggregation, it was important to understand if this aggregation could lead to immunotoxic 
events during mAb administration to patients. The effect of the heat stressed mAbs on immune 
activation was assessed by a human skin explant assay, T cell proliferation and cytokine release 
assays. PBMCs and skin biopsies from five healthy donors were stimulated with heat stressed 
aggregated samples of Rituximab and Herceptin (at 1 and 10µg/mL) and assessed for increased 
immune activation.  
Responses in the skin explant assay showed tissue damage in response to both aggregated 
Rituximab and Herceptin samples (Figure 49). Using Lerner’s skin damage classification 
system, positive skin damage is considered a grade II or higher (Figure 50). At a concentration 
of 1µg/mL, Herceptin caused significant tissue damage (p<0.05) with grade III damage in three 
out of five donors at the 40°C testing condition for 48 hours, when compared to the negative 
control (Figure 49). Herceptin tested at 4°C and 37°C, caused either a negative grade I or weak 
positive grade II skin damage, which was not statistically different from the negative control. 
At a concentration of 10µg/mL, Herceptin caused significant tissue damage when tested at 
40°C for 48 hours (p<0.05), with grade III skin damage being observed in four out of five 
donors. OKT3 was the positive control and caused significant grade III skin damage at both 1 
and 10µg/mL. The positive control for aggregation (pH=3) caused a grade II damage response 
in three out of five donors at both 1µg/mL and 10µg/mL and a grade III damage response in 
one out of five donors at 10µg/mL. While still considered to be positive for skin damage, it 
fails to be statistically significant from the negative control. 
At 1µg/mL, Rituximab did not cause any significant skin damage as all temperature testing 
conditions caused either a negative grade I or weak positive grade II skin damage response and 
responses were not significantly different from the negative control. OKT3 caused significant 
damage (p<0.05), with a grade II response in three out of five donors and a grade III response 
in one donor. At 10µg/mL, Rituximab tested at 40°C for 48 hours caused a positive grade III 
skin damage response in three out of five donors.   
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The fact that Herceptin caused significant skin damage at both 1 and 10µg/mL while 
Rituximab only caused significant damage at 10µg/mL, suggested aggregated Herceptin and 
Rituximab have different immunotoxic potency profiles due to their aggregation levels. This 
also links in with the protein analysis results, where the reported monomer content for 
Herceptin was lower than for Rituximab meaning higher aggregation levels. Consequently, 
Herceptin caused more histopathological damage than Rituximab.  
These results corroborate previous findings done in cell activation assays, where Herceptin 
was shown to cause higher rates of immune activation than Rituximab by activation of CD4+ 




Figure 49. Skin explant assay results from exposure to heat stressed mAb samples. Heat stressed samples of Herceptin and Rituximab (1 and 10µg/mL) were incubated with PBMCs 
















































































































































































































































































































































































































































Figure 50. Histopathological damage from exposure to heat stressed mAb samples. H&E staining of the skin explant after incubation with the heat-stressed samples of Herceptin and 
Rituximab at 1 and 10µg/mL. Black arrows represent histopathological damage of the skin. Scale bars represent 200µm. The endpoint is a grading score of histopathological damage: score I 
(intact upper epidermis layer), score II (minor vacuolisation of the skin), score III (start of separation between epidermis and dermis layers) and score IV (complete separation of the skin layers). 
Scale bar of 200µm from negative control is representative and similar in all testing conditions.   
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The T cell proliferation assay showed no significant increase in T cell proliferation responses 
upon exposure to aggregated Herceptin and Rituximab (Figure 51) in any of the testing 
conditions. Only OKT3 elicited positive T cell stimulation indices above the log(2)-fold 
threshold, in all tests at 1 and 10µg/mL.  
 
 
Figure 51. T cell proliferation responses following exposure to heat stressed mAb samples. Herceptin and Rituximab 
mAbs (1 and 10µg/mL) were exposed to a heat stress protocol (4, 37 and 40ᵒC for 0 and 48 hours). Immune activation 
threshold was positive if it was regarded as log(2)-fold increase in the T cell proliferation results (dotted line) *p < 0.05. 
 
Cytokine levels of IFN-γ, IL-10 and TNF-α were measured from the cell culture 
supernatants of the skin explant assay for each testing condition. At 1µg/mL, IL-10, IFN-γ and 
TNF-α levels were only significantly elevated after exposure to OKT3 in both Rituximab and 
Herceptin (Figure 52). At 10µg/mL, the positive control for aggregation for Rituximab showed 
a significant increase in IL-10 levels (Figure 53). While not statistically significant, the same 
trend could be observed for the positive control for aggregation of Herceptin at 10µg/mL, with 
two out of five donors showing expression of IL-10 above the log(2)-fold threshold. 
An overall trend for increased levels of IFN-γ at 10 µg/mL was observed, especially in some 
donors exposed to aggregated Rituximab. More specifically, expression of IFN-γ was elevated 




































































































































































































































































































Figure 52. Pro-inflammatory cytokine profile at 1µg/mL. Quantification in log(2)-fold-increase of Interferon-γ, IL-10 and TNF-α upon exposure to aggregated Herceptin and Rituximab at 


























































































































































































































































































































































































































































































































Figure 53. Pro-inflammatory cytokine profile at 10µg/mL. Quantification in log(2)-fold-increase of Interferon-γ, IL-10 and TNF-α upon exposure to aggregated Herceptin and Rituximab at 



















































































































































































































































































































































































































































































































While an increase in T cell proliferation was not observed upon exposure to heat stressed 
mAbs, significant histopathological damage and IL-10 supernatant expression were reported in 
the in vitro skin explant assay. To further understand these events of immune activation, 
immunofluorescence staining for cell death was performed. Tissue sections from the in vitro 
skin explant assay containing histopathological damage were stained for Heat Shock Protein 
(HSP) 70 and Caspase (Casp) 3. Figure 54 shows positive HSP 70 staining (bright green) for 
the 37°C and 40°C conditions in both Herceptin and Rituximab at 10µg/mL. Positive control 
for aggregation (pH=3) also showed positive expression of HSP70. No positive expression of 
Casp3 was observed for any of the temperature conditions. These results suggested that heat 
stressed Rituximab and Herceptin caused mild apoptotic damage, not strong enough to cause 
cell death hence lack of positive staining of Casp3. 
In summary, results from the heat stressed aggregated mAbs showed that the skin explant 






Figure 54. Cell death caused by mAb aggregation. Heat stressed aggregated samples of Herceptin and Rituximab at 10µg/mL were stained for HSP70 and Casp3 (green) by 
immunofluorescence. DAPI was used as nuclear marker (blue). White arrows indicate positive staining. Scale bar of 200µm from negative control is representative and similar in all testing 





5.3. Discussion of the results 
 
To our knowledge, this study is the first to show the use of a human in vitro skin explant 
assay to determine the potential of aggregated monoclonal antibodies samples to induce an 
immune response. Developing a method for in vitro assessment of immunotoxicity potentially 
caused by mAb aggregation would be an indispensable downstream service in the pipeline of 
mAb development. 
Previous studies addressing the immunotoxic potential of mAb aggregation used heat stress 
protocols of temperatures, as high as 65°C (Joubert et al., 2012), 70°C (Ahmadi, Bryson, 
Cloake, Welch, Filipe, Romeijn, Hawe, Jiskoot, Baker, et al., 2015) or 80°C (Boll et al., 2017; 
Rombach-Riegraf et al., 2014). In comparison to those protocols, the maximum temperature 
condition set for this study was 40°C. The temperature test points were chosen for its relevance 
from a physiological perspective. Our results show that there is some level of protein unfolding 
and consequent rearrangement of the mAb secondary structure by evidence of the presence of 
larger molecules in aggregated samples (as demonstrated by SV-AUC results). These 
thermodynamic changes accounted for  less than 4% aggregation of the total protein content, 
which is in accordance with previous reports of 3% aggregation (Ahmadi, Bryson, Cloake, 
Welch, Filipe, Romeijn, Hawe, Jiskoot, Baker, et al., 2015) of the total protein content. 
There is evidence that protein aggregation can occur at different stages of mAbs production 
or during further storage, imposing a health risk to patients upon administration of therapeutic 
mAbs (Kent et al., 2018; Kiese et al., 2008; Peters et al., 2013). We have studied the potential 
immunotoxic effect of mAb aggregation by investigating T cell proliferation, cytokine release 
and histopathological assessment of cell damage in a novel in vitro skin explant assay. Overall, 
the heat stressed Herceptin and Rituximab samples did not enhance the immune activation (by 
T cell proliferation) but rather triggered a cascade of cell death events, by activating apoptosis 
pathways that ultimately led to histopathological damage of the skin. Cytokine release analysis 
of skin culture supernatants showed increased levels of anti-inflammatory IL-10 cytokine in 4 
out of 5 donors. IL-10 is an immunosuppressive cytokine that inhibits expression of pro-
inflammatory cytokines (Murray, 2005). Elevated expression of IL-10 in the positive control 
for aggregation (pH=3) could suggest that cells are actively forming a protection mechanism 
from the damage caused by the aggregated mAbs. It could also help explain why the positive 
control for aggregation did not cause evident histopathological damage.  
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A trend for elevated expression of IFN-γ was observed at 10µg/mL for Herceptin and 
Rituximab. This could be related to the significant increase of IL-10 for this same condition, as 
a counter-acting anti-inflammatory defence mechanism (Joubert et al., 2012). 
The combination of increased levels of cytokine expression combined with the 
histopathological damage caused could suggest that heat stressed Rituximab and Herceptin do 
cause some degree of immune activation. These results do not fully corroborate previously 
published studies, where it was shown that mAb aggregation by heat stress elicits in vitro innate 
and late-stage T cell responses (Joubert et al., 2012), activates dendritic cells to stimulate T 
cells (Rombach-Riegraf et al., 2014) and induces CD4+ T cell proliferation from pro-
inflammatory cytokine release (Ahmadi, Bryson, Cloake, Welch, Filipe, Romeijn, Hawe, 
Jiskoot, Baker, et al., 2015) as results from the T cell proliferation assay did not shown any cell 
activation. However, it is important to notice that this characterization was not done using the 
same method as described in published studies. Therefore, assessment of T cell activation by 
flow cytometry using cell activation markers might be more sensitive for determination of cell 
activation. Also, these studies were performed in larger cohorts (more than 50 donors) so it 
would be important to test both the in vitro skin explant assay and the T cell activation assay in 
a larger cohort than the one described in this study. 
Further examination of the results from the immune activation experiments indicates that 
aggregated Herceptin and Rituximab cause mild apoptotic damage shown by the positive 
staining for HSP70. This heat shock protein serves as a molecular chaperone in cases of cell 
stress (as heat shock or oxidative stress). HSP70 is crucial for cell survival after apoptotic 
stimuli (Mosser, Caron, Bourget, Denis-larose, & Massie, 1997; Qi et al., 2011), as shown by 
Klein et al. (2002) in which macrophages heat-stressed for two hours at 42°C showed 
overexpression of HSP70 (Klein & Brune, 2002). Upregulation of HSP70 can supress heat-
shock damage, by inactivating the upstream action of caspase 3, preventing cell death by 
apoptosis (Klein & Brune, 2002; Mosser et al., 1997). For the apoptotic stimuli to be severe 
(and thus irreparable), Caspase 3 would be positively stained due to upregulation of the caspase 
pathway. Since this was not the case, the results could be attributable to HSP70 actively 
protecting the cell from apoptotic stimuli caused by the aggregated mAb by inhibiting the 
apoptotic pathway, hence no positive staining for Caspase 3 (Klein & Brune, 2002; Li, Lee, 
Ko, Kim, & Seo, 2000). HSP70 is most likely involved in the protein refolding after exposure 
to the aggregated Herceptin and Rituximab and its overexpression could be rescuing the cells 
from apoptotic death, hence the mild histopathological damage.  
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A recent study regarding HSP70 impurities has shown that a recombinant mouse-derived 
HSP70 bonded to aggregates of different IgG2 mAbs but not to the monomer forms of the same 
IgG mAbs (Rane et al., 2019). Moreover, it also reported increased IFN-γ production from 
dendritic cells stimulated with the aggregated IgG mAbs. Overall, this novel work suggests that 
HSP70 can selectively adhere to mAb aggregates, influencing the immunogenic responses to 
therapeutic proteins. These findings could help corroborate the results from our study, as 
immunofluorescence staining showed an increased in HSP70 expression for the heat-stressed 
Herceptin and Rituximab samples, and not in Caspase 3. 
Regarding the different heat-stressed samples, only the highest testing temperature (40°C) 
caused significant histopathological damage in comparison to the baseline condition. Grade III 
skin damage was observed in most of the donors, while at 4°C and 37°C an overall weak 
positive grade II was observed. While the outcome is not a severe grade, these results still show 
a weak positive skin damage response caused by heat stressed aggregated mAbs. Therefore, it 
is probable that heat stress alters the structural conformation of the monoclonal antibody, which 
then elicits an adverse immune effect. Considering that the positive control for aggregation 
(pH=3) contained a higher level of aggregation (more than 70% aggregation), it was surprising 
that it did not cause an immune activation response. However, it did elicit increased expression 
of IL-10 – an anti-inflammatory cytokine. The higher condition of heat stress (40°C) did cause 
more severe histopathological damage than the positive control. Highly aggregated mAbs (as 
in the case of the positive control) can affect the normal binding of these proteins to the antigen-
presenting cells (Rombach-Riegraf et al., 2014). It has been shown that the structural mAb 
rearrangements that result from exposure to temperature shock can lead to neo-epitopes (Boll 
et al., 2017) (new epitopes formed during aggregation), glycosylation/pegylation changes 
(Hermeling, Crommelin, Schellekens, & Jiskoot, 2004) and other post-translational 
modifications that break tolerance towards these mAbs, thus causing immunotoxicity. 
Furthermore, it has been shown that only covalently modified aggregates can induce 
immunogenicity (Bessa et al., 2015). 
However, in order for aggregated mAbs to cause an immunogenic response, it is vital that 
conformation of the protein’s active site remains preserved regardless of aggregation (Boll et 
al., 2017). Thus, we can speculate that the internal positive control denatured to such an extent 
that protein conformation was lost by denaturation during the heat stress. The consequential 
aggregation occurring after denaturation impeded preservation of the protein’s active site.  
These results also highlight the fact that protein aggregation does not always results in 
immunogenicity. While structural changes might occur due to aggregation, it does not mean 
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that protein functionality is compromised. Previous studies showed that immunogenicity is only 
achieved if the primary structure of the mAb protein is deeply modified after aggregation stress 
(Bessa et al., 2015). Therefore, it can be argued that the internal positive control did not cause 
a great level of immune activation/cell death due to the new structural rearrangement of the 
protein, hiding its active site. 
Further work is required to better understand the potential use of the skin explant assay in 
assessment of immunogenicity. Nevertheless, it should still be emphasized that this novel skin 
explant assay could detect immune activation as accurately as previous studies with much larger 
sample sizes. For example, Ahmadi et al. reported a significant increase in CD4+ T cell 
proliferation upon stimulation with heat stressed Herceptin in only four out of 25 donors 
(Ahmadi, Bryson, Cloake, Welch, Filipe, Romeijn, Hawe, Jiskoot, Baker, et al., 2015). The 
skin explant assay results are comparable with these results, highlighting the sensitivity level 
of skin explant assay. Ultimately, this in vitro skin explant assay proved to be a potentially 




















6. Concluding remarks and future work 
As mentioned previously in section 1.10, the main research hypothesis of this project was: 
How can we improve assessment of sensitization using in vitro test methods, in a more accurate 
and human relevant manner? This hypothesis was then broke down into two parallel 
hypotheses: 
- Is it possible to develop an open source in vitro epidermal model that can compete with 
the commercially available ones for assessment of skin irritation? Can this optimized 
in vitro epidermal model be free of animal components, reproducible and demonstrate 
accurate identification of irritants vs non-irritant chemicals in the context of safety 
testing regulations? 
- Considering immunotoxicity as a form of sensitization, is it possible to assess 
immunotoxicity using a human-based in vitro assay for the effect of aggregated 
monoclonal antibodies? 
 
To answer the first question, results from chapter 3 and 4 indicated that, yes, it is possible 
to develop an open source in vitro epidermal model for assessment of skin irritation, with 
correct identification of irritants vs non-irritant chemicals. Optimization of cell culture, 
nutrients and scaffold specifications was performed, and results suggested that the optimal 
conditions for development of a 3D epidermal skin model was seeding of 
1x106keratinocytes/scaffold in a collagen-coated Alvetex Strata membrane for 14 days at ALI 
enriched with 1.5mM vitamin C and calcium for proper development of stratum corneum and 
stratum basale layers (confirmed by immunofluorescence staining). It could be argued that 
coating of the scaffold with human collagen is an expensive step but since this step allows to 
shorten the ALI culture time to 14 days, it might compensate for all the culturing medium and 
supplements required for 30 days at ALI.  
Furthermore, the 3D epidermal skin model was able to correctly identify all 6 irritant 
chemicals and 4 out of 6 non-irritant chemicals. Most importantly, performance of the 3D 
epidermal skin model was comparable with EpiDermTM (commercially available from MatTek) 
as no statistical significance was found in their capability to assess irritancy. All together, these 
results validate the initial research hypothesis and strongly indicate that the 3D epidermal skin 
model could be a valuable in vitro tool for assessment of irritancy. Future work on the 
development of the 3D epidermal skin model would focus on its reproducibility and 
improvement of its manufacturing with advanced technologies like 3D bioprinting.  
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Regarding the second hypothesis, results from chapter 5 showed that the aggregated 
samples of Rituximab and Herceptin at 40°C for 48 hours caused significant grade III skin 
damage with positive expression of cell death marker HSP70. These results indicate that 
Skimune® could be used as a valid tool for assessment of aggregated monoclonal antibodies 
but further studies need to be conducted to validate if skin damage as output of the Skimune® 
assay is immune-related or not. Current results seem to indicate that the damage provided by 
the aggregated monoclonal antibodies might happen at the cellular level, by death of the 
keratinocytes. The lack of T cell activation of cytokine involvement might suggest that is this 
cell death event is unrelated to unwanted immune activation, i.e. immunotoxicity. Therefore, 
further studies using a larger cohort of donor samples and different aggregated monoclonal 
antibodies would have to be tested. Nevertheless, the Skimune® assay was able to detect 
damage by the aggregated monoclonal antibodies.  
 
From a commercial perspective, there are multiple applications for 3D skin models, either 
for research or commercial studies of skin toxicity, skin metabolism and skin absorption. Skin 
toxicity is a common regulatory concern as allergic contact dermatitis is estimated to be one of 
the main reported causes of occupational illness (Duarte, Lazzarini, & Rotter, 2010; Thyssen, 
Linneberg, Menné, & Johansen, 2007). In fact, it is estimated that 15 to 20% of the general 
population will develop an allergic reaction to any chemical in their lifetime (Thyssen et al., 
2007), leading to a negative impact on the quality of life.  
Governmental bodies like the European Union and OECD have given the first step to 
recognise skin toxicity as an important occupational health issue, by implementing laws and 
directives to reduce animal experimentation in safety testing of commercial products intended 
for human consumption. One of the most important bans was the Cosmetic Directive, 
implemented in 2013 by the European Union, to stop testing of cosmetic products on animals 
models in Europe (European Commission, 2009). One other effort to improve cosmetic safety 
for human health is the implementation of Cosmetovigilance, a health surveillance concept.  
Cosmetovigilance is defined as the ongoing monitoring of all human health related safety 
issues regarding cosmetics, aiming to detect and compile adverse effects to cosmetic products 
in the form of official reports. This way, it is possible to collect genuine information of 
marketed cosmetic products that caused adverse effects impacting human health and have a 
quantitative measurement of cosmetic safety on human health. Regulatory organizations can 
also take advantage of the outcome feedback of Cosmetovigilance to evaluate current directives 
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or the necessity of tougher legislations for potentially hazardous cosmetic products (Vigan & 
Castelain, 2014).  
Despite the efforts made from these entities to reduce animal experimentation by giving 
preference to alternative in vitro models, there are currently no gold standard alternative 
methods to assess skin toxicity. However, different in vitro and in silico tools are available to 
improve prediction of skin toxicity without using animal models. From the use of AOPs for 
risk assessments to QSAR tools for prediction of toxicity, there are a plenitude of decision-
making tools working as a framework for better prediction of toxicity. 
Some in vitro cell-based and 3D RHE models have received formal EURL-ECVAM 
validation for assessment of skin toxicity in its different dimensions – irritation, corrosion, 
sensitization. For the last 10 to 15 years, the 3D RHE models have been widely accepted as the 
more suitable alternative method for skin toxicity studies, as their physiologically much more 
similar to human skin than in vitro cell-based assays. The commercially available EpiDermTM, 
EpiSkinTM and SkinEthicTM models are the most used models worldwide as they are currently 
validated by EURL-ECVAM for skin irritation, corrosion, UV exposure, among other toxicity 
studies. In fact, many of the Testing Guidelines from OECD for standardized skin toxicity 
studies have been defined resourcing to these RHE models.  
For example, TG 439 for skin irritation testing provides a standardized protocol for skin 
irritation using the RHE mentioned above by quantification of cell viability by MTT (OECD, 
2013). The MTT assay is a sensitive, affordable and fast method used in TG 439 to evaluate 
tissue viability of RHE models after chemical exposure, determining GHS category 2 irritants 
from non-irritant chemicals. EURL-ECVAM guidelines state that this protocol can actually be 
used as a replacement of the in vivo Draize test (rabbit skin sensitization) for hazard 
identification of irritant chemicals (ECVAM, 2009d).  
Many newly developed 3D RHE models seeking formal EURL-ECVAM validation follow 
TG 439 for comparative performance analysis with the commercially available 3D RHE 
models. The first objective of this study was to develop an animal-free 3D epidermal skin 
culture model for assessment of skin irritation following TG 439. Therefore, a comparative 
analysis was performed between the 3D epidermal skin model, the EpiDermTM model, a 3D 
RHE model using collagen-based scaffold and a keratinocyte monolayer culture. 
The results presented in this work showed that the 3D epidermal skin culture model was 
able to correctly classify 4 out of 6 non-irritants and 6 out of 6 irritants in a total of 10 
keratinocyte donor samples. Moreover, the same 10 keratinocyte donor samples were used to 
develop a keratinocyte monolayer culture and performance results from TG 439 showed that 
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the keratinocyte monolayer culture was only able to correctly predict 3 out 6 non-irritants and 
6 out of 6 irritants with big standard variations. Additionally, the 3D epidermal skin model 
“overpredicted” the irritancy of two non-irritants. As these two non-irritants currently have no 
GHS category, it could be argued that they do in fact have an irritancy potential but lack of 
irreputable in vivo data makes it impossible to determine their irritancy potential so far. Thus, 
these results could highlight the predictive capacity of the 3D epidermal skin culture model and 
its sensitivity to assess hazardous irritant chemicals.  
Ultimately, the results presented in this work indicate that the 3D epidermal skin culture 
developed could be employed as a relevant in vitro test method for evaluation of skin irritation. 
Direct comparison of the predictive capacity of the different in vitro test methods used for this 
study showed no statistically significant difference between the 3D epidermal skin culture and 
the commercially available 3D RHE model. These findings are vital to support the 
establishment of the 3D epidermal skin model as an in vitro test method for skin irritation 
purposes and could also be used as preliminary data for validation. 
Commercialization of the 3D epidermal model would broaden Alcyomics service pipeline. 
Currently, Alcyomics focus on pre-clinical screening of novel drugs and biopharmaceuticals 
and has already patented an in vitro skin explant assay for assessment of adverse immune events 
to chemicals, the Skimune® assay. Further modifications were made to the Skimune® to use 
it for detection of adverse events to monoclonal antibodies.  
In this study, the Skimune® assay was used to assess adverse immune events to aggregated 
monoclonal antibodies. It is still unclear the direct consequences of administration of 
aggregated monoclonal antibodies to the human immune system. Previous reports from cell-
based studies indicate that low levels of aggregated monoclonal antibodies caused unwanted 
activation of the immune system (Ahmadi, Bryson, Cloake, Welch, Filipe, Romeijn, Hawe, 
Jiskoot, Baker, et al., 2015; Joubert et al., 2012; Rombach-Riegraf et al., 2014). One of the big 
limitations of these reports is the fact that only a small percentage of the overall cohort 
presented significant cell activation, meaning that large cohorts are necessary to study immune 
activation by aggregated mAbs. As mentioned before, this can be complex to achieve during 
drug development phase, as it can be necessary to screen several drug compounds in a time and 
a cost-efficient manner. Therefore, development of a faster, but still accurate, in vitro method 
for assessment of adverse events by mAb aggregation is needed.  
Novel approaches like “immunoprofiling” are now emerging as assessment tools for the 
study of immunogenicity by mAb aggregation in a clinical setting. This tool allows to compare 
antibody responses from both the monomer and the aggregate form of clinically used IgG 
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mAbs, by peptide microarray analysis to identify patterns of antibody recognition against 
libraries of peptide antigens (Legutki et al., 2014). Immunoprofiling has been used in vaccine 
studies to improve their efficacy, by studying abnormal antibody elevated responses to 
particular epitopes in certain individuals (Legutki & Johnston, 2013). Moreover, 
immunoprofiling of epitope mapping has been used to identify aggregate-specific 
“immunosignatures”. As mentioned previously in section 5.3, misfolding of therapeutic 
proteins is a risk factor for immunogenicity, as neo-epitopes are formed or exposed during 
protein unfolding, which can increase the aggregated mAb response (Maas, Hermeling, Bouma, 
Jiskoot, & Gebbink, 2007). Homann et al. have characterized immunogenic epitopes to the 
TNF-α targeted MAbs Infliximab and Adalimumab, which are known to cause 
immunogenicity. Screening of serum samples from patients treated with Infliximab showed six 
relevant B cell epitopes in the variable region of Infliximab with an N-glycosylation sequence 
(Homann, Röckendorf, Kromminga, Frey, & Jappe, 2015). Individual IgG epitopes of anti-drug 
antibodies against adalimumab were also identified by epitope mapping via peptide microarray 
(Homann et al., 2017). Further studies in animal models have also identified aggregate-specific 
B cell epitopes upon protein unfolding. Peptide microarray analysis of an IgG2 mAb showed 
partial unfolding of the variable domain region of the mAb, with a critical replacement of 
tryptophan with alanine (Eyes et al., 2019). Overall, these findings can help identify 
aggregation-specific “immunosignatures” from anti-drug antibody serum responses of clinical 
patients, improve the existing methods for detection of immunogenicity and ultimately enhance 
the design of the therapeutic mAbs.  
This study aimed to also contribute with a possible in vitro approach for detection of 
immunogenicity by mAb aggregation. A skin explant assay was used in combination with T 
cell proliferation and cytokine quantification methods to assess the immunotoxicity caused by 
heat-stressed Herceptin and Rituximab. The fact that Skimune® could predict the same 
outcome as the previously reported studies but in a much smaller cohort, can only highlight the 
specificity of this in vitro method, which was the ultimate goal of this study. 
Ultimately, this project has provided new insights for animal-free in vitro test methods with 
reliable predictive capacity to improve the hazardous classification of any compound designed 




6.1. Future work 
This project was designed to develop novel in vitro test methods for assessment of skin 
irritation and adverse immune events relevant to human safety. Results from chapter 3 showed 
that a new 3D epidermal skin model using the Alvetex Strata membrane was optimized and 
could, additionally, be used for skin irritation testing (chapter 4). Likewise, results from chapter 
5 indicate that Skimune® could be modified to assess immunotoxicity by aggregated 
monoclonal antibodies. But while results are promising, there are still several questions or 
issues that need to be addressed regarding these novel in vitro test methods, like: 
- how reproducible is the 3D epidermal skin model? 
- is the 3D epidermal skin model ready for commercialization – quality control, storage, 
shipping? 
- can the 3D epidermal skin model be used for different form of skin toxicity? 
 
Regarding the Skimune® test for immunotoxicity: 
- can it be used for different monoclonal antibodies? 
- will it be able to detect different levels of aggregated monoclonal antibodies? 
 
Therefore, further experiments would be required to address these questions. In order to 
achieve official EURL-ECVAM validation, the 3D epidermal skin culture model would have 
to show intra- and inter-laboratorial reproducibility for all 20 reference chemicals, meeting all 
the quality standards defined in TG 439. However, considering that formal EURL-ECVAM 
validation can be a long process, Alcyomics short-term pipeline development strategies could 
include the 3D epidermal skin culture as an in-house service assay for skin toxicity studies or 
as a commercial RHE model. The in-house service assay strategy would require quality control 
evaluation by intra-laboratorial review and possibly a new product development phase to assess 
applicability of the 3D epidermal skin culture for skin corrosion, phototoxicity or absorption 
studies. The commercialization of the 3D epidermal skin culture model would also require 
quality control studies, as well as reproducibility, long term stability and shipment stability 
validation. Nevertheless, all these validation studies would be relevant as pre-validation data 
for formal EURL-ECVAM validation.  
 
Regarding Skimune®, the in vitro skin explant assay for assessment of immunotoxicity, 
further validation with a larger range of aggregated mAbs would robust the data already 
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collected in this work. From testing Skimune® in monoclonal antibodies with different IgG 
subclasses (i.e. IgG1 or IgG2) to monoclonal antibodies with different levels of aggregation, 
further testing would be crucial to strengthen the use of Skimune® as a valid platform for 
assessment of aggregated monoclonal antibodies.  
Furthermore, it would be crucial to understand if the skin damage readout from Skimune® 
assay is immune-related or not. Different testing conditions in the presence and absence of 
immune cells would help clarify the role of immune cells (more specifically T cells) in the 
















7. Appendices  
 
Appendix A – Publications  
 
Published abstracts: 
• Ana Ribeiro, Shaheda Ahmed, Anne Dickinson. Skimune® - a novel in vitro tool for 
detection of immunogenicity by mAb aggregation. ESBES 12th edition 2018 (Lisbon, 
Portugal) Oral Presentation 
• Ana Ribeiro, Shaheda Ahmed, Anne Dickinson. Skimune® - a novel in vitro tool for 
detection of immunogenicity by mAb aggregation. PEGS 14th edition 2018 (Boston, USA) 
Oral Presentation and poster 
• Ana Ribeiro, Shaheda Ahmed, Anne Dickinson. Skimune® - a novel in vitro tool for 
detection of immunogenicity and adverse immune reactions to novel compounds. MCAA 
General Assembly and Annual Conference 2018 (Leuven, Belgium) Poster Presentation  
• Ana Ribeiro, Shaheda Ahmed, Anne Dickinson. Skimune® - a novel in vitro tool for 
detection of immunogenicity and adverse immune reactions to novel compounds. 
EUSAAT, 2016 (Linz, Austria) Oral Presentation  
• Ana Ribeiro, Shaheda Ahmed, Anne Dickinson. Skimune® - a novel in vitro tool for 
detection of immunogenicity and adverse immune reactions to novel compounds. ICM 
Postgrad poster session, 2017 (Newcastle, UK) Poster Presentation (award 2nd best 
poster) 
• Ana Ribeiro, Shaheda Ahmed, Anne Dickinson. Skimune® - a novel in vitro tool for 
detection of immunogenicity and adverse immune reactions to novel compounds. ESBES 
10th edition, 2016 (Dublin, Ireland) Poster Presentation  
• Ana Ribeiro, Shaheda Ahmed, Anne Dickinson. Skimune® - predicting adverse immune 
reactions to biologics. WPC 15th edition, 2016 (Boston, USA) Poster Presentation  
• Ana Ribeiro, Shaheda Ahmed, Anne Dickinson. Skimune® - a novel in vitro tool for 
detection of immunogenicity by mAb aggregation. ICM research Seminar, 11th January 






• Martins-Ribeiro A, Kizhedath A, Ahmed SS, Glassey J, Dickinson AM. A human skin 
explant test as a novel in vitro assay for the detection of adverse immune reactions to 




Appendix B – Personal development 
Training weeks (TW) from BIORAPID 
• TW1 and 2 – 24th August 2015 to 04th September 2015 - Experimental procedures & 
Entrepreneurship, organized by Newcastle University and Alcyomics (NCL, UK) 
• TW3 – 05th December 2015 to 09th December 2015 - Modelling/data interpretation & 
QbD training, organized by Technical University of Denmark (Ghent, Belgium) 
• TW4 – 03rd April 2016 to 08th April 2016 - Microscale and small-scale reactors for 
process development training, organized by Technische Universität Berlin (Berlin, 
Germany) 
• TW5 – 29th May 2017 to 02nd June 2017 - Sensor technology & Innovative product 
design, organized by Linköping University and ACREO (Linköping, Sweden) 
• Biorapid Mid-Term project meeting: project update meeting, January 2017 (NCL, UK) 
 
Secondment trainings: 
• Toxicology Department – March 2016 (with Prof. Simon Wilkinson group) – to gain 
knowledge of in vitro toxicology testing to later apply this knowledge in the Skimune® 
technology for toxicity testing 
• FUJIFILM (Billingham) – March 2017 (with Prof. Graham McCreath) – to gain 
knowledge of biopharma manufacture of monoclonal antibodies; industrial process of 




• Flow Cytometry training 
• ePortfolio and Personal Development training 
• Managing your PhD, MD or MPhil 
• Introduction to Statistical Considerations in Experimental Research 
• Learning Agreement 
• Endnote 
• Chemical Safety training 
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• Basic fire training induction 
• ICM induction morning 
• Public speaking 
• Risk assessment 
• Biological Agents and GMO 
• Insights from industry, Good manufacturing practice 
• Recording your research (Lab books, research diaries, etc) 
• Robust research methodologies for Literature Review 
• Very basic Stats 
• Haematology department sample tracking system training 
• Academic writing 
• Convincing CVs and Covering Letters 
• Research ethics 
• Thesis writing 
• Human Tissue Act training 
• ISIS database training 
• Database training 
• Basic Rad protection workshop 
• Second year annual review: your research outputs 
• Communication and presentation skills 
• ILTHE – Introduction to Learning and Teaching 
 
Additional activities: 
• BIORAPID newsletter issue 1 and 2 – article on Paris internship and experience 
• BIORAPID promotional video  
 https://www.youtube.com/watch?v=HSXyvEoaXXM&t=2s  
• Engineering Futures - Outreach activity in Hotspur Primary School for STEM 
awareness (May 2017) 
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